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Abstract 
Neuromodulation, the alteration of nerve activity through the use of targeted 
electrical stimulation or pharmacology, is a rapidly advancing field with 
applications in a plethora of conditions e.g. epilepsy. Many of these 
techniques are invasive and expensive such as vagus nerve stimulation 
limiting their applicability to patient populations. Autonomic nervous system 
imbalance is a characteristic of many conditions including heart failure. The 
ability to favourable alter autonomic function non-invasively would, therefore, 
offer potential therapeutic benefit to a large number of patients. This thesis 
investigated the effects of two non-invasive neuromodulatory techniques on 
cardiovascular autonomic function in humans – transcutaneous vagus nerve 
stimulation (tVNS) and transcranial direct current stimulation (tDCS). 
 tVNS was performed using surface electrodes placed on the ear to 
stimulate the auricular branch of the vagus nerve (ABVN). High pulse width 
and frequency tVNS was found to alter heart rate variability (HRV) towards 
parasympathetic predominance in healthy participants (n = 34) and heart 
failure patients (n = 8). Furthermore, microneurography recordings 
performed in healthy participants (n = 10) revealed that this effect may have 
been  mediated, at least in part, by a reduction in muscle sympathetic nerve 
activity (MSNA). 
 tDCS was performed by placing electrodes over the motor cortex and 
the contralateral supraorbital region of healthy participants (n = 22). Anodal 
stimulation (positive electrode over the motor cortex) altered HRV towards 
sympathetic predominance and increased MSNA whereas cathodal and 
sham tDCS had no effect. 
 tVNS and anodal tDCS over the motor cortex had opposite effects on 
cardiovascular autonomic function. These techniques may be tailored to the 
needs of individual patients to shift cardiovascular autonomic function 
towards either parasympathetic (tVNS) or sympathetic (tDCS) 
predominance. tVNS and tDCS are simple, non-invasive and inexpensive 
allowing a wide cohort of patients to access these potential therapies. 
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Chapter 1 
General Introduction: the autonomic nervous system in 
health and disease 
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1.1 The autonomic nervous system  
The autonomic (Greek auto = self, nomos = rule) nervous system (ANS) is 
appropriately named as it generally operates without conscious input to 
regulate visceral function and maintain homeostasis. The ANS has three 
divisions; the sympathetic, parasympathetic and enteric divisions. The 
enteric division is situated in the gastrointestinal tract and controls digestive 
reflexes. The sympathetic and parasympathetic divisions innervate cardiac 
muscle, smooth muscle and exocrine glands. Many organs receive dual 
input from both the sympathetic and parasympathetic divisions and these 
divisions are often considered to be functionally antagonistic. For example, 
the sympathetic division is regarded as responsible for the ‘fight or flight’ 
response e.g. increasing heart rate and the parasympathetic division as 
active during ‘rest and digest’ conditions e.g. decreasing heart rate. In reality 
the ANS is more sophisticated; both sympathetic and parasympathetic 
divisions are tonically active providing integrated and co-ordinated 
responses that allow fine-tuned control of visceral function and homeostasis. 
Indeed, heart rate is under tonic inhibition at rest through parasympathetic 
input to the sino-atrial node (Jose and Collison, 1970). The initial increase in 
heart rate during exercise is due to parasympathetic withdrawal that is 
followed by increased sympathetic activity to further increase heart rate 
(Fagraeus and Linnarsson, 1976). The ability to rapidly alter sympathetic 
and parasympathetic activity in response to changing physiological demands 
is essential to healthy function. This can be impaired in numerous conditions 
such as heart failure with detrimental results. 
 
1.1.1 The sympathetic nervous system 
The sympathetic nervous system is widely distributed throughout the body 
and innervates many organs including lungs, heart, blood vessels, sweat 
glands, erector pili muscles and many abdominal and pelvic organs. The cell 
bodies of sympathetic preganglionic neurones are located in the lateral 
horns of the spinal cord from the level of the first thoracic segment to the 
second lumbar segment (T1-L2). The small–diameter, myelinated axons of 
these neurones exit the spinal cord in the ventral nerve roots and enter the 
- 3 - 
ganglia of the sympathetic chain through the white rami communicantes 
(Gilbey and Spyer, 1993). The axons of preganglionic sympathetic neurones 
may travel rostrally or caudally in the sympathetic chain before synapsing 
with postganglionic sympathetic neurones (Gilbey and Spyer, 1993). Non-
myelinated postganglionic sympathetic neurones exit the sympathetic chain 
through the grey rami communicantes and are distributed to their respective 
organs in branches of the spinal nerves or along the carotid arteries. Some 
preganglionic neurones pass through the sympathetic chain without 
synapsing and exit as the sympathetic splanchnic nerves. These project to 
the prevertebral ganglia including the coeliac, superior mesenteric and 
inferior mesenteric ganglia and then synapse with postganglionic neurones. 
Some of the preganglionic fibres in the greater splanchnic nerve project 
directly to the medulla of the adrenal gland (Strack et al., 1989). The cells of 
the adrenal medulla are modified postganglionic sympathetic neurones that 
secrete adrenaline and noradrenaline.  
The neurotransmitters used in the sympathetic nervous system are 
acetylcholine and noradrenaline. Sympathetic preganglionic neurones 
release acetylcholine (ACh) which activates postganglionic sympathetic 
neurones. Postganglionic sympathetic neurones primarily use noradrenaline 
which acts on alpha or beta receptors of the effector organ. The exception is 
sympathetic innervation of sweat glands through cholinergic postganglionic 
sympathetic axons (Dale and Feldberg, 1934) which act on muscarinic 
receptors (Patton, 1948).  
 
1.1.2 The parasympathetic nervous system 
The parasympathetic nervous system is described as having a craniosacral 
outflow as preganglionic parasympathetic neurones are located in brainstem 
nuclei and sacral spinal cord segments (S2-4). The parasympathetic 
brainstem cranial nerve (CN) nuclei include the Erdinger-Westphal nucleus 
(CN III – oculomotor nerve), the superior and inferior salivatory nuclei (CN 
VII – facial nerve and CN IX – glossopharyngeal nerve), the dorsal vagal 
nucleus (DVN) and nucleus ambiguus (NA; both CN X – vagus nerve). The 
majority of cardiac preganglionic neurones are located in the NA as revealed 
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by retrograde labelling following injection of cholera-toxin conjugated to 
horse radish peroxidase into rat myocardium (Izzo et al., 1993). Extracellular 
recordings of cardiac preganglionic neurones in the NA of cats revealed that 
they fire in synchrony with the cardiac cycle (McAllen and Spyer, 1978). 
Simultaneously recording afferent baroreceptor activity from the carotid 
sinus nerve confirmed that this is due to baroreceptor input and synchrony 
could be abolished by compressing the carotid arteries and sectioning the 
aortic nerve (McAllen and Spyer, 1978). In contrast to the sympathetic 
nervous system, the axons of parasympathetic preganglionic neurones are 
much longer as parasympathetic ganglia are located close to the target 
organ, however, they also use ACh as a neurotransmitter. Postganglionic 
parasympathetic neurones are relatively short and use ACh as a 
neurotransmitter which acts on muscarinic receptors of the target tissue.  
 
1.1.3 The enteric nervous system 
The enteric nervous system is relatively independent, however, it does 
receive some sympathetic and parasympathetic input. It is composed of two 
nerve plexuses that extend the length of the gastrointestinal tract. The 
myenteric (Auerbach’s) plexus between the circular and longitudinal muscle 
layers is responsible for co-ordinating muscle contraction. The submucosal 
(Meissner’s) plexus lies between the circular muscle and mucosa and 
regulates secretion. The enteric nervous system is vital in regulating 
gastrointestinal function, however, as this is not the focus of this thesis it will 
not be described in detail. 
 
1.1.4 Central control of cardiovascular autonomic function 
Precise and dynamic regulation of the autonomic control of the 
cardiovascular system is essential for healthy function and to respond to 
changing physiological demands. To achieve this, afferent information from 
the cardiovascular system is integrated into central pathways which control 
autonomic outflow. The nucleus tractus solitarius (NTS), located in the 
dorsal medulla, is essential in processing cardiovascular reflexes and 
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maintaining cardiovascular homeostasis e.g. arterial baoreceptor reflex 
controlling blood pressure. The NTS is the principal recipient of 
cardiovascular receptor afferents conveying information from baroreceptors 
and chemoreceptors through the glossopharyngeal and vagus nerves. This 
was evidenced by retrograde neuronal tracing of the carotid sinus nerve and 
aortic depressor nerve in cats (Ciriello et al., 1981). The NTS also receives 
many other visceral and somatic inputs that influence cardiovascular 
function including afferents from skeletal muscles (Kalia et al., 1981) and 
kidneys (Weiss and Chowdhury, 1998). 
The NTS also receives afferents from other autonomic centres both 
medullary (e.g. ventrolateral medulla and medullary raphe nuclei) and 
supramedullary (e.g. paraventricular nucleus [PVN], lateral hypothalamic 
nucleus, central nucleus of the amygdala and insular cortex) as 
demonstrated by neuronal tracing studies in rats (van der Kooy et al., 1984) 
(Ross et al., 1981) and rabbits (Schwaber et al., 1982; Gieroba et al., 1991). 
Furthermore, the NTS also projects to parts of the brain and spinal cord 
important for cardiovascular control including the lateral horn of the spinal 
cord, rostral and caudal ventrolateral medulla, NA, PVN and central nucleus 
of the amygdala and receives reciprocal projections from these areas too as 
demonstrated by anterograde and retrograde neuronal tracing in cats 
(Loewy and Burton, 1978) and rats (Ricardo and Koh, 1978; Ross et al., 
1985). These numerous and reciprocal projections to the NTS allow the NTS 
to integrate and influence reflex autonomic control at the level of the 
brainstem and also allows higher centres to influence autonomic function. 
 In addition to the NTS, other brainstem areas important for autonomic 
control include the DVN, NA, caudal ventrolateral medulla (CVLM) and 
rostral ventrolateral medulla (RVLM). As mentioned in Section 1.1.2, the 
DVN and NA contain preganglionic parasympathetic neurones. The DVN lies 
ventral to the NTS and the NA lies dorsolateral to the inferior olivary nucleus. 
There are also sparse preganglionic parasympathetic neurones located in 
the reticular formation which lies between the DVN and NA (Izzo et al., 
1993). The majority of cardiac preganglionic neurones are located in the NA 
which also contains motor neurones innervating the muscles of the pharynx 
and larynx. It is possible to differentiate between these two groups of 
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neurones electrophysiologically as cardiac neurones show pulse 
synchronous activity that is abolished by baroreceptor denervation (McAllen 
and Spyer, 1978).  
The RVLM is vital in regulating blood pressure (Dampney, 1994) and 
has projections to the lateral horn of the spinal cord demonstrated by 
microinjecting the retrograde neuronal tracer horseradish peroxidase into the 
RVLM (Ross et al., 1984b). It was later shown that the RVLM projects 
directly to sympathetic preganglionic neurones in the spinal cord by 
combining anterograde tracing of RVLM projections with retrograde tracing 
of preganglionic neurones innervating the adrenal medulla and visualising 
the results using electron microscopy (Zagon and Smith, 1993). Electrical 
stimulation of the RVLM in anesthetised rats caused increased blood 
pressure and heart rate plus increased plasma noradrenaline levels. (Ross 
et al., 1984a). Microinjection of excitatory amino acids (L-glutamate and 
kainic acid) into the RVLM also increased blood pressure and heart rate 
whereas the inhibitory amino acid GABA decreased blood pressure and 
heart rate (Ross et al., 1984a). The RVLM is pivotal in maintaining blood 
pressure and lesioning of this area caused a decrease in resting blood 
pressure (Dampney and Moon, 1980) indicating that the RVLM has a tonic 
influence on vasoconstriction. The importance of different cell types in the 
RVLM is being investigated using optogenetics. By introducing a virus into 
the RVLM that expresses channel rhodopsin under the control of a specific 
promoter it is possible to selectively stimulate neurones using light. This 
elegant method has recently revealed that stimulating only 
catecholaminergic neurons within the NTS increased blood pressure and 
sympathetic nerve activity providing direct evidence that catecholaminergic 
neurones in the RVLM are sympathoexcitatory (Abbott et al., 2009). 
The CVLM projects to the RVLM and is essential in regulating 
neuronal activity of the RVLM. Direct projections from the CVLM to 
sympathetic premotor neurones of the RVLM were demonstrated by 
combining injection of an anterograde neuronal tracer into the CVLM and a 
trans-ganglionic retrograde tracer into the adrenal medulla which revealed 
double labelled neurones in the RVLM (Li et al., 1992). Neurones in the 
CVLM have an inhibitory effect on the RVLM that can be elicited by 
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microinjecting glutamate into the CVLM causing a decrease in blood 
pressure (Blessing, 1988). This effect was abolished by injecting bicuculline 
(GABA antagonist) into the RVLM, indicating that the CVLM acts on the 
RVLM through a GABAergic pathway (Blessing, 1988). These robust 
findings could be enhanced through the use of optogenetics to directly 
stimulate CVLM neurones, however, this has not yet been performed. 
The raphe nuclei, located in the midline of the medulla, project to both 
supramedullary areas of autonomic control (PVN) (Standish et al., 1995) and 
the lateral horn of the spinal cord (Allen and Cechetto, 1994; Standish et al., 
1995) as revealed by retrograde neuronal tracing. The raphe nuclei also 
project to the ventral horn of the spinal cord and injections of neuronal tracer 
into lateral and ventral horns revealed double labelled neurones in the raphe 
nuclei (Allen and Cechetto, 1994). This suggests that the raphe nuclei may 
integrate autonomic and somatic motor activity. Stimulation of the raphe 
nuclei in cats caused both increases and decreases in blood pressure 
providing direct evidence of their involvement in autonomic regulation 
(McCall, 1984). 
Supramedullary areas also play an important role in autonomic 
regulation. The hypothalamus is key in integrating neuroendocrine and 
autonomic functions whereas the insular cortex and the central nucleus of 
the amygdala co-ordinate emotional responses. The PVN of the 
hypothalamus has projections to the RVLM and preganglionic sympathetic 
neurones in the lateral horn of the spinal cord as demonstrated by injecting 
fluorescent retrograde tracers into these areas (Pyner and Coote, 2000). 
The PVN also projects to the DVN and NA (Portillo et al., 1998; Palkovits, 
1999) and thereby influences parasympathetic activity. In addition to these 
diverse projections, the PVN is also neurochemically diverse containing 
GABAergic, glutamatergic, dopaminergic, oxytocinergic and 
vasopressinergic neurones (Pyner, 2009). This variety explains the 
conflicting results of stimulation studies of the PVN which caused either 
increases or decreases in blood pressure (Yang and Coote, 1998). 
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1.1.5 Reflex control of cardiovascular autonomic function 
Reflex control of cardiovascular function permits tight regulation of the 
cardiovascular system and rapid responses to physiological challenges such 
as postural changes. The arterial baroreceptor reflex is a good example of 
reflex autonomic regulation to maintain blood pressure and prevent 
excessive perturbations. Baroreceptors are specialised stretch receptors 
located in the carotid sinus and aortic arch which project to the NTS through 
the vagus (aortic) and glossopharyngeal (carotid) nerves (Ciriello et al., 
1981). An increase in blood pressure causes stretching of carotid and aortic 
arterial walls and increases baroreceptor firing. Through a glutamatergic 
projection from the NTS, this causes activation of the CVLM which inhibits 
the RVLM (Agarwal et al., 1990). This, in turn, decreases sympathetic 
outflow resulting in vasodilation to decrease blood pressure. The NTS also 
activates the NA to increase cardiac parasympathetic activity and decrease 
heart rate (Neff et al., 1998). Conversely, a decrease in blood pressure 
disinhibits the RVLM leading to an increase in sympathetic activity and 
vasoconstriction to preserve blood pressure (Minson et al., 1994). 
In addition to the arterial baroreceptor reflex, cardiopulmonary 
reflexes mediated by low pressure stretch receptors in the heart, great 
vessels and lung vasculature modulate central sympathetic outflow (Mitchell 
and Victor, 1996; Minisi, 1998). Application of lower body negative pressure 
< -20 mmHg unloads cardiopulmonary baroreceptors by decreasing central 
venous pressure without altering arterial blood pressure, allowing the effects 
of cardiopulmonary reflexes to be studied (Jacobsen et al., 1993). Recording 
muscle sympathetic nerve activity (MSNA) during lower body negative 
pressure in healthy humans revealed increased burst frequency, incidence 
and amplitude (Vissing et al., 1989; Jacobsen et al., 1993). Activation of 
cardiopulmonary baroreceptors has also been investigated in humans using 
lower body positive pressure. Pressures of 10-20 mmHg caused an increase 
in atrial dimensions measured using echocardiography and this was 
accompanied by a decrease in MSNA (Fu et al., 1998). Vagal afferents are 
involved in this reflex as blocking the cervical vagus nerves in dogs by 
cooling to 0 – 2 ºC attenuated cardiopulmonary reflex responses (Bishop 
and Peterson, 1978). The cardiopulmonary reflex may influence the arterial 
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baroreflex particularly during exercise when the arterial baroreflex is reset. 
Using manoeuvres to increase central blood volume and hence load 
cardiopulmonary baroreceptors during exercise e.g. cycling in a supine 
position as opposed to upright, attenuated the increase in blood pressure 
and resetting of the baroreflex sensitivity curve (Ogoh et al., 2007).  
The chemoreflex is also an important component in maintaining 
homeostasis and influences sympathetic activation. The peripheral 
chemoreceptors are located in the carotid bodies and respond most 
sensitively to hypoxia whereas central chemoreceptors in the brainstem 
respond to hypercapnia (Guyenet, 2000). Peripheral chemoreceptor 
afferents project to the NTS and activation of the chemoreflex causes 
increased blood pressure, bradycardia and tachypnoea. The increase in 
blood pressure, through increased sympathetic vasoconstrictor activity, is 
mediated by the RVLM and is abolished by bilateral microinjection of the 
glutamate receptor antagonist kynurenic acid into the RVLM (Koshiya et al., 
1993).  
Similarly, central chemoreceptor activation causes 
sympathoexcitation, increased blood pressure and tachypnoea, however, 
the mechanisms are unclear (Somers et al., 1989). Sympathetic nerve 
activity varies with respiration, first described in anaesthetised rabbits and 
anaesthetised or decerebrate cats (Adrian et al., 1932). Respiratory 
modulation of muscle sympathetic nerve activity has also been 
demonstrated in humans using microneurography, with a peak in activity at 
end-expiration and minimum activity at end-inspiration (Eckberg et al., 
1985). The source of this respiration dependent modulation is unclear 
however, simultaneous extracellular recordings of barosensitive GABAergic 
CVLM neurones and phrenic nerve activity in the rat revealed a central 
respiratory drive of neuronal activity in the CVLM (Mandell and Schreihofer, 
2006). GABAergic CVLM neurones inhibit RVLM neurones which also 
exhibit central respiratory drive activity that mirrors that of CVLM neurones 
and this could explain respiration dependent modulation of sympathetic 
activity (Mandell and Schreihofer, 2006). Independent of central respiratory 
drive, CNS PCO2 also influences sympathetic activity (Guyenet et al., 2010). 
It is postulated that this could be mediated by neurones of the retrotrapezoid 
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nucleus that are sensitive to PCO2 and project to the CVLM and RVLM 
(Rosin et al., 2006) in rats, however, there is currently no direct evidence of 
this pathway.  
Metabolically sensitive muscle afferents (group III and IV afferents) 
activated by metabolites (e.g. lactate, ATP, pH) also influence 
cardiovascular autonomic control through the metaboreflex (Guyenet, 2006). 
This was first described in man by Alam and Smirk (1937) who reported that 
placing inflatable cuffs around exercising limbs to prevent blood flow and 
induce ischaemia increased blood pressure to a greater degree than 
exercise with unimpeded circulation. Furthermore, leaving the cuffs in place 
to preserve ischaemia after exercise had ceased maintained the increase in 
blood pressure. Recording MSNA during post-exercise ischaemia, induced 
by inflating arm cuffs after isometric handgrip exercise, revealed that in 
addition to a maintained increase in blood pressure, there was also a 
maintained increase in MSNA burst frequency and amplitude (Mark et al., 
1985). Interestingly, heart rate was only elevated during exercise and 
decreased during post exercise ischaemia (Mark et al., 1985). There has 
been some debate as to the effects of the metaboreflex on the autonomic 
control of heart rate. Recently, the effects of metaboreflex activation on heart 
rate have been elucidated through the use of parasympathetic 
(glycopyrrolate) and beta-adrenergic (metoprolol or propanolol) blocking 
agents administered to healthy human volunteers who performed leg cycling 
and isometric handgrip exercises. Parasympathetic blockade augmented the 
elevation in heart rate during post exercise ischaemia induced after isometric 
handgrip exercise performed at 25% of maximal voluntary contraction but 
had no effect when this exercise was performed at 40% MVC (Fisher et al., 
2010; Fisher et al., 2013). Parasympathetic blockade also had no effect on 
heart rate during post exercise ischaemia following leg cycling exercise 
(Fisher et al., 2013). Beta blockade abolished heart rate elevation following 
isometric handgrip exercise at 25% MVC and attenuated heart rate elevation 
following 40% MVC handgrip exercise and had no effect on heart rate 
elevation following leg cycling exercise. The increase in heart rate following 
greater effort (40% MVC isometric handgrip) or larger muscle mass (leg 
cycling exercise) appears to be mediated by increased cardiac sympathetic 
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activity with cardiac parasympathetic withdrawal whereas exercise at lower 
intensity (25% MVC isometric handgrip) causes a smaller elevation in heart 
rate which may be due to parasympathetic reactivation. It therefore requires 
larger exercising muscle mass or greater effort for the metaboreflex to 
overcome the reflex decrease in heart rate and parasympathetic activation 
that occurs after cessation of exercise. 
 
1.2 Measuring cardiovascular autonomic function 
The majority of techniques to measure autonomic function in humans are 
indirect due to the difficulty and invasiveness of direct recordings. This 
approach provides estimates of autonomic balance rather than directly 
quantifying sympathetic and parasympathetic activity. 
 
1.2.1 Non-invasive estimates of autonomic function  
1.2.1.1 Resting heart rate 
Resting heart rate (RHR) is one of the simplest measures of sympathovagal 
balance and is usually 60-80 beats per minute (bpm). RHR can be much 
lower in trained athletes at 30 bpm and, conversely, can be as high as 100 
bpm in sedentary individuals (Cook et al., 2006). High RHR (implying 
increased sympathetic activity and/or decreased parasympathetic activity) in 
healthy population studies was associated with an increased risk of mortality 
(Shaper et al., 1993; Jouven et al., 2005). A long term study of 5713 
asymptomatic working men aged 42 to 53 years (Jouven et al., 2005) found 
that a RHR > 75 bpm resulted in a four-fold risk of sudden death compared 
to a RHR < 60 bpm. RHR is an indicator of the net contribution of the 
parasympathetic and sympathetic nervous systems to cardiac control. 
 
1.2.1.2 Heart rate recovery 
The decline in heart rate after exercise is another indication of autonomic 
cardiovascular regulation. The immediate heart rate recovery (HRR) after 
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exercise is mainly due to vagal activity as vagal blockade with atropine slows 
HRR in the 2 minute post exercise period (Imai, 1994). Studies investigating 
HRR in various populations have found that a low rate of recovery can be a 
strong predictor of mortality (Cole et al., 1999; Shetler et al., 2001; Jouven et 
al., 2005). A long term study of HRR in 2428 patients who had been referred 
for first time coronary angiography found that, after adjustments for age, sex, 
medication and resting heart rate etc, a HRR of ≤12 bpm in the first minute 
after exercise was a strong predictor of mortality (adjusted relative risk 2.0; p 
< 0.001) (Cole et al., 1999). This finding was confirmed by Shetler et al. 
(2001) who also examined HRR in 2193 patients referred for coronary 
angiography and reported that a HRR <22 bpm was predictive of a higher 
risk of mortality. This value differs from that given by Cole et al., however, 
Shetler et al. used a longer recovery time of 2 minutes after exercise. Of 
particular interest is a long term study of HRR in 5713 asymptomatic men 
(42-53 years) (Jouven et al., 2005) which reported that HRR < 25 bpm was a 
strong predictor of sudden death from myocardial infarction (MI) (relative 
risk, 2.2). 
 
1.2.1.3 Baroreflex sensitivity 
Baroreflex sensitivity (BRS) can be investigated through the change in heart 
rate in response to a change in blood pressure (BP). There are a number of 
techniques to measure BRS in the laboratory, however, some are invasive 
e.g. using drugs (phenylephrine/nitroprusside) to produce transient changes 
in blood pressure (Parati et al., 2000; La Rovere et al., 2008). Traditionally, 
measurements of BRS utilised intra-arterial monitoring of blood pressure, 
however, a strong correlation was found between measurements using this 
technique and non-invasive BP measurement using photoplethysmography 
(Pinna et al., 2000). This offers an easily implemented technique to measure 
BRS. 
A non-pharmacological alternative to induce changes in BP is to use 
the Valsalva manoeuvre. This requires forced expiration (straining) either 
against a closed glottis or resistance such as blowing into a tube connected 
to a manometer (approximately 40 mmHg). The changes in blood pressure 
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and heart rate during the Valsalva manoeuvre can be divided into 4 phases 
(Freeman, 2006). In phase I, at the onset of straining, there is a transient 
increase in blood pressure and a fall in heart rate. This is a result of the 
increase in intra-thoracic pressure compressing the aorta and forcing blood 
into the peripheral circulation. In phase II (during straining) there is a 
decrease in blood pressure due to impaired venous return. This results in 
sympathetic activation with tachycardia and vasoconstriction (Parati et al., 
2000; La Rovere et al., 2008). At the end of straining (phase III) there is a 
decrease in blood pressure and an increase in heart rate due to the release 
of intra-thoracic pressure. This is followed by an increase in blood pressure 
above baseline values (overshoot, phase IV) due to unimpaired venous 
return and residual vasoconstriction. This leads to parasympathetic 
activation to reduce heart rate and thereby decrease blood pressure (Parati 
et al., 2000; La Rovere et al., 2008). The Valsalva manoeuvre can be 
considered a natural challenge to the baroreceptors compared to 
pharmacological methods, however, it can be difficult to perform. The neck 
chamber technique, which can apply positive or negative pressure to the 
neck leading to deactivation or activation of the baroreceptors, is better 
tolerated although the equipment is expensive (Parati et al., 2000; La 
Rovere et al., 2008). Alternatively, spontaneous changes in blood pressure 
can be used to assess BRS and are arguably more physiological requiring 
no interventions.  
There are two main approaches to measuring spontaneous BRS – 
the sequence method and spectral methods. The sequence method 
identifies sequences of 3 or more heart beats where increases or decreases 
in systolic blood pressure are followed by lengthening or shortening of inter-
beat intervals measured between the R peaks of the ECG (R-R intervals) 
(Parati et al., 2000; La Rovere et al., 2008). Spectral methods use a transfer 
function between oscillations in systolic blood pressure and R-R interval in 
the same frequency band to estimate BRS (Parati et al., 2000; La Rovere et 
al., 2008). The benefits of both these techniques are that they are simple, 
non-invasive and inexpensive, however they provide estimates of BRS 
rather than direct measurements. 
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Impaired BRS (<3 ms/mmHg) has been shown by the ATRAMI 
(Autonomic Tone and Reflexes After Myocardial Infarction) study to be an 
independent predictor of mortality (La Rovere et al., 1998). This was 
demonstrated by measuring BRS using the phenylephrine technique in 
almost 1300 patients after a recent MI (< 28 days). Impaired BRS, using 
non-invasive methods of BRS measurement, has also been shown to be a 
significant risk factor (Pinna et al., 2005), however, this technique is limited 
as it cannot be applied if ectopic beats (e.g. premature ventricular 
complexes) occur. 
 
1.2.1.4 Heart rate turbulence 
Heart rate turbulence (HRT) takes advantage of the oscillations in heart rate 
that occur during an ectopic heart beat and may provide an alternative to 
BRS in subjects prone to ectopic heart beats. There is an initial acceleration 
in heart rate preceding an ectopic beat followed by a deceleration. The 
percentage difference between heart rate deceleration and acceleration is 
measured as the turbulence onset (TO). There is also a fall in systolic blood 
pressure following an ectopic beat due, in part, to the short diastolic filling 
time (Bauer et al., 2010). Through the baroreflex, this leads to vagal 
withdrawal and sympathetic activation which can be measured as changes 
in the intervals between heart beats (R-R intervals) plotted as a linear 
regression (turbulence slope - TS) (Bauer et al., 2010). Impaired HRT has 
been shown to be an independent risk factor post MI, however, 17-19% of 
patients were excluded from this study due to atrial fibrillation or absence of 
ectopic beats (Schmidt et al., 1999). 
 
1.2.1.5 Heart rate variability 
Normal heart rate varies beat to beat and is a reflection of both 
parasympathetic and sympathetic input to the sinoatrial node in response to 
a variety of factors e.g. baroreceptors, circadian rhythm, renin-angiotensin 
system, respiration and exercise. There are two main methods to analyse 
heart rate variability (HRV) either using time domain measures or frequency 
domain measures.  
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Time domain measures are perhaps the simplest as they comprise 
simple statistical and geometric analyses of R-R intervals (also termed 
normal-normal [N-N] intervals). Time domain measures are recommended 
for long term (24 hour) ECG recordings and include SDNN (the standard 
deviation of all N-N intervals) which is a measure of overall HRV; SDANN 
(the standard deviation of the averages of N-N intervals in all 5 min 
segments of the entire recording) which is a measure of long-term 
components of HRV and RMSSD (the square root of the mean of the sum of 
the squares of differences between adjacent N-N intervals) and pNN50 
(number of pairs of adjacent N-N intervals differing by > 50 ms) which are 
measures of short term components of HRV such that a higher value 
indicates increased vagal modulation (Task Force of the European Society 
of Cardiology and the North American Society of Pacing Electrophysiology, 
1996). 
Frequency domain measures use power spectral analysis to describe 
how variance (power) distributes as a function of frequency. There are a 
number of algorithms that can be used in frequency analysis but the Fast 
Fourier Transform (FFT) is most commonly used. The components of HRV 
spectral analysis are: very low frequency (< 0.04 Hz; VLF); low frequency 
(0.04-0.15 Hz; LF) and high frequency at (0.15-0.4 Hz; HF). Studies have 
shown that the HF component of HRV is related to rapid variations in heart 
rate associated with respiratory sinus arrhythmia mediated by vagal activity 
(Malliani, 2005). Akselrod et al. (1981) investigated the effect of 
parasympathetic and sympathetic blockade (using glycopyrrolate and 
propanolol respectively) on HRV in conscious dogs. Parasympathetic 
blockade abolished the HF component of HRV whereas sympathetic 
blockade had little effect confirming that HF is a reflection of 
parasympathetic activity. Interpretation of the LF component has been 
subject to debate. Some claim the LF component is a reflection of 
sympathetic activity only (Malliani, 2005) whereas others believe that both 
sympathetic and parasympathetic activity contribute to the LF component 
(Akselrod et al., 1981). Studies have shown that sympathetic blockade with 
propanolol significantly decreased the LF component in rats but did not 
completely abolish it (Aubert et al., 1999). Parasympathetic blockade with 
- 16 - 
atropine, as well as completely abolishing the HF component, also reduced 
LF power indicating that both sympathetic and parasympathetic activity 
contribute to the LF component (Aubert et al., 1999; Lahiri et al., 2008). It is 
agreed that the relative ratio of LF/HF is a reflection of sympathovagal 
balance (Task Force of the European Society of Cardiology and the North 
American Society of Pacing Electrophysiology, 1996). This means that HRV 
analysis provides information about the degree of autonomic modulation 
rather than the level of autonomic tone. Kleiger et al. (1987) first 
demonstrated that reduced HRV, indicating reduced parasympathetic 
influence on heart rate, was a risk factor by investigating the standard 
deviation of R-R intervals of patients post MI. This revealed a 5.3 times 
greater risk of mortality in patients with SD of R-R intervals (SDNN) < 50 ms 
compared to those with a SDNN >100 ms.  
 
1.2.2 Invasive measures of autonomic function  
Indirect measures of autonomic function such as those described above are 
useful, however, they are an estimate of autonomic function. There is no 
method to directly measure parasympathetic activity in humans, however, it 
is possible to directly assess sympathetic activity. The development of 
radiotracer-derived measurements of noradrenaline spill-over to plasma and 
microneurography revolutionised investigations of sympathetic activity 
(Engleman et al., 1968; Hagbarth and Vallbo, 1968). 
 
1.2.2.1 Plasma noradrenaline levels 
Noradrenaline is the neurotransmitter released by sympathetic adrenergic 
nerve endings. Most noradrenaline is removed by reuptake mechanisms, 
however, approximately 20% diffuses into plasma (Esler et al., 1985). 
Although only a little of the noradrenaline released enters the circulation, 
perturbations that increase sympathetic nerve activity such as exercise 
cause a prompt increase in plasma noradrenaline indicating that it may be 
used as a measure of sympathetic activity (Cohn et al., 1984). The first 
approach to measure systemic noradrenaline levels as an insight to 
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sympathetic function analysed urinary levels of excreted noradrenaline. 
(Chidsey et al., 1965). Urinary noradrenaline originates from the filtration of 
plasma noradrenaline at the glomerulus and noradrenaline released by renal 
sympathetic nerves within the kidney. This technique may therefore be 
biased by renal sympathetic activation. Noradrenaline levels in plasma were 
also measured from blood samples as an indicator of systemic sympathetic 
activity (Cohn et al., 1984). Both urinary and plasma measures of 
noradrenaline levels are crude, depending on the rate of noradrenaline 
reuptake and clearance from circulation. Measuring noradrenaline spill-over 
using a radiotracer derivative is a more accurate measurement of 
sympathetic activity. This requires infusion of radiolabelled noradrenaline 
into a peripheral vein until a steady state is achieved (approx. 90 mins). 
Blood samples are then taken from another vein and the proportion of 
endogenous noradrenaline to infused radiolabelled noradrenaline is used as 
a measure of noradrenaline spill-over into plasma (Esler et al., 1985). This 
technique has been further refined by placing catheters into the venous 
drainage of specific organs to measure regional differences in noradrenaline 
spill-over and thereby sympathetic activity. This is a powerful but highly 
invasive technique e.g. cardiac noradrenaline spill-over is measured by 
placing the catheter into the cardiac sinus. A less invasive method to assess 
sympathetic activity is microneurography. 
  
1.2.2.2 Microneurography 
Microneurography was pioneered in the late 1960s and involves inserting a 
tungsten microelectrode into a superficial nerve, commonly the peroneal 
(fibular) nerve as it courses round the neck of the fibula (Hagbarth and 
Vallbo, 1968). Microneurography allows the direct recording of sympathetic 
nerve activity to intramuscular blood vessels (Hilz and Dutsch, 2006; 
Charkoudian and Rabbitts, 2009). Initially, this technique was used to record 
bursts of muscle sympathetic nerve activity (MSNA), however, this was 
subsequently refined to permit the recording of individual vasoconstrictor 
neurones (single units) (Macefield et al., 1994). 
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 Muscle sympathetic nerve activity is closely related to blood pressure 
and the arterial baroreflex. Negative feedback through the baroreflex results 
in bursts in MSNA that are pulse synchronous. Indeed, bilateral baroreceptor 
deactivation through injection of lidocaine around the vagus and 
glossopharyngeal nerves in the neck abolishes the rhythmicity of MSNA in 
humans (Fagius et al., 1985). This technique is rather crude as anaesthetic 
was applied to these nerves as they exited the skull thereby affecting other 
afferent information e.g. from cardiopulmonary receptors, however, animal 
studies confirm that complete baroreceptor denervation abolishes pulse 
synchronous muscle sympathetic nerve activity (Gebber, 1980). Further 
confirmation of the importance of the baroreflex in the regulation of 
sympathetic nerve activity comes from stimulation of the carotid sinus nerve 
which led to a decrease in MSNA activity (Wallin et al., 1975). 
Microneurography has contributed much to the study of sympathetic activity, 
however, its application is restricted to superficial peripheral nerves and, 
unlike regional noradrenaline spill-over studies, cannot provide information 
on regional variations in sympathetic activity. Combining both invasive and 
non-invasive measures of autonomic function has led to the appreciation of 
the role of sympathetic activation in many conditions including heart failure. 
 
1.2.3 Sympathoexcitation and heart failure 
Heart failure is a complex syndrome arising from an abnormality in heart 
structure or function at rest that prevents the heart supplying adequate levels 
of oxygen to body tissues (Members et al., 2012). Heart failure is 
characterised by neurohumoral activation involving activation of the 
sympathetic nervous system and renin angiotensin system. Initially, this is 
compensatory for the initial abnormality, however, chronic sympathetic 
activation is cardiotoxic and leads to the progression of heart failure. The 
symptoms of heart failure are assessed using the New York Heart 
Association (NYHA) classification (I-IV). Patients in class I are 
asymptomatic, however, as heart failure progresses symptoms worsen. 
Patients in class II and III experience fatigue and dyspnoea that limits 
physical activity and patients in class IV experience dyspnoea even at rest. 
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Heart failure is a leading cause of mortality and it is estimated that 45-60% 
of patients die within 5 years of diagnosis (Bui et al., 2011). 
The first evidence of sympathetic activation in heart failure came from 
analysis of catecholamine excretion in urine from heart failure patients (n = 
110) compared to normal subjects (n = 13) (Chidsey et al., 1965). 
Noradrenaline excretion was significantly higher in NYHA class III and IV 
heart failure patients (46.4 and 58.1µg/day respectively) compared to normal 
subjects and combined class I and II heart failure patients (22.5 and 22.4 
µg/day respectively). This finding may reflect the renal sympathetic 
activation that occurs in heart failure patients (Petersson et al., 2005). 
Increased sympathetic activity in heart failure was confirmed by 
measuring plasma noradrenaline levels which were significantly elevated 
compared to control subjects and correlated with the severity of heart failure 
(Thomas and Marks, 1978). The more refined method of regional 
noradrenaline spill-over revealed not only regional differences in the degree 
of sympathetic activation in heart failure but also an impairment in 
noradrenaline reuptake. This may lead to overestimation of 
sympathoexcitation, however, cardiac noradrenaline spill-over was markedly 
higher compared to plasma and renal (Hasking et al., 1986). Importantly, the 
degree of sympthoexcitation in heart failure, measured using plasma 
noradrenaline, is correlated with an increased risk of mortality (Cohn et al., 
1984; Kaye et al., 1995) 
Further direct evidence of sympathoexcitation in heart failure comes 
from microneurography studies. The frequency of both MSNA bursts and 
single units was elevated in heart failure patients (n = 8) (Macefield et al., 
1999). Additionally, high levels of MSNA (> 49 bursts/ min) were associated 
with a significantly lower survival rate in heart failure patients followed up for 
1 year (n = 122) (Barretto et al., 2009). 
Heart rate variability is impaired in heart failure and indicates a shift in 
autonomic balance towards sympathetic predominance. The UK Heart 
Failure Evaluation and Assessment of Risk Trial (UK-HEART) (Nolan et al., 
1998) was the first large prospective study of HRV in heart failure and its 
potential in identifying patients with an increased risk of death. 433 
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outpatients with chronic heart failure were recruited and HRV was analysed 
using time domain measures. Patients with a standard deviation of all N-N 
intervals (SDNN) of < 50 ms had a mortality rate of 51.4% compared to 5.5% 
of patients with SDNN > 100 ms. This is similar to findings of studies 
investigating predictors of post myocardial infarction prognosis (Kleiger et 
al., 1987; La Rovere et al., 1998).  
Baroreflex sensitivity is another index of impaired autonomic function 
in heart failure. Both phenylephrine and non-invasive techniques have 
shown that BRS is an indicator of prognosis in heart failure. The 
phenylephrine method of BRS determination revealed that BRS of < 3 
ms/mmHg was an independent predictor of sudden death or cardiac 
transplantation in heart failure patients (n = 282) (Mortara et al., 1997). 
Impaired BRS using the spectral method (<3.1 ms/mmHg) was also 
associated with a significantly higher risk of cardiac death (n = 228) (Pinna et 
al., 2005). 
Overall, these disparate methods of assessing autonomic function 
illustrate that increased sympathetic activity is associated with poor 
prognosis in heart failure. To combat this, pharmaceutical interventions have 
targeted the sympathoexcitation underlying the pathophysiology of heart 
failure in order to alleviate symptoms and slow disease progression. 
 
1.2.4 Treatment of heart failure 
Current drug treatments for heart failure include beta blockers to combat the 
effects of sympathoexcitation. Lampert et al. (Lampert et al., 2003) 
investigated the effect of the beta blocker propanolol on HRV indices in 88 
patients hospitalised with acute MI. After 6 weeks, patients treated with 
propanolol had a significant decrease in LF/HF ratio compared to patients 
given a placebo (n= 96) indicating an improvement in sympathovagal 
balance toward parasympathetic predominance. There was also an 
improvement in outcome with a decreased incidence of death, MI or 
congestive heart failure in propanolol treated patients (9% propanolol vs 
23% placebo; p = 0.02). Carvedilol, another beta blocker, increased BRS 
and the HF frequency component of HRV and reduced cardiac 
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noradrenaline spill-over in heart failure patients treated for 4 months (n = 
10). This indicates that beta blocker therapy may also augment vagal activity 
through the withdrawal of the inhibitory effects of noradrenaline (Kubo et al., 
2005). 
Despite the availability of treatments such as beta blockers, ambulant 
outpatients with heart failure have an annual mortality rate of 10% (Nolan et 
al., 1998) therefore the development of new therapies is essential. Recently, 
increasing parasympathetic activity has become a target in the treatment of 
heart failure. 
 
1.2.3 The parasympathetic nervous system and heart failure 
Heart failure is not only characterised by sympathoexcitation but also 
parasympathetic/vagal withdrawal (Triposkiadis et al., 2009; Sabbah et al., 
2011a). Eckberg et al. (1971) first demonstrated impaired parasympathetic 
activity in heart failure patients compared to normal subjects as an impaired 
increase in heart rate in response to parasympathetic blockade using 
atropine. Heart rate increased by 55% in healthy subjects compared to 23% 
in heart failure patients. Vagally mediated heart rate recovery after exercise 
is attenuated in heart failure patients (Imai, 1994) and the magnitude of the 
increase in heart rate to parasympathetic blockade was attenuated in a 
canine model of heart failure compared to controls (Dunlap et al., 2003). 
Modulation of the parasympathetic nervous system e.g. vagus nerve 
stimulation therefore presents a new approach to altering the underlying 
autonomic imbalance in heart failure. 
 
1.3 Neuroanatomy of the vagus nerve  
The vagus nerves are the tenth and longest pair of cranial nerves and 
originate from the medulla. The vagus nerve is appropriately named as it 
derives from the Latin for ‘wanderer’. The vagus nerves exit the skull through 
the jugular foramina of the skull then pass through the neck and thorax to 
reach the abdomen. The vagus nerve is normally regarded as the main 
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parasympathetic output of the autonomic nervous system, however, it has 
many diverse functions. Indeed, counts of afferent and efferent fibres in 
silver preparations of feline cervical vagus nerve sections (n  = 11) revealed 
that it is composed of 80% afferent fibres and only 20% efferent fibres 
(DuBois and Foley, 1936).  
The afferent component of the vagus nerve consists of general 
visceral, special visceral and general somatic afferent fibres. The general 
visceral afferent fibres carry sensory information from thoracic and 
abdominal internal organs including the larynx, trachea, lungs, heart and 
gastrointestinal tract up to the splenic flexure of the colon (Figure 1.1). There 
is also some evidence of vagal afferents from the uterus (Berthoud and 
Neuhuber, 2000). The vagus nerve also carries baroreceptor and 
chemoreceptor information from the aortic arch. Special visceral afferent 
vagal fibres carry taste information from taste buds on the epiglottis. The cell 
bodies of visceral afferent sensory neurones reside in the nodose ganglion 
of the vagus nerve and project to the NTS through which they play an 
important part in the reflex control of respiration, blood pressure, heart rate, 
swallowing and digestion (Ruffoli et al., 2011). Unlike visceral afferent 
neurones, the cell bodies of the somatic afferent neurones are located in the 
jugular ganglion and project to the spinal trigeminal nucleus. The vagus 
nerve carries somatic sensory information from the lower pharynx, larynx, 
trachea, oesophagus, posterior dura mater and parts of the external ear 
(Figure 1.1). Interestingly, there are reports of activation of visceral reflexes 
in response to stimulation of the ear e.g. ear syringing can evoke cough or 
even bradycardia responses in a small percentage of the population 
(Prasad, 1984; Boghossian et al., 2010) indicating that the neuroanatomy of 
the vagus nerve is not fully understood and requires further investigation. 
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Figure 1.1 Representation of the distribution and central connections 
of the vagus nerve. All cervical and thoracic branches are bilateral 
and may have been omitted for clarity. The right recurrent laryngeal 
nerve (not shown) passes round the right subclavian artery instead of 
the arch of the aorta. Left and right vagus nerves form the oesophageal 
plexus and then become anterior and posterior trunks as they pass 
through the diaphragm to supply the abdominal viscera up to 2/3 along 
the transverse colon. NTS- nucleus tractus solitarius; DVN- dorsal 
vagal nucleus; SpV N- spinal trigeminal nucleus; NA- nucleus 
ambiguus. 
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The efferent component of the vagus nerve may be smaller but is no 
less vital. It consists of general and special visceral efferent components. 
The general visceral efferent component consists of preganglionic 
parasympathetic neurones that originate primarily in the DVN. These 
synapse in parasympathetic ganglia close to or in the walls of the organs 
they supply which are the organs of the thoracic and abdominal cavities 
including the gastrointestinal tract up to the splenic flexure of the colon. 
There is an additional contribution of preganglionic fibres from the NA 
supplying the heart. The vagus nerve has a special visceral efferent 
component that supplies the muscles of the 4th branchial pouch in the 
embryo. Neuronal tracing studies found that these motor neurones 
originated in the NA and supplied the striate muscle of the palate, larynx, 
pharynx (except stylopharyngeus) and the upper oesophagus (Bieger and 
Hopkins, 1987; Kitamura et al., 1991).  
The importance of the vagus nerve in relaying sensory information 
that influences the regulation of internal organs and its extensive distribution 
throughout the body means it is little wonder that modulation of vagal activity 
is being investigated as a possible therapy for a wide range of conditions.  
 
1.3.1 Vagus nerve stimulation 
Stimulation of the vagus nerve was first pioneered as a therapy for epilepsy 
over 100 years ago and is now an approved therapy for treatment resistant 
epilepsy. Vagus nerve stimulation (VNS) is also an approved therapy for 
treatment resistant depression in the USA and is being investigated in a 
range of other conditions including heart failure, tinnitus, obesity and 
inflammatory conditions (Clancy et al., 2013). 
 
1.3.1.1 Vagus nerve stimulation for epilepsy 
Epilepsy is one of the most common neurological disorders and is estimated 
to affect 70 million people worldwide. Epilepsy encompasses a wide number 
of syndromes characterised by recurrent seizures. The mechanisms of 
epileptogenesis are not fully understood, however, an underlying feature is 
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hyperexcitability of the cortex (Badawy et al., 2009). Approximately 30% of 
epilepsy patients have refractory epilepsy or unacceptable side effects from 
anti-epileptic drug treatment (Connor et al., 2012). Resective surgery is an 
alternative approach for treating patients with partial epilepsy where the 
epileptogenic focus can be located and removed (Connor et al., 2012). 
Refractory epilepsy patients who are not candidates for resection or whose 
epilepsy is still uncontrolled after surgery rely on palliative interventions 
including corpus callostomy, ketogenic diet and vagus nerve stimulation 
(Beleza, 2009). 
Electrical stimulation of the vagus nerve to treat epilepsy was first 
proposed in 1880s by Corning, an American neurologist. It was believed that 
cerebral hyperaemia was responsible for epilepsy, therefore, Corning 
attempted to reduce blood flow to the brain by compressing the carotid 
arteries and reducing cardiac output through transcutaneous electrical 
stimulation of the cervical vagus nerves (Corning, 1884). However, direct 
electrical stimulation of the central end of the cervical vagus nerve was later 
shown to reduce strychnine induced seizures in cats (Schweitzer and 
Wright, 1937). Further, electrical vagal stimulation desynchronised EEG 
activity in spinally transected (C1), aortic baroreceptor-denervated 
anaesthetised cats and reduced strychnine induced epileptic like activity in 
the cortex (Zanchetti et al., 1952). This demonstrated that VNS could 
modulate cortical activity independent of cardiovascular alterations and was 
dependent on vagal afferent stimulation. 
The first human studies of cervical VNS in epilepsy were conducted in 
the late 1980s (Penry and Dean, 1990; Terry et al., 1990). An electrode was 
wrapped around the left cervical vagus and connected by a lead to a pulse 
generator embedded subcutaneously below the clavicle. The generator can 
subsequently be programmed non-invasively to alter stimulation parameters. 
VNS is generally well tolerated and side effects (hoarseness, coughing, pain 
etc.) tend to be mild and transient. VNS has been used to treat over 50,000 
patients with refractory partial epilepsy and long term trials have shown VNS 
to be effective in reducing seizure frequency by 50% or more in 
approximately 40-50% of patients (Shahwan et al., 2009).  
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The mechanism by which VNS alleviates epilepsy symptoms is poorly 
understood. The original hypothesis was that stimulation of vagal afferents 
could alter the excitability of the cortex through relays in the NTS. The vagus 
nerve is composed of myelinated A- and B-fibres and unmyelinated C-fibres 
which have different activation thresholds. A-fibres have the lowest threshold 
(0.02-0.2mA), followed by B-fibres (0.4-0.6mA) and C-fibres require the 
highest stimulation parameters for activation (>2mA) (Erlanger and Gasser, 
1930). Therapeutic VNS parameters vary but are below levels required to 
activate C-fibres suggesting the anti-epileptic effects of VNS are mediated 
through A- and B-fibres (Ruffoli et al., 2011). Indeed, destruction of C-fibres 
through administration of capsaicin in rats did not affect VNS reduction of 
pentylenetetrazol (PTZ) induced seizures further supporting that C-fibres are 
not involved in the anti-epileptic mechanism of VNS (Krahl et al., 2001). This 
study was carried out using anaesthetised rats and may not apply to 
conscious animals. In addition, there is no selective method to destroy A- 
and B-fibres therefore the importance of different fibre types in VNS 
therapeutic effects requires further investigation. 
It has been suggested that VNS may alter neurotransmitter levels or 
processing in the brain. GABA is the major inhibitory neurotransmitter of the 
central nervous system and could play an important part in seizure 
reduction. Marrosu et al. (2003) investigated the possible role of GABA 
receptors in the anti-epileptic effects of VNS using single photon emission 
computed tomography (SPECT) to image GABAA receptor density before 
VNS and after 1 year of VNS therapy in 10 patients with refractory partial 
epilepsy. A significant correlation between reduced seizure frequency and 
increased GABAA receptor density suggested that increased GABA 
mediated inhibition is an important component of the VNS mechanism.  
Noradrenergic and serotonergic signalling are also altered by VNS 
and may influence epileptic activity (Dorr and Debonnel, 2006). The effects 
of VNS on locus coeruleus (LC) noradrenergic neurones and dorsal raphe 
serotonergic neurones basal firing rates were recorded extracellularly in vivo 
(rats). Long term (2 weeks to 3 months) VNS increased firing rates of both 
LC noradrenergic neurones and dorsal raphe serotonergic neurones (Dorr 
and Debonnel, 2006) which in turn influence the function of many higher 
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CNS regions (Fornai et al., 2011). Both chronic and acute LC lesions 
significantly reduced the anti-seizure effects of VNS in rats (Krahl et al., 
1998). Another hypothesis is that VNS acts to reduce inflammation 
associated with epilepsy (De Herdt et al., 2009). It therefore appears likely 
that the anti-epileptic effects of VNS are polymodal and much more work is 
required before the mechanisms involved are fully understood.  
 
1.3.1.2 Vagus nerve stimulation as a treatment for depression 
Depression is a disabling condition and it is estimated that 30-45% of major 
depressive disorder (MDD) patients are treatment resistant (Schosser et al., 
2012). Vagus nerve stimulation is also approved by the US Food for Drug 
Adminstration (FDA) for MDD treatment. Anti-depressive effects of VNS 
were first observed in patients with refractory epilepsy. Improvement in 
mood was observed even in those patients who experienced little or no 
change in seizure frequency (Harden et al., 2000). VNS for treatment 
resistant depression has been somewhat controversial due to the lack of 
controlled studies of its efficacy in depression (Martin and Martín-Sánchez, 
2012). In one randomised controlled trial of VNS in patients with depression, 
VNS performed no better than placebo (Rush et al., 2005a). However, this 
trial only lasted 10 weeks and VNS effects displayed increasing response 
rates at 3, 6, 9 and 12 months suggesting that it may be a long term 
adjunctive therapy rather than an acute treatment (Rush et al., 2005b). 
 
1.3.1.3 Vagus nerve stimulation as an anti-inflammatory therapy 
The vagus nerve is a critical component of the inflammatory reflex. This 
reflex has received much attention recently and parts of the pathway 
involved have been elucidated. The afferent arm of the reflex is the vagus 
nerve which is activated by pro-inflammatory cytokines (Tracey, 2009). The 
central pathway is unknown, however, as the vagus nerve projects to the 
NTS which in turn projects to the hypothalamus this is thought to be key in 
mediating the efferent response which is also through the vagus nerve. The 
efferent arm of this reflex is debated. Stimulation of the vagus nerve 
increases acetylcholine (ACh) release from ACh synthesising T cells in the 
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spleen (Rosas-Ballina et al., 2011). This in turn acts on the α7 nicotinic 
acetylcholine receptor expressed by macrophages to reduce cytokine 
release. Vagus nerve stimulation can reduce pro-inflammatory cytokine 
release and tissue injury in models of inflammatory diseases (Borovikova et 
al., 2000). This led to the suggestion that efferent vagal fibres may synapse 
with splenic nerves in the coeliac ganglion and thereby influence 
acetylcholine production in the spleen (Rosas-Ballina et al., 2011). However, 
electrophysiological experiments in the rat revealed that stimulation of vagal 
efferents had no effect on the splenic nerve activity (Bratton et al., 2012). 
Furthermore, combining retrograde tracing of splenic nerve fibres and 
anterograde tracing of vagal efferents revealed no putative synaptic contacts 
using confocal analysis (Bratton et al., 2012). This provides strong evidence 
that the anti-inflammatory effects of VNS are not mediated through the 
splenic nerve and require further investigation.  
Whilst the mechanisms underlying the anti-inflammatory reflex are 
unknown, this reflex is a potential therapeutic target in many conditions in 
which excessive inflammation plays a role in tissue damage, including heart 
failure. Indeed, VNS attenuated the increase in plasma C reactive protein (a 
marker of systemic inflammation) compared to the control group in a canine 
model of heart failure (Zhang et al., 2009b). 
 
1.3.1.4 Vagus nerve stimulation to reverse pathological remodelling in 
tinnitus 
The potential neuroplastic effects of VNS through alterations in CNS 
neurotransmitter levels and/or processing have led to considering VNS as a 
potential therapy for tinnitus. Tinnitus is the perception of ‘ringing in the ear’ 
despite the absence of an external sound. Persistent tinnitus affects 
approximately 10-15% of the population over their lifetime and can impair 
the ability to concentrate, follow conversations or it can even disturb sleep 
(Baigi, 2011; Schnupp, 2011). Tinnitus is usually caused by excessive noise 
exposure that leads to pathological plasticity of the auditory cortex. Engineer 
et al. (2011) investigated a potential method to reverse this process in a rat 
model of tinnitus by playing tones (outside the putative tinnitus frequencies) 
- 29 - 
and simultaneously stimulating the left cervical vagus nerve to induce and 
target plasticity. After 10 days of VNS paired with tones, noise exposed rats 
significantly improved in detecting a gap in presented background noise 
compared to sham treated rats. This improvement persisted for the 3 weeks 
tested post-treatment. A neurophysiological correlate was determined since 
tinnitus-induced increases in auditory cortical responses to tone presentation 
were almost reversed by VNS. These results have led to a clinical pilot study 
of VNS paired with tones in patients with tinnitus (n = 12) (Vanneste et al., 
2012). 4 weeks of treatment resulted in improved symptoms indicating that 
this may be an effective therapy for tinnitus. The potential for VNS to induce 
cortical plasticity is very exciting and could be exploited in the treatment of 
many conditions. Indeed, pairing VNS with movement increased motor 
cortical representation of the movements (Porter et al., 2011). This could 
potentially be used to treat movement disorders including the rehabilitation 
of stroke patients. 
 
1.3.1.5 Obesity and vagus nerve stimulation 
Weight loss has been observed in patients receiving VNS therapy for 
epilepsy and may be a welcome side effect for some patients (Burneo et al., 
2002). This observation was also made in a group of patients receiving VNS 
for refractory depression. Furthermore, the degree of weight loss correlated 
with baseline BMI (Pardo et al., 2007). This has led to the investigation of 
VNS as a potential strategy to tackle obesity. The vagus nerve plays an 
important role in satiety, signalling gastric distension and the release of 
gastrointestinal hormones such as cholecystokinin and leptin (Berthoud, 
2008). The vagus nerve therefore offers a potential target to modify appetite, 
however, results are conflicting. Another study investigating the effects of 
VNS on weight loss in epilepsy patients found no significant effect (Koren 
and Holmes, 2006). These patients were followed up for 2 years after VNS 
therapy commenced, similar to the other studies, however baseline BMI 
information is not provided. Since the degree of weight loss is dependent on 
BMI (Pardo et al., 2007) then it may be that the participants recruited in this 
study were already under the threshold for a significant effect of VNS. 
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 There has been no dedicated study of the effects of VNS on weight 
loss in obese humans, however, animal studies report positive results. 
Stimulation of the left subdiaphragmatic vagus nerve reduced food intake 
and weight gain in rats fed a high fat diet (Gil et al., 2011), however, this is 
not a suitable model for weight loss in obesity. To combat this, Val-Laillet et 
al. (2010) utilised obese mini-pigs (n = 8) to study the effects of bilateral 
stimulation of the thoracic vagus nerves. VNS did not cause weight loss, 
however, weight gain was significantly lower in VNS animals compared to 
sham from 5 weeks post operatively until the end of the study (14 weeks). In 
addition, VNS animals consumed significantly less compared to sham 
animals. Intriguingly, VNS also altered the food preferences of treated 
animals with a diminished preference for sweet food (Val-Laillet et al., 2010). 
These results are encouraging, however, the sample numbers used in the 
animal studies are small. Larger studies are required to confirm these 
findings before VNS can be investigated in obese humans. 
 
1.3.1.5 Vagus nerve stimulation as a potential heart failure therapy 
Early support of VNS in heart failure came from animal studies. In a canine 
model of heart failure (healed MI) there was a significant reduction in the 
number of dogs with ventricular fibrillation during exercise and coronary 
artery occlusion in the group that received VNS compared to the control 
group (10% vs. 92%) (Vanoli et al., 1991). This striking result indicates that 
vagal stimulation is protective against ventricular fibrillation. Indeed, when 
exercise was repeated in the VNS group with the stimulators switched off, 
89% developed ventricular fibrillation. VNS also improved survival in a rat 
model of chronic heart failure. Compared to the control heart failure group, 
the vagal stimulation heart failure group had improved left ventricular 
function, decreased biventricular weight and a 73% reduction in relative risk 
ratio of death (Li et al., 2004). Interestingly, the VNS treated heart failure rats 
also had significantly reduced plasma noradrenaline levels indicating 
attenuated sympathetic activation compared to the control heart failure 
group. The autonomic effects of VNS were also investigated in a canine 
ventricular pacing heart failure model (Zhang et al., 2009a). LF/HF ratio was 
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significantly lower in VNS treated heart failure dogs with significantly 
reduced LF power and increased HF power indicating a shift towards 
parasympathetic predominance. BRS was also significantly increased in the 
VNS group and plasma noradrenaline and C reactive protein levels were 
reduced. These results corroborate evidence that VNS may reduce 
sympathetic activation and may also increase parasympathetic activity in 
heart failure. In addition, these results suggest that VNS has an anti-
inflammatory effect that may be beneficial in heart failure. These numerous 
beneficial effects are encouraging, however, this study also reported side 
effects including coughing, retching, vomiting and reduced food intake. 
Dedicated research into the cardiovascular autonomic effects of VNS 
in humans is sparse, however Kamath et al. (1992) studied the effect of VNS 
of the left cervical vagus nerve on HRV in 8 epilepsy patients. Patients in the 
low stimulation group (n = 4; 2 Hz, 130 ms pulse) showed no significant 
change in LF/HF ratio after two weeks of stimulation whereas patients in the 
high stimulation group (30 Hz, 500 ms pulse) showed a significant decrease 
in LF/HF ratio and a significant increase in HF power indicative of increased 
vagal tone.  
The first clinical study of VNS in heart failure patients was conducted 
by Schwartz et al. (2008), in which 8 patients with advanced heart failure 
reported improved quality of life scores and had improved left ventricular 
function at 1, 3 and 6 months. Extension into a multicentre trial with an 
additional 24 heart failure patients revealed that chronic right sided VNS 
could improve NYHA classification, quality of life scores and left ventricular 
function at 3 months and these changes were maintained or accentuated at 
1 year follow up (De Ferrari et al., 2011). These results are encouraging, 
suggesting VNS may be a powerful adjunctive therapy to improve the 
symptoms and quality of life of heart failure patients, however, VNS is an 
invasive and expensive procedure that is associated with complications and 
side effects. This includes technical and surgical complications such as 
wound infection, cardiac arrhythmia under test stimulation and electrode 
malfunction (Spuck, 2010). In addition, side effects include hoarseness, 
dysphagia, cough and pain (Elliott et al., 2011). A non-invasive method of 
VNS with reduced side effects is desirable. The vagus nerve has a small 
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cutaneous distribution to the external ear through the auricular branch of the 
vagus nerve (ABVN). This offers an easily accessible point for non- invasive 
VNS.  
 
 
 
 
Figure 1.2 The peripheral distribution of the auricular branch of the 
vagus nerve. The shaded area represents the distribution of the ABVN 
(extrapolated from (Peuker and Filler, 2002)). T – tragus, C – concha, 
CyC – cymba concha. 
 
 
 
1.3.2 The auricular branch of the vagus nerve 
The auricular branch of the vagus nerve (ABVN) originates from the superior 
(jugular) ganglion and traverses the temporal bone to reach the external ear. 
Information regarding the terminal distribution of the ABVN is sparse. Peuker 
& Filler (2002) dissected 14 ears in 7 human cadavers and demonstrated 
that the ABVN was the sole innervation of the cymba conchae (100%). They 
also reported that the ABVN contributed to innervation of the antihelix (73%), 
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tragus (45%) and cavity of concha (45%; Figure 1.2). The variability of the 
distribution of the ABVN is unknown, therefore, further investigation of the 
terminal distribution of the ABVN is required to confirm this finding.  
 
1.3.2.1 Central projections of the auricular branch of the vagus nerve 
Little is known about the central projections of the ABVN. Chien et al. (1996) 
traced the central projections of auricular nerves in the dog. The rostral, 
middle or caudal auricular nerves were isolated in the pinna and treated with 
cholera toxin subunit B conjugated with horse radish peroxidise (CTB-HRP) 
but this included the trigeminal, facial and vagus nerves. The rostral 
auricular nerve of the dog is regarded as the auriculotemporal branch of the 
trigeminal nerve. Chien et al. (Chien et al., 1996) found that the majority of 
fibres of the middle and caudal auricular nerves were vagal (88% and 79% 
respectively) with some fibres from the facial nerve. Labelling from the 
middle and caudal auricular nerves was found in the spinal trigeminal 
nucleus, the cuneate nucleus, DVN, and NTS. Afferents from the ear 
projecting to the NTS could be involved in autonomic control (Chien et al., 
1996).  
Nomura & Mizuno (1984) provide the only study of the central 
projections of the ABVN alone. Using cats, they isolated the ABVN in the 
mastoid canaliculus of the temporal bone before it reached the facial canal 
and used HRP to trace its central connections in the brainstem. The results 
showed that fibres of the ABVN project to the principle sensory trigeminal 
nucleus, spinal trigeminal nucleus, cuneate nucleus and NTS, similar to the 
findings of Chien et al. (1996). The principle sensory trigeminal nucleus and 
spinal trigeminal nucleus are both responsible for somatic sensation. It is 
interesting that some of the fibres from the ABVN terminated in the NTS of 
the brainstem as this is where general visceral afferents terminate. 
Moreover, these terminations were located in the dorsomedial part of the 
caudal NTS which corresponds with the subdivision of the NTS that receives 
baroreceptor afferents (Ciriello et al., 1981). This indicates that the ABVN 
may be capable of influencing cardiovascular and visceral autonomic control 
through the NTS.  
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The ABVN has been reported to mediate several somatovisceral 
reflexes the most common being the ear-cough reflex (Arnold’s reflex) 
(Gupta et al., 1986; Tekdemir et al., 1998). This reflex can be elicited by 
impacted cerumen, foreign bodies or syringing the ear. The incidence of this 
reflex is estimated to be 2.3% by Tekdemir et al. (1998) who examined 514 
patients (admitted to the ear, nose and throat department) using a blunt 
probe to palpate the external auditory meatus. Gupta et al. (1986) used the 
same method to study 500 randomly selected out-patients and found a 4.2% 
incidence. Gupta et al. (1986) also observed the auriculo-palatal reflex (gag 
reflex) in 1.8%, the auriculo-lacrimal reflex in 2% and the auriculo-cardiac 
reflex (auricular syncope) in 0.6%. Another interesting phenomenon 
involving the ABVN is pain referred to the external ear from viscera supplied 
by the vagus nerve in conditions such as lung cancer (Bindoff and Heseltine, 
1988; Abraham et al., 2003; Palmieri, 2006), gastroeosophageal reflux 
(Blau, 1989) and myocardial infarction (Rothwell, 1993; Amirhaeri, 2010). 
Furthermore, cervical vagus nerve stimulation has also been reported to 
cause ear pain (Myers, 2008; Schwartz et al., 2008). The ABVN may 
therefore provide a non-invasive alternative to cervical VNS, that could be 
accessible to many more patients than surgical implantation of an electrode 
round the cervical vagus nerve. 
 
1.3.3 Transcutaneous vagus nerve stimulation  
Stimulation of the peripheral distribution of the ABVN to the external ear – 
transcutaneous vagus nerve stimulation (tVNS) – is receiving increasing 
interest as a non-invasive method of VNS. Electroencephalography (EEG) 
revealed that tVNS of the tragus elicits vagus sensory evoked potential 
(VSEPs; n = 6) (Fallgatter et al., 2003). These had a similar latency to 
cochlear nerve evoked potentials (2-5 ms) and were only produced by 
stimulation of the tragus. Stimulation of other parts of the ear not supplied by 
the ABVN (ear lobe, scapha, superior crus of the antihelix and the top of the 
helix) did not produce a VSEP. Functional magnetic resonance imaging 
(fMRI) during tVNS of the tragus revealed similar activation patterns to 
conventional VNS (Kraus et al., 2007). Recently, these results have been 
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confirmed and strengthened with the inclusion of a sham stimulation 
comparison (Kraus et al., 2013). Furthermore, this study found changes in 
brainstem signals of the NTS and locus coeruleus during tVNS of the 
anterior auditory canal (i.e. inner tragus) but not the posterior auditory canal. 
These results indicate that the tragus may be an acceptable site for tVNS. 
Few studies have investigated the cardiovascular effects of tVNS 
(Table 1.1 and Table 2.2). Electroacupuncture and manual acupuncture of 
the concha caused a significant decrease in heart rate and blood pressure in 
anaesthetised rats (n = 18) (Gao et al., 2008). The mechanisms behind 
these effects were investigated through extracellular recordings of cardiac-
related NTS neurones during manual acupuncture of the concha (n = 58 
rats) (Gao et al., 2011). Neurones were classified as cardiac-related if they 
displayed spontaneous activity synchronised with the R peak of the ECG (n 
= 34). The firing rate of these neurones increased during stimulation while 
blood pressure and heart rate decreased. Intravenous administration of 
atropine attenuated the decrease in heart rate and blood pressure in 
response to stimulation and also attenuated the increased firing rate of 
cardiac-related neurones in the NTS. These results indicate that the NTS 
plays a key role in mediating the cardiovascular effects of tVNS. tVNS of the 
right tragus using surface electrodes has also been found to suppress atrial 
fibrillation in a canine rapid atrial pacing model (n = 10) (Yu et al., 2013). 
Crucially, this effect was abolished by sectioning left and right vagus nerves 
indicating that these must also be intact. 
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Table 1.1 Animal studies of VNS and tVNS 
Paper Animal VNS location VNS Parameters Results 
Gao et al. 
(2008) 
Rats – healthy (n = 
18) 
A1-apex helix  
A2-middle of helix 
A3-tail of helix  
A4-inferior concha 
A5- middle 
antihelix 
Electroacupuncture for 30 s 
at: 4 Hz; 0.4 mA; 4 Hz; 1.0 
mA; 100 Hz; 0.4 mA; 100 Hz; 
1.0 mA 
Manual acupuncture for 30s 
Low frequency electroacupuncture (EA) had no 
significant effects. High frequency EA evoked a 
significant decrease in BP at all 5 areas and heart 
rate at A3, A4 and A5. Manual acupuncture 
reduced heart rate only in A4 and BP in A1, A3 and 
A4. 
Gao et al 
(2011) 
Rats – healthy (n = 
58) 
Inferior concha Manual acupuncture Significant decrease in HR and BP and increase in 
firing rate of cardiac related neurons in NTS. Effect 
eliminated by intravenous atropine.  
Li et al. 
(2003) 
Rats – 1 month after 
MI (VNS = 11; 
control = 13) 
Right cervical 
vagus nerve 
0.2 ms; 20 Hz; 0.1-0.13 mA 
for 6 weeks 
Significantly lower heart rate 40bpm and improved 
left ventricular haemodynamics. Significantly lower 
mortality (14% vs 50% p = 0.008). No effect on BP.  
Tsutsumi 
et al. 
(2008) 
Mice – 28 days after 
MI (VNS = 6; control 
= 6) 
Right cervical 
vagus 
1 ms; 500 mV; 10 Hz for 
15mins. 
Decrease in heart rate 10% below baseline and a 
significant reduction in cardiac norepinephrine level 
Vanoli et 
al. (1991) 
Dogs – 1 month 
after MI (VNS = 30; 
control = 24) 
Right cervical 
vagus nerve 
3 ms; 3-8 Hz; 1.0-3.0 mA 
during exercise and 
ischaemia test 
VF significantly (p < 0.001) lower in VNS group 
compared to control group (11.5% vs. 92%) 
Yu et al., 
(2013) 
Dogs – 6 hours rapid 
atrial pacing (n = 10) 
Right tragus 1 ms; 20 Hz; 80% below 
voltage required to slow sinus 
rate 
Increased effective refractory period and 
suppressed atrial fibrillation. Eliminated by 
sectioning left and right vagi. 
Zhang et 
al. (2009) 
Dogs – 8 weeks into 
high rate ventricular 
pacing (VNS = 8; 
control = 7) 
Right cervical 
vagus 
1.5 mA ± 0.6 mA; 20Hz; for 8 
weeks 
No effect on BP. Left ventricular function improved 
in VNS group. After 4 weeks VNS group had 
significant increase in HF power and lower LF/HF 
ratio; improved BRS; lower plasma levels of CRP 
and NA. 
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Table 1.2 Studies of tVNS in healthy humans 
Paper Sample 
Group 
Study Design Electrode 
positions 
Stimulation 
parameters 
Study outcomes 
Fallgatter et 
al. (2003) 
Healthy 
participants 
(n = 6) 
Pilot study Right tragus, ear 
lobe, helix, anti-
helix,  
scapha 
0.1 ms pulses of 8 mA 
at 2 s intervals. 
Vagus Sensory Evoked Potentials 
(VSEP) only elicited with stimulation 
of the tragus. 
Haker et al. 
(2000) 
Healthy 
participants  
(n = 12) 
Pilot study Left concha Manual acupuncture 
25 mins with manual 
stimulation every 5th 
min. 
Significant increase in HF during 
stimulation and post-stimulation 
period of 60mins. No significant 
change in heart rate or BP 
Kraus et al. 
(2007) 
Healthy 
participants 
(n = 8)  
Pilot study Left tragus 20 µs; 8 Hz; 30.7-33.1 
V for 4x30 s at 1 min 
intervals.  
No effects on heart rate or BP. fMRI 
shows similar activation pattern to 
invasive VNS. 
Kraus et al., 
2013 
Healthy 
participants 
(n = 16) 
Sham 
controlled 
crossover 
study 
Left auditory canal: 
anterior wall or 
posterior wall 
20 µs; 8 Hz; 14 – 57 V 
for 4x30s at 1 min 
intervals. 
fMRI during tVNS of anterior 
auditory wall shows similar activation 
pattern to invasive VNS plus 
changes in brainstem areas. 
La Marca et 
al. (2010) 
Healthy 
participants 
(n = 14) 
Sham 
controlled 
cross-over 
study 
Left concha Manual + electro-
acupuncture 30 
minutes 
2.65 V; 0.5 s; 10 Hz 
Manual acupuncture no effect, 
electroacupunture increased 
respiratory sinus arrhythmia.  
Polak et 
al.(2009) 
Healthy 
participants 
(n = 20) 
Pilot study Left and right tragus 5-10 mA; 0.1 ms at 2 s 
intervals 
Optimal intensity 8mA for VSEP 
detection without pain. No effect of 
side or gender on VSEP amplitude. 
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Only two studies have specifically investigated the autonomic effects of 
tVNS in humans. Manual acupuncture of the left concha in healthy 
volunteers caused no change in heart rate or blood pressure, however, HRV 
analysis revealed a significant increase in the HF component, representing 
vagal modulation of heart rate, during stimulation (n = 12) (Haker et al., 
2000). Electroacupuncture of the same site (left concha) was also found to 
increase respiratory sinus arrhythmia mediated by the vagus nerve (n = 14) 
(La Marca et al., 2010). These results suggest that tVNS may be capable of 
modulating cardiovascular autonomic control and merits further 
investigation. Indeed, electroacupuncture of the concha has been reported 
to alleviate symptoms in coronary artery disease patients and reduce the 
use of vasodilator medication (Zamotrinsky et al., 1997; Zamotrinsky et al., 
2001). 
Vagus nerve stimulation is not the only neuromodulatory technique 
currently receiving interest. Transcranial direct current stimulation (tDCS) is 
a non-invasive neuromodulatory technique used to influence cortical 
excitability. This is under investigation in a range of conditions including 
depression (Brunoni et al., 2013a), pain (Borckardt et al., 2011), Parkinson’s 
disease (Pereira et al., 2013) and stroke rehabilitation (Schulz et al., 2013). 
 
1.4 Transcranial direct current stimulation 
Neuromodulation, the alteration of nerve activity through the use of targeted 
electrical stimulation or pharmacology, is a rapidly advancing field with 
applications in a plethora of conditions that have previously proven difficult to 
treat. In addition to vagus nerve stimulation (Section 1.3.1) other 
neuromodulation techniques, such as renal nerve ablation and carotid sinus 
stimulation, are being investigated as potential therapies for treatment 
resistant hypertension (Esler et al., 2010; Jordan et al., 2012). Another 
neuromodulatory technique of interest is transcranial direct current 
stimulation (tDCS). 
The use of cranial electric therapy dates back to the Roman physician 
Scribonius Largus (AD 46) who applied live electric torpedo fish to the scalp 
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to treat headache (Kellaway, 1946). Pliny the Elder and the Greek physician 
Galen also described similar findings and the Muslim physician Ibn-Sidah 
(11th century) recommended the use of live electric catfish applied to the 
forehead to treat epilepsy (Kellaway, 1946). Scientific investigations of the 
effects of electrical cranial stimulation were not carried out until much later 
when Galvani and Volta (18th century) introduced the field of 
electrophysiology (Priori, 2003). Indeed Galvani’s nephew, Aldini, reported 
the successful use of transcranial galvanic/direct current stimulation in the 
treatment of melancholia in 1804 (Priori, 2003). The results of subsequent 
tDCS studies were variable and, with the introduction of electroconvulsive 
therapy (ECT) by Bini and Cerlutti in the 1930s (Endler, 1988), interest in 
tDCS diminished (Stagg and Nitsche, 2011). ECT is still currently used in 
therapy resistant depression (Kellner et al., 2012), however, the principles 
between this and tDCS differ significantly. ECT is performed using much 
higher currents (200 – 900 mA) (d'Elia G, 1983) with the aim of inducing 
seizure activity whereas tDCS is performed at 1 mA and modulates 
spontaneous neuronal activity (Nitsche et al., 2003b). tDCS was revived in 
recent years due to improved understanding of the mechanisms involved. 
 
1.4.1 Mechanisms of transcranial direct current stimulation  
tDCS has been shown to influence the spontaneous activity of cortical 
neurones. In vivo studies, applying direct current directly to the cortex in cats 
and rodents, have shown a sub-threshold depolarisation of the resting 
membrane potential of neurones underlying the anode (positive electrode) 
(Creutzfeldt et al., 1962; Bindman et al., 1964; Purpura and McMurtry, 1965; 
Nitsche and Paulus, 2000). Anodal tDCS does not directly elicit action 
potentials, rather the sub-threshold depolarisation enables other inputs to 
reach threshold. This was demonstrated by measuring motor evoked 
potentials (MEPs) elicited using transcranial magnetic stimulation before and 
during anodal tDCS. The amplitude of MEPs was significantly higher during 
anodal tDCS (1 mA) compared to baseline (Nitsche and Paulus, 2000). 
Conversely, beneath the cathode (negative electrode) there is 
hyperpolarisation causing a decrease in spontaneous neuronal activity 
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(Creutzfeldt et al., 1962; Bindman et al., 1964; Purpura and McMurtry, 1965; 
Nitsche and Paulus, 2000). 
 Remarkably the polarity specific alteration in cortical activity persists 
after stimulation has ceased. In vivo, direct current stimulation of 5-10 
minutes resulted in effects that lasted 1-5 hours (Bindman et al., 1964). The 
effects of tDCS in humans are similar with effects lasting up to 90 minutes 
after 13 minutes of stimulation (Nitsche and Paulus, 2000, 2001). The long-
term effects of tDCS depend on both the duration and strength of current 
application (Bindman et al., 1964; Purpura and McMurtry, 1965) and are 
thought to be mediated by N-methyl-D-aspartate (NMDA) receptors (Stagg 
and Nitsche, 2011). Indeed, the residual effects of both anodal and cathodal 
tDCS in healthy humans (n = 11) were blocked using dextromethorphan 
(DMO), an NMDA receptor antagonist (Liebetanz et al., 2002). This suggests 
that synaptic plasticity, such as long term potentiation or long term 
depression, mediates the effects of tDCS (Lang et al., 2005; Stagg and 
Nitsche, 2011). 
Positron emission tomography of regional cerebral blood flow (rCBF) 
has shown that the effects of tDCS are not limited to the area of cortex 
underlying the electrode. Both anodal and cathodal tDCS caused 
widespread changes in rCBF not only in other areas of the cortex but also in 
subcortical structures (Lang et al., 2005). Modelling studies also predict 
widespread distribution of the electric field used in tDCS suggesting that it 
may even induce an electric field in the brainstem (Im et al., 2012). While 
widespread activation of the cortex may facilitate plasticity, there is potential 
that this may have unintentional effects on brain function. For example, this 
may affect central regulation of autonomic function, not only through the 
possible spread of the electrical field to the brainstem but also through 
cortical projections from the areas under stimulation that may influence 
autonomic control. The potential effects of tDCS on autonomic function have 
received little attention and the results are conflicting (Table 1.3) (Accornero 
et al., 2007; Vandermeeren et al., 2010; Montenegro et al., 2011; Raimundo 
et al., 2012). This may be due to the different electrode positions and 
stimulation parameters used in these studies. As tDCS is being investigated 
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as potential therapy in patient groups that often exhibit autonomic 
dysfunction e.g. stroke patients, this merits further consideration. 
 
1.4.2 tDCS in stroke rehabilitation therapy 
The ability of tDCS to modulate cortical excitability and perhaps induce 
synaptic plasticity led to investigation of tDCS as a therapy to enhance 
stroke motor rehabilitation. Approximately 56% of stroke patients suffer 
marked hemiparesis up to 5 years post stroke (Bolognini et al., 2009). This 
limits the ability of patients to carry out activities of daily life, reducing 
independence and quality of life scores. Anodal tDCS over the motor cortex 
improved motor learning (Boggio et al., 2006; Reis et al., 2009) in healthy 
subjects and improved motor function in stroke patients compared to sham 
stimulation (Fregni et al., 2005b; Boggio et al., 2007; Stagg et al., 2012). To 
date, tDCS studies involving stroke patients are few with small sample 
numbers, however, a recent meta-analysis of tDCS in motor rehabilitation 
found significant improvement compared to sham (Butler et al., 2013).
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Table 1.3 Studies of the effects of tDCS on autonomic variables 
Paper Sample Group Electrode Positions Stimulation 
Parameters 
Study Outcomes 
Accornero et al. 
(2007) 
Healthy participants (n = 
20) 
Occipital region and 
neck base 
1 mA for 3 or 10 
mins 
No change in heart rate, blood 
pressure or body temperature 
during anodal or cathodal tDCS. 
Montenegro et 
al. (2011) 
Healthy participants; 
athletes (n = 10) and non–
athletes (n = 10) 
Left temporal lobe (T3) 
and contralateral 
supraorbital region 
2 mA for 20 mins Anodal tDCS increased HF 
component of HRV and reduced 
LF/HF in athletes. No effect in 
non-athletes. 
Raimundo et al. 
(2012) 
Healthy participants (n = 
50) 
Left motor cortex (C3) 
and contralateral 
supraorbital region 
1mA for 20 mins No change in heart rate, blood 
pressure, body temperature or 
respiratory rate. 
Vandermeeren 
et al. (2010) 
Healthy participants (n = 
30) 
Midline frontal cortex 
(Fz) and right tibia 
1mA for 20 mins Compared to sham stimulation 
there was no effect on heart rate, 
blood pressure, respiratory rate 
or HRV. 
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1.4.3 tDCS in the treatment of depression 
A greater understanding of the mechanisms underlying tDCS has led to 
consideration of this technique in the treatment of major depressive disorder 
(Fregni et al., 2005), however, the results are conflicting. Anodal tDCS over 
the left dorsolateral prefrontal cortex has been reported to cause a 
significant improvement in mood in MDD patients compared to sham tDCS 
(Fregni et al., 2006a; Loo et al., 2012). Conversely, this technique has been 
reported to perform no better than sham tDCS (Palm et al., 2012). A meta-
analysis of randomised control trials of tDCS in MDD patients found no 
difference between active and sham conditions (Berlim et al., 2013). 
Subsequently, the efficacy of tDCS compared to a selective serotonin 
reuptake inhibitor (sertraline) has been investigated in MDD patients (n = 
120). There was a significant improve in depression scores in the active 
tDCS group compared to sham. Furthermore, combined tDCS and sertraline 
treatment resulted in a significant improvement compared to either treatment 
on its own (Brunoni et al., 2013b). Further investigation into the anti-
depressive effects of tDCS is warranted, particularly as tDCS may offer an 
alternative to ECT in treatment resistant depression. 
 
1.4.4 tDCS and cognition 
Alterations in cortical excitability are observed in cognitive processes which 
has led to investigation of tDCS as a potential method to improve cognition 
(Kuo and Nitsche, 2012). Anodal tDCS over the posterior parietal cortex 
improved attention in healthy humans during a visual exploration task 
(Bolognini et al., 2010). Working memory was also improved by anodal tDCS 
over the left dorsolateral prefrontal cortex in healthy humans who were 
asked to recall specific letters (Ohn et al., 2008). Interestingly, studies of 
tDCS in patients with depression also found improvements in working 
memory and attention (Fregni et al., 2006a; Loo et al., 2012). The effects of 
tDCS on cognition may contribute to the improvement in symptoms reported 
in depression patients.  
tDCS has also been investigated in learning and long term memory 
studies. Anodal tDCS of the left motor cortex in healthy humans over three 
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sessions improved learning of a visually guided pinch task (Schambra et al., 
2011) supporting the application of tDCS in stroke rehabilitation. In addition, 
anodal tDCS has also been reported to improve verbal learning (de Vries et 
al., 2009) and arithmetic abilities (Cohen Kadosh et al., 2010) in healthy 
volunteers by targeting different areas of the cortex (Broca’s area and right 
parietal lobe respectively). There are few studies of the cognitive effects of 
tDCS, however, the potential ability of tDCS to improve learning may have 
ethical implications in the future. 
 
1.4.5 tDCS and chronic pain therapy 
The prevalence of chronic pain in the adult European population is estimated 
to be around 19% and can severely impact quality of life (Luedtke et al., 
2012). Chronic pain is often unresponsive to pharmacological therapy 
therefore surgical interventions, including brain stimulation, are being 
investigated. A multi-centre trial of deep brain stimulation of the 
periaqueductal grey matter or the thalamus showed modest improvements in 
short term pain perception in patients (3 and 6 months) but was not effective 
long term (Coffey, 2001). Stimulation of the motor cortex has also been 
investigated in chronic pain patients and reduced pain perception (Lima and 
Fregni, 2008), however, this is an invasive technique requiring surgery. 
tDCS over the motor cortex has been proposed as a non-invasive alternative 
therapy in chronic pain. Preliminary results of clinical studies indicate that 
anodal tDCS over the motor cortex may reduce pain in a range of 
neuropathic pain conditions including spinal cord injury (Fregni et al., 2006b; 
Soler et al., 2010), fibromyalgia (Fregni et al., 2006c) and chronic pelvic pain 
(Fenton et al., 2009). These results suggest that tDCS may be a non-
invasive method to alleviate pain symptoms, however, the studies are based 
on small sample groups and larger control trials are required. 
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1.5 General Hypothesis 
It is possible to non-invasively alter autonomic function using 
neuromodulatory techniques. Transcutaneous vagus nerve stimulation and 
transcranial direct current stimulation will alter cardiovascular autonomic 
function.  
 
1.6 Aims and Objectives 
The aim of this thesis was to investigate the effects of 2 non-invasive 
neuromodulatory techniques on cardiovascular autonomic function. These 
techniques were transcutaneous vagus nerve stimulation (tVNS) and 
transcranial direct current stimulation (tDCS). The objectives for the tVNS 
study were to:  
1. investigate the effects of tVNS on non-invasive estimates of 
cardiovascular autonomic function (HRV and BRS) in healthy human 
volunteers 
2. determine the optimal stimulation parameters and electrode 
placement for tVNS to increase parasympathetic predominance 
3. investigate the mechanisms of tVNS effects on cardiovascular 
autonomic control through direct recordings of sympathetic nerve 
activity (microneurography) and neuronal tracing of the ABVN in fixed 
human tissue 
4. investigate the effects of tVNS on HRV and BRS in heart failure 
patients 
5. investigate the tolerability of tVNS in HF patients 
The objectives for the tDCS study were to: 
1. investigate the effects of anodal and cathodal tDCS on non-invasive 
estimates of cardiovascular autonomic function (HRV and BRS) in 
healthy human volunteers 
2. investigate the mechanisms of tVNS effects on cardiovascular 
autonomic control through direct recordings of sympathetic nerve 
activity (microneurography). 
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Chapter 2 
The influence of transcutaneous vagus nerve stimulation on 
autonomic function 
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2.1 Introduction 
Electrical stimulation of the cervical vagus nerve has been approved for 
treatment resistant epilepsy in Europe and the USA for over 15 years 
(Shahwan et al., 2009). VNS is also an approved therapy for treatment 
resistant depression in the USA (Milby et al., 2008) and has been 
investigated as a potential therapy for a wide range of conditions including 
inflammation (De Herdt et al., 2009), Alzheimer’s disease (Merrill et al., 
2006), obesity (Val-Laillet et al., 2010), chronic pain (Kirchner A. et al., 2000) 
and tinnitus (Engineer et al., 2011). Indeed, VNS has proven effective in pilot 
studies for the treatment of heart failure (Schwartz et al., 2008) and in a 
subsequent multi-centre trial that is on-going (ClinicalTrials.gov Identifier: 
NCT01303718)(De Ferrari et al., 2011). However, despite positive 
indications from pilot studies, large scale trials are rare. 
One factor that may hinder larger trials is the invasive nature of VNS. 
VNS requires surgical implantation of a bipolar electrode around the cervical 
vagus nerve and implantation of a generator subcutaneously in the thoracic 
wall. This is associated with technical and surgical complications including 
wound infection, cardiac arrhythmia under test stimulation and electrode 
malfunction (Spuck, 2010). In addition, side effects include hoarseness, 
dysphagia, cough and pain (Elliott et al., 2011).  
A potential non-invasive route for VNS is electrical stimulation of the 
auricular branch of the vagus nerve (ABVN), which is distributed to the 
external ear (Peuker and Filler, 2002). This stimulation can be performed 
transcutaneously by applying surface electrodes or acupuncture needles to 
the external ear (tVNS). tVNS has been piloted in some patient groups as an 
alternative to implanted VNS e.g. tinnitus (Lehtimäki et al., 2012). Short term 
tVNS (7 treatments lasting 45-60 mins over 10 days) paired with sound 
therapy in tinnitus patients decreased perception of tinnitus and improved 
mood and symptoms assessed using questionnaires (n = 10) (Lehtimäki et 
al., 2012). Furthermore, magnetoencephalography revealed a decrease in 
amplitude of evoked auditory cortical responses during tVNS (Lehtimäki et 
al., 2012). Conversely, tVNS has been reported to have no effect on tinnitus 
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(n = 24) (Kreuzer et al., 2012), however, this study did not use simultaneous 
sound therapy. 
As VNS is currently used in refractory epilepsy, tVNS has been 
piloted as a non-invasive alternative. tVNS was investigated in 7 patients 
with refractory epilepsy (Stefan et al., 2012). Patients were treated for 9 
months (1 hour 3 times daily) and kept logs of seizures. Patients also 
underwent EEG at baseline and every 3 months during the study, however, 
as 4 of the 7 patients showed no clinical seizures in the baseline EEG, 
comparisons were limited. 2 of the patients exhibited a significant reduction 
in seizure number (29% and 50% decrease) during EEG at 9 month follow-
up whereas 1 patient had a significant increase in seizure number (175%) 
(Stefan et al., 2012). From the patients’ logs, 5 experienced a decrease in 
seizure frequency whereas 2 reported an increase. These mixed preliminary 
results make it unclear if tVNS is beneficial in refractory epilepsy. A larger 
sample group, with the addition of a suitable control such as sham tVNS, is 
required. 
tVNS is also being investigated as a possible non-invasive therapy in 
depression. 2 weeks of tVNS (15 minutes 1-2 times daily 5 days a week) 
significantly decreased depression rating scores using the Beck Depression 
Inventory compared to sham tVNS, however, there was no difference in 
scores assessed using the Hamilton Depression Rating Scale (Hein et al., 
2013). Interestingly, the Beck Depression Inventory is utilised by patients 
whereas the Hamilton Depression Rating Scale is based on clinicians’ 
ratings of symptoms, therefore, there was an improvement in patient rated 
scores but not in clinician scores. This may suggest a placebo effect or it 
may reflect the limitations of depression rating scales. Alternatively, the 
conflicting results may also be due to the short treatment time; evidence 
from invasive VNS for depression suggests that long term stimulation is 
required for therapeutic effects (Rush et al., 2005b). 
tVNS may also be a therapeutic approach to reduce pain perception. 
tVNS in healthy participants (n = 48) reduced pain sensitivity in response to 
tonic heat and increased mechanical and pressure pain thresholds when 
compared to sham tVNS (Busch et al., 2013). tVNS has also been 
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investigated in patients with chronic pain (endometriosis; n = 15) - responses 
to evoked mechanical pain stimuli were decreased compared to sham 
stimulation (Napadow et al., 2012). 
Electroacupuncture of the ear has also been reported to improve 
symptoms in coronary artery disease patients (Zamotrinsky et al., 1997; 
Zamotrinsky et al., 2001). 15 minutes of stimulation per day for 10 days 
abolished angina symptoms at rest and reduced the use of vasodilator 
medication. Furthermore, patients subsequently underwent coronary artery 
bypass surgery and had improved postoperative outcomes compared to the 
control group.  
These recent studies of tVNS in the clinical setting have provided 
some positive initial results, however, the outcomes investigated are varied 
and mostly subjective. In addition, the stimulation parameters used differ 
widely (Table 2.1), therefore, little is known about the optimal parameters for 
tVNS. There is also a dearth of information regarding the potential effects of 
tVNS on central autonomic control. Neuronal tracing studies in cats and 
dogs revealed projections of the ABVN to the NTS (Nomura and Mizuno, 
1984; Chien et al., 1996). The NTS receives visceral vagal afferents and 
plays a key role in integrating autonomic control through projections to the 
DVN, NA, CVLM and RVLM (see General Introduction 1.1.4), therefore, 
stimulation of the ABVN may increase efferent vagal parasympathetic 
activity and/or decrease sympathetic outflow. Indeed, acupuncture of the 
concha of the ear in healthy volunteers has been reported to significantly 
increase the HF component of HRV indicating an increase in 
parasympathetic modulation of the heart (Haker et al., 2000). Many of the 
clinical pilot studies recorded ECG data to ensure that tVNS was safe to use 
and reported no effect on heart rate (Kreuzer et al., 2012; Lehtimäki et al., 
2012; Napadow et al., 2012; Busch et al., 2013). However, heart rate is a 
crude measure of autonomic function and the sample sizes were small. If 
tVNS can be shown to influence autonomic control towards parasympathetic 
predominance it could provide a method to correct autonomic imbalance in 
conditions with parasympathetic withdrawal such as heart failure. 
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2.2 Hypothesis 
Transcutaneous stimulation of the auricular branch of the vagus nerve will 
alter cardiovascular autonomic control. 
 
2.3 Aims and Objectives 
The aim of this study was to investigate the effects of tVNS on 
cardiovascular autonomic function in healthy human volunteers. The 
objectives were to:  
1. determine an optimal tVNS protocol by investigating the effects of 
different electrode positions and stimulation parameters (pulse width 
and frequency) on cardiovascular autonomic function (measured by 
HRV and BRS analyses).  
2. determine the effects of the optimal tVNS protocol on sympathetic 
nerve activity measured by microneurography.  
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Table 2.1 Studies of tVNS in patient populations. 
Paper Sample Group Study 
Design 
Electrode 
positions 
Stimulation 
parameters 
Study outcomes 
Hein et al. 
(2013) 
Major depression 
patients (tVNS = 
17; sham = 20) 
Sham 
controlled 
Left and right 
ears 
1.5 Hz; 0-600 µA Decreased depression rating scores using the Beck 
Depression Inventory; no difference in scores using 
the Hamilton Depression Rating Scale. 
Kreuzer et al. 
(2012) 
Tinnitus patients 
(n = 24) 
Pilot study 
(no control) 
Exact site 
unclear 
25 Hz; 0.1 – 10  
mA; 24 weeks 
No effect on tinnitus symptoms. No effect on heart 
rate. Reduction in QRS complex duration. 
Lehtimäki et 
al. (2013) 
Tinnitus patients 
(n = 10) 
Pilot study 
(no control) 
Left tragus 25 Hz; approx. 0.8 
mA and sound 
therapy; 10 days 
Improved mood and tinnitus severity. Reduced 
amplitude of evoked auditory cortical responses. No 
effect on heart rate. 
Napadow et 
al. (2012) 
Endometriosis 
patients (n = 15) 
Sham 
controlled 
cross-over 
Left cymba 
concha and 
anti helix 
450 µs; 30 Hz; 
during exhalation 
Reduced pain responses to evoked mechanical pain 
stimuli and reduced anxiety. No effect on HRV (n = 
10). 
Stefan et al 
(2012) 
Epilepsy patients 
(n = 7) 
Pilot study 
(no control) 
Left ear. 
Exact site 
unclear 
300 µs; 10 Hz; 
25V; 9 months 
Reduced seizure frequency. 
Zamotrinsky 
et al. (1997) 
Coronary artery 
disease patients 
(VNS = 10; 
control = 10) 
 
Randomised 
control trial 
Left and right 
ears 
Exact site 
unclear 
Electro-
acupuncture 
0.2-1.5mA; 
3Hz;1.5ms 
15mins/day for 10 
days 
After day 4 angina did not develop at rest. After day 7 
patients had increased tolerance to exercise. Patients 
no longer needed vasodilators (glycerol trinitrate). 
Effects lasted 2-3 weeks after tVNS treatment. 
Zamotrinsky 
et al. (2001) 
Coronary artery 
disease patients 
(VNS = 8; 
control = 10) 
 
Randomised 
control trial 
Left and right 
ears 
Exact site 
unclear  
Electro-
acupuncture 0.2-
1.5mA; 3Hz;1.5ms 
15mins/day for 10 
days 
tVNS caused a transient decrease in heart rate and 
BP during first 4-5 days. After 4-5 days heart rate and 
BP chronically lower compared to baseline. Reduction 
in angina episodes and reduced need for medication. 
Improved postoperative outcome compared to control 
group. 
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2.4 Methods 
2.4.1 General Protocol 
The study was approved by the University of Leeds Ethics Committee 
(Appendix - BIOSCI 09-021) and was conducted in accordance with the 
Declaration of Helsinki. Informed written consent was obtained from all 
participants. 150 healthy participants were recruited for the study. Inclusion 
criteria for healthy participants were male or female over the age of 18 
years. Exclusion criteria were a history of cardiovascular disease, diabetes 
or hypertension. To avoid possible confounding factors, all experiments were 
carried out in a similar manner between 8-10 am to limit the effect of 
circadian variation on autonomic function. The study was conducted in a 
dedicated study room at 21 ± 2°C. All participants were asked to avoid 
alcohol and intense exercise 12 hours prior to attendance. They were also 
asked to avoid caffeine and nicotine on the morning of the study. Each 
participant was asked to have a light breakfast and to void their bladder 
before the study commenced. Demographic data including age, weight, 
height, medication and activity levels were recorded. Participants were 
asked to lie on a couch with a memory foam mattress topper in a semi-
supine position while heart rate, blood pressure and respiration were 
monitored continuously. Following experimental set up, participants rested 
for 10-20 minutes while heart rate and blood pressure were monitored until a 
steady state was reached. Data were recorded at baseline, during tVNS and 
during recovery for 15 minutes each. Between each recording, participants 
rested until heart rate and blood pressure returned to baseline levels. 
Participants were asked to remain still and refrain from talking during 
recordings. 
 
2.4.2 Transcutaneous Vagus Nerve Stimulation (tVNS) 
tVNS was performed using a Transcutaneous Electrical Nerve Stimulation 
(TENS) device (V-TENS Plus, Body Clock Health Care Ltd, UK) with 
modified surface electrodes (auricular clips, Body Clock Health Ltd, UK). 
tVNS was applied for 15 minutes. The effects of varying several stimulation 
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parameters were investigated; electrode position, single vs. bilateral 
stimulation and the pulse with and pulse frequency of stimulation. In all 
experiments, amplitude was adjusted to the level of sensory threshold (10-
50 mA). 
 
2.4.2.1 Electrode positioning for tVNS 
Three different electrode configurations were investigated in healthy 
participants (n = 63); tragus (n = 34), tragus + cymba (n = 15) or concha (n = 
14; Figure 1.2). tVNS was performed with a pulse width of 20 µs at 15Hz for 
15 minutes. 
 
2.4.2.2 The effects of tVNS of the right ear vs. bilateral tVNS 
In the same group of participants (n = 63) in which electrode positioning was 
investigated, the efficacy of tVNS of either the right ear only (n = 21) or both 
ears simultaneously (n = 42) was also investigated. tVNS was performed 
with a pulse width of 20 µs at 15Hz for 15 minutes. 
 
2.4.2.3 Stimulation parameters for tVNS 
The effects of different pulse width and frequency stimulation was 
investigated. As no significant difference was found between different 
electrode positioning and sides on HRV, this group were termed the low 
pulse width and pulse frequency group (L-tVNS; 20 µs pulse width at 15 Hz; 
n = 63). A further 34 participants were recruited for the high pulse width and 
frequency group (H-tVNS).  
 
2.4.2.4 Sham tVNS 
Sham tVNS (n = 14) was performed by placing the electrodes on the tragus 
and increasing amplitude until the participant reported feeling sensation. 
Participants were then told that the amplitude would be reduced slightly to 
prevent discomfort but the electrode leads were disconnected from the 
TENS machine without the participants’ knowledge. 
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2.4.3 Heart Rate Variability (HRV) 
A three lead ECG was used to monitor and record heart rate. Electrodes 
(Ambu, UK) were placed on left and right clavicles and costal margins 
enabling electrode polarities to be changed to select the lead that detected 
the most prominent R peak for subsequent HRV analysis (normally lead II). 
HRV was analysed offline using LabVIEW (National Instruments, USA) 
software. A threshold was set to detect R peaks from an 8 minute ECG 
recording and R-R intervals used to produce a tachogram. The ECG was 
inspected to ensure all R peaks were detected and there were no 
abnormalities in the ECG such as ectopic beats (e.g. premature ventricular 
complexes). Ectopic beats could be corrected using a linear spline to 
average the R-R interval prior to and following the ectopic. If more than 2 
ectopic beats were detected the recording was excluded. The resulting 
tachogram was resampled at 5 Hz and underwent 512 point Fast Fourier 
Transform (78% overlap) with a Hanning window to calculate the power 
spectrum of HRV with the low frequency (LF) component at 0.04 - 0.15 Hz 
and the high frequency (HF) component at 0.15 - 0.40 Hz (Figure 2.1). LF 
and HF powers were also converted to normalised units as a percentage of 
the total power minus very low frequency power (VLF; 0.00 – 0.04 Hz) to 
determine the LF/HF ratio. The HF component reflects parasympathetic 
modulation of heart rate (Chapleau and Sabharwal, 2011) and the LF 
component reflects both sympathetic and parasympathetic modulation of 
heart rate (Akselrod et al., 1981). The ratio of low frequency and high 
frequency oscillations of heart rate variability can be used as an index of 
cardiac autonomic balance such that a decrease in LF/HF ratio indicates a 
shift in cardiac autonomic balance towards parasympathetic predominance 
(Task Force of the European Society of Cardiology and the North American 
Society of Pacing Electrophysiology, 1996; Chapleau and Sabharwal, 2011).  
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Figure 2.1 Example of heart rate variability analysis. The high frequency (HF) component of HRV represents 
parasympathetic/vagal modulation of heart rate whereas the LF component reflects both sympathetic and parasympathetic 
influences. The ratio of LF/HF can be used as an estimate of cardiac sympathovagal balance. 
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2.4.4 Respiration 
A piezo-electric transducer (Pneumotrace, UFI, USA) was placed round the 
upper thorax to monitor and record respiration rate. A respiration rate <10 
breaths/min was unacceptable for HRV analysis as the HF component is 
respiration dependent. At slow respiration rates the HF peak of the HRV 
spectrum can merge with the LF peak (Malliani, 2005). In this case 
participants were asked to use a breathing metronome set at 16 breaths/min 
(n = 3).  
 
2.4.5 Blood pressure 
A Finometer device (Finometer Medical Systems B.V., Arnhem, 
Netherlands) was used to monitor and record blood pressure continuously 
including pulse-to-pulse changes. This device utilises the volume clamp 
method proposed by Peňáz in 1973 (Parati et al., 2003). An inflatable cuff 
was placed round the middle phalanx of the middle finger on the left hand. 
The finger cuff has an infrared light source and sensors that detect changes 
in blood volume (photoplethysmography). The finger cuff was connected to 
the front-end unit that was strapped to the subject’s wrist. This receives 
plethysmography data and adjusts pressure in the finger cuff to keep the 
diameter of the digital arteries constant (clamped). The front-end unit on the 
wrist was connected to the main unit of the Finometer. The main unit 
consists of a pump used to inflate the finger cuff and the PhysioCal software 
that calculates the set point at which the artery wall is unloaded i.e. when the 
intra-arterial pressure of the digital artery matches air pressure in the finger 
cuff. PhysioCal was switched off during recordings as it interferes with data 
collection but it was switched on again between recordings to ensure 
accurate measurements. The Finometer output screen displayed the arterial 
waveform and also the numerical values for heart rate, systolic, diastolic, 
and mean blood pressure.  
 The device also has a hydrostatic height correction system to 
compensate for hand position with respect to the level of the heart. One 
sensor was placed at the level of the heart and another on the finger cuff. An 
agreement within 10 mmHg for systolic and diastolic values obtained by the 
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Finometer device and blood pressure readings from the arm using an 
automatic blood pressure machine was sought. If there was a discrepancy 
then a variety of adjustments were tried including: 
1. reapplying the finger cuff 
2. using a different sized finger cuff 
3. warming the hands 
4. using a different finger 
Although precise values of systolic and diastolic blood pressure cannot be 
obtained using the Finometer device, this does provide accurate 
measurement of beat-to-beat changes in blood pressure that are required for 
baroreflex sensitivity measurement (Parati et al., 2003). The alternative 
method is the use of an intra-arterial catheter to measure the precise values 
for systolic and diastolic blood pressure which is highly invasive and was not 
feasible. La Rovere et al. (1997) simultaneously measured intra-arterial 
blood pressure and finger cuff blood pressure during BRS assessment in 
620 patients and found a high correlation between the two methods (r = 
0.92, p = 0.001). 
 
2.4.6 Baroreflex sensitivity (BRS) 
Spontaneous BRS can be used as an index of cardiovagal activity (La 
Rovere et al., 2008). Systolic blood pressure variability was calculated using 
a similar method to HRV except the threshold was set to detect peak systolic 
pressure. Cross spectral analysis of oscillations in systolic blood pressure 
and R-R interval was performed. The alpha index was used as an estimate 
of BRS and was calculated as the square root of the ratio of HRV LF power 
over systolic blood pressure LF power (Robbe et al., 1987). Coherence 
between oscillations in systolic blood pressure and heart rate exceeded 0.5 
for BRS analysis to be accepted. 
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2.4.7 Microneurography 
Muscle sympathetic nerve activity (MSNA) was recorded as previously 
described (Macefield et al., 1994; Greenwood et al., 1999) in 10 healthy 
volunteers in the H-tVNS group (8 male, 2 female; 29-59 years). The right 
leg was flexed at the knee (approximately 70º) and supported with foam 
cushions. The peroneal nerve was identified by palpation as it coursed round 
the neck of the fibula (Figure 2.2) and the skin was cleaned using alcohol 
wipes. Microneurography was not performed if there were skin lesions 
present in the area of electrode insertion. Two tungsten microelectrodes 
(FHC Inc., USA) were inserted percutaneously below the knee. The 
electrodes were 35 mm long with a diameter of 200 µm tapering to a tip. The 
recording electrode was epoxy insulated with an impedance of 0.3 ± 0.6 MΩ. 
An electrode with high impedance was used as this limits the area over 
which neural activity is picked up and is necessary for single unit MSNA 
recordings (Macefield et al., 2002). This was inserted into the peroneal nerve 
and the second (reference) electrode was inserted into subcutaneous tissue 
1-2 cm away. The electrodes were connected to a headstage (Neurolog 
NL100AK, UK) which was connected to an AC pre-amplifier (x50k 
amplification; Neurolog NL104A, UK). The signal was passed through a 
Humbug (Quest Scientific, Canada) to filter out mains noise at 50 Hz and a 
bandpass filter (0.7-2.0 kHz; Neurolog NL125/6, UK). The signal was 
sampled at 16 kHz and digitised (Power 1401, CED, UK). The signal was 
then passed to a PC (Dell laptop) where it was displayed in real time and 
recorded using Spike2 software (version 7; CED, UK). The time base could 
be expanded to allow inspection of individual action potentials during the 
experiment. The recording microelectrode was manipulated until a prominent 
single action potential could be visualised. Manipulations were small and 
limited to 45 minutes in accordance with guidelines (Mano et al., 2006).  
To confirm that action potentials were recorded from a sympathetic 
vasoconstrictor fibre the following criteria were used;  
1) the action potential occurred in diastole  
2) there was an inverse relationship between single unit activity and 
blood pressure as expected of a sympathetic vasoconstrictor fibre  
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3) single unit activity increased in response to cold pressor test or 
isometric handgrip exercise  
4) there was an absence of paraesthesia and no change in single 
unit activity in response to cutaneous stimuli (stroking the skin of 
the lateral leg and the dorsum of the foot).  
Further confirmation was obtained during off-line analysis by superimposing 
all putative MSNA single units to ensure the amplitude and shape remained 
constant indicating that the same unit was recorded throughout the recording 
period. MSNA frequency (per min) was calculated by counting all single units 
that occurred in the first 2 minutes of each recording. MSNA incidence (per 
100 heart beats) was also calculated to limit the effect of any changes in 
heart rate. Baseline data were normalised to 1 and stimulation and recovery 
data were normalised to baseline due to a high degree of inter-individual 
variation. Raw values of MSNA frequency and incidence are presented in 
Table 2.7. 
 
2.4.7.1 Cold pressor test 
Control data were recorded for 1 minute then the participant was asked to 
submerge the entire left hand and wrist into ice water (approximately 4ºC). 
The hand was submerged for 1 minute unless the discomfort level was too 
high. The hand was removed from the water and placed in a towel while a 
further 1 minute of recovery data was obtained. The cold pressor test is 
useful in discriminating between MSNA and skin sympathetic nerve activity 
(SSNA). The cold pressor test evokes an increase in blood pressure that 
correlates well with increasing MSNA (Fagius et al., 1989; Kregel et al., 
1992). Crucially, there is a delay in the increase of MSNA of approximately 
30 s. The degree of increased MSNA is related to the perceived level of 
discomfort and this may account for the variation in onset (Victor et al., 1987; 
Kregel et al., 1992) whereas there is no consistent change in skin 
sympathetic activity (Kregel et al., 1992). The response to the cold pressor 
test was therefore derived from the last 30 s of immersion compared to the 
control period. 
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Figure 2.2 The course and distribution of the common, deep and 
superficial peroneal (fibular) nerves in the leg (Flanigan and 
DiGiovanni, 2011) 
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2.4.7.2 Isometric handgrip exercise (IHG) 
Maximal voluntary contraction (MVC) was determined during the 
experimental set up by asking the participant to squeeze a handgrip as hard 
as possible. The handgrip was connected to a dynamometer (MIE Medical 
Research Ltd, UK) which provided a numerical display. In addition, the 
signal from the dynamometer was digitised (Coulbourn Lab Sinc V, 
Coulbourn Ltd, USA), passed to a PC and displayed as a dial on the monitor 
to aid participants during the exercise. Control data were recorded for 1 
minute then the participant was asked to squeeze the handgrip until the 
pointer was in the green area of the dial, representing 30-40% of MVC, and 
to maintain this for 2 minutes. Participants were asked to try and keep all 
other muscles as relaxed as possible and to avoid breath holding during the 
handgrip. After 2 minutes participants were asked to stop the handgrip and a 
further 1 minute of recovery data was recorded. IHG causes an immediate 
and continuous increase in blood pressure mediated in the initial stage by 
tachycardia and subsequently by increased MSNA (Seals et al., 1988). This 
exercise is useful in differentiating between muscle and skin SNA as SSNA 
increases abruptly at the start of exercise and remains constant whereas the 
increase in MSNA is delayed for 30-60 s and then gradually increases 
throughout the exercise (Seals et al., 1988; Saito et al., 1990) (Figure 2.3). 
MSNA from the second minute of IHG was therefore compared to the control 
period.  
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Figure 2.3 Example isometric handgrip exercise recording. There are 2 
putative MSNA units during the 1 minute control period and during the 
first minute of exercise. The firing of this unit increases during the 
second minute of exercise to 5 units indicating that this is a sympathetic 
vasoconstrictor unit (* = single unit). 
 
 
 
2.4.8 Data acquisition 
ECG, blood pressure and respiration data were split into two channels and 
fed into two data amplification systems (Coulbourn Lab Sinc V, Coulbourn 
Ltd, USA and Neurolog, CED, UK). The data were sampled at 12 kHz and 
stored on hard drives. Channels were independently calibrated before 
digitisation and storage on PCs. Data channels were then displayed on 
monitors using LabVIEW (National Instruments, USA) and Spike2 (CED, 
UK) software.  
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2.4.9 Statistical analysis 
All statistical analyses were carried out using SPSS (version 18). 
Independent t-tests or Mann-Whitney U tests were used to compare group 
characteristics. Repeated measures ANOVA was used to analyse time effect 
(baseline, stimulation, recovery) in each group alone with post hoc 
Bonferroni correction. To analyse the effects of different methods of 
stimulation, mixed mode ANOVA with group (electrode site, side or 
stimulation parameters) and time was used. For groups that differed at 
baseline, ANCOVA was used with baseline values held constant as 
covariates. Where interactions were revealed, post hoc analyses were 
undertaken using repeated measures ANOVA on each group separately. 
The Greenhouse – Geisser correction was used where data did not meet 
sphericity. Linear regression was used to explore the relationship between 
variables. Data are presented as group mean ± standard error of the mean 
(S.E.M.) unless stated otherwise. A 2-tailed probability value < 0.05 was 
considered statistically significant.  
 
2.4.10 Study Failures 
There were 132 volunteers for the first part of the study investigating the 
effects of different stimulation protocols on cardiovascular autonomic control, 
however, 21 records were excluded for the following reasons: 
 6 had multiple ectopic beats 
 5 had pre-existing conditions (hypertension, type 1 diabetes, 
persistent cough, back pain and stroke) 
 3 had cardiac arrhythmia  
 2 were excluded due to moving and talking during recordings 
 1 file was corrupted 
 1 had poor signal to noise ratio in ECG 
 1 had vasomotor symptoms of menopause 
 1 needed to urinate 
 1 was excluded due to noise from on-going building works 
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There were 18 volunteers for the second part of the study utilising 
microneurography however, 8 were excluded for the following reasons: 
 6 were excluded due to failure to locate an acceptable MSNA 
unit  
 1 had a poor signal to noise ratio  
 1 had a lesion present at the electrode insertion site. 
 
 
2.5 Results 
2.5.1 Electrode positioning for tVNS 
The auricular branch of the vagus nerve is distributed to parts of the external 
ear including the tragus, concha and cymba concha (Peuker and Filler, 
2002) (Figure 1.2). The effect of stimulating these three areas by specific 
electrode placement at the ear was investigated in 63 healthy volunteers (34 
female, 29 male; 20-66 years old). L-tVNS was performed for 15 minutes 
using a TENS machine (pulse width 20 µs; pulse frequency 15 Hz) and 
modified surface electrodes. Repeated measures ANOVA revealed there 
was no significant change in HRV or BRS during tVNS (Figure 2.5 A; Table 
2.2– L-tVNS group). To test if this was due to the inter-individual variation in 
resting cardiac autonomic control, HRV was analysed for responders (those 
who had a decrease in LF/HF ratio during tVNS; n = 31) and non-responders 
(n = 32; Table 2.3). This decision was validated by the fact that there was a 
significant difference in baseline LF/HF ratios between responders and non-
responders suggesting higher vagal tone in the non-responder group (1.32 
and 1.04 respectively; p = 0.038; Table 2.3). There was no significant 
difference between responder and non-responder groups in other baseline 
characteristics such as body mass index (BMI), age, resting heart rate and 
blood pressure (Mann-Whitney U test, Table 2.4– L-tVNS group). Mixed 
mode ANOVA confirmed there was no significant change in LF/HF ratio 
(time effect, p > 0.05). There was also no impact of group (responder or non-
responder main effect, p > 0.05), however, there was a significant interaction 
between group and time (p < 0.0005). Further analysis of the interaction 
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using a repeated measures ANOVA of LF/HF ratio in the responder group 
alone revealed a significant decrease in LF/HF ratio (Figure 2.5; time effect, 
p < 0.0005) during L-tVNS indicating a shift in autonomic balance towards 
parasympathetic predominance. Conversely, there was a significant 
increase in LF/HF ratio in the non-responder group (time effect, p < 0.0005) 
indicating that the interaction is due to an increase in LF/HF ratio in the non-
responder group compared to a decrease in the responder group. There was 
no significant change in LF or HF power. There was no impact of electrode 
site on LF/HF in the responder group alone (tragus n = 34; concha n = 14; 
tragus + cymba n = 15; Figure 2.4; main effect for site, p > 0.05; Figure 2.5). 
In addition, there was no interaction between electrode site and time. There 
was a significant decrease in heart rate (time effect p < 0.0005) in the 
responder group alone (Figure 2.4). There was a significant decrease in 
heart rate (time effect, p > 0.0005) and an increase in mean BP in the non-
responder group (time effect, p = 0.001). There was no impact of electrode 
site on heart rate (main effect for side, p > 0.05) or mean BP (main effect for 
side p > 0.05) and there was no interaction between electrode site and time.  
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Figure 2.4 Cardiovascular variables of responder and non-responder 
groups during L-tVNS of different electrode sites. In the responder group 
alone, there is a significant decrease in heart rate (time effect, p < 0.0005) 
and no change in mean BP (time effect, p > 0.05). There is a significant 
decrease in heart rate (time effect, p > 0.0005) and an increase in BP in the 
non-responder group (time effect, p = 0.001). Electrode site had no effect on 
heart rate (main effect for site, p > 0.05) or mean BP (main effect for side, p 
> 0.05) and there was no interaction between site and time (* = significantly 
different from baseline).  
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Figure 2.5 Effects of different L-tVNS electrode positions on HRV in responder and non-responder groups. There was no 
significant change in LF/HF (A; time effect p > 0.05) and group (responder or non-responder) had no impact (main effect for 
group (p > 0.05), however there was a significant interaction between group and time (p < 0.0005). In the non-responder group 
alone, there was a significant increase in LF/HF (time effect, p < 0.0005; n = 32). There was a significant decrease in LF/HF ratio 
during L-tVNS in the responder group (p < 0.0005; n = 31). There was no impact of  electrode site on the concha (n = 14), tragus 
(n = 34) or tragus + cymba concha (n = 15; main effect for site, p > 0.05; C) and no interaction between electrode site and side (* 
= significantly different from baseline). 
B. Non-responders C. Responders A. All inclusions 
* * 
* 
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2.5.2 L-tVNS of the right ear vs. bilateral tVNS 
In the same group of participants in which electrode positioning was 
investigated, the effect of stimulating just the right ear (n = 21) versus left 
and right ears simultaneously was investigated (n = 42; Figure 2.6). Mixed 
mode ANOVA revealed no significant change in LF/HF (time effect, p >0.05) 
and no impact of group (responder or non-responder), however there was a 
significant interaction between group and time. Further analysis of the 
interaction using a repeated measures ANOVA of the responder group alone 
revealed a significant increase in LF/HF ratio (time effect, p < 0.0005). There 
was a significant increase in LF/HF ratio in the non-responder group (p > 
0.0005). There was no impact of side on LF/HF (main effect for side, p > 
0.05) and there was no interaction between side and time. There was a 
significant decrease in heart rate (time effect, p < 0.0005) and increase in 
mean BP (time effect, p < 0.0005) in the responder group alone (Figure 2.6). 
There was also a decrease in heart rate (time effect, p < 0.0005) and an 
increase in mean BP in the non-responder group (time effect, p < 0.0005).  
There was no impact of electrode site on heart rate (main effect for side, p > 
0.05) or mean BP (main effect for side p > 0.05) and there was no interaction 
between electrode site and time (Figure 2.7). Based on these results, tVNS 
of the tragus of both left and right ears was used for all subsequent 
experiments due to ease of application. 
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A. All Inclusions                     B. Non-responders           C. Responders 
    
Figure 2.6 Effects of L-tVNS of the right ear only compared to left and right ears simultaneously. There was no significant 
change in LF/HF (A; time effect p > 0.05) and group (responder or non-responder) had no impact (main effect for group, p > 0.05), 
however there was a significant interaction between group and time (p < 0.0005). In the non-responder group alone, there was a 
significant increase in LF/HF (time effect, p < 0.0005; n = 32). There was a significant decrease in LF/HF ratio during L-tVNS in the 
responder group alone (time effect, p < 0.0005; n = 31).  There was no impact of side (main effect for side, p > 0.05; C) and no 
interaction between side and side (* = significantly different from baseline).  
0.5
0.7
0.9
1.1
1.3
1.5
1.7
Baseline Stimulation Recovery
LF
/H
F 
All
Responders
Non-responders
0.5
0.7
0.9
1.1
1.3
1.5
1.7
1.9
Baseline Stimulation Recovery
LF
/H
F 
Left and right
Right only
0.5
0.7
0.9
1.1
1.3
1.5
1.7
Baseline Stimulation Recovery
LF
/H
F 
Left and right
Right only
* 
* * 
- 71 - 
 
 
 
 
 
 
Figure 2.7 Cardiovascular variables of responder and non-responder 
groups during L-tVNS of right vs. both ears simultaneously. In the 
responder group alone, there is a significant decrease in heart rate 
(time effect, p < 0.0005) and an increase in mean BP (time effect, p < 
0.0005). There is also a decrease in heart rate (time effect, p < 0.0005) 
and an increase in mean BP in the non-responder group (time effect, p 
< 0.0005). Electrode site had no effect on heart rate (main effect for 
site, p > 0.05) or mean BP (main effect for site, p > 0.05) and there was 
no interaction between site and time (* = significantly different from 
baseline). 
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2.5.2 Stimulation parameters for tVNS 
The cardiovascular autonomic effects of different stimulation parameters 
were investigated in 111 healthy volunteers (58 female, 53 male; 20-66 
years old). tVNS was performed with low pulse width and pulse frequency 
(L-tVNS = 20 µs at 15 Hz; n = 63), high pulse width and pulse frequency (H-
tVNS = 200 µs at 30 Hz; n = 34) or sham stimulation (electrodes placed on 
the ear without electrical stimulation; n = 14) and HRV analysed (including 
responders and non-responders). The L-tVNS group included stimulation 
using different electrode positions but as no significant difference was found 
between positions all were included for investigation of stimulation 
parameters. Mixed mode ANOVA revealed a significant decrease in LF/HF 
during tVNS (time effect, p = 0.040). Stimulation parameters (L-tVNS or H-
tVNS group) had no impact on LF/HF ratio (main effect of stimulation 
parameters, p > 0.05), however, there was a significant interaction between 
stimulation parameters and time (p = 0.048; Figure 2.8). Further analysis of 
the interaction using a repeated measures ANOVA of the H-tVNS group 
alone revealed a significant decrease in LF/HF ratio (time effect, p = 0.026; 
Figure 2.8). There was no significant change in LF/HF ratio in L-tVNS and 
sham groups. Splitting the H-tVNS group into responders to tVNS and non-
responders again revealed a significant difference in baseline LF/HF ratios 
between responders and non-responders (1.54 and 0.64 respectively; p = 
0.001; Table 2.3). Repeated measures ANOVA revealed a significant 
decrease in LF power during tVNS in the H-tVNS responder group (time 
effect, p = 0.001; Table 2.3) whereas total power and HF power did not 
change significantly. There was no significant change in total power, LF 
power or HF power in the non-responder group during H-tVNS.  
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Table 2.2 Heart rate variability values for Sham tVNS, L-tVNS and H-
tVNS groups including responders and non-responders. There was 
a significant decrease in LF/HF during tVNS (time effect, p = 0.040). 
Stimulation parameters (L-tVNS or H-tVNS group) had no impact on 
LF/HF ratio (main effect of stimulation parameters, p > 0.05), however, 
there was a significant interaction between stimulation parameters and 
time (p = 0.048). There was a significant decrease in LF/HF ratio during 
tVNS in the H-tVNS group alone (time effect, p = 0.026). There was no 
significant difference in baseline total power, LF power, HF power or 
LF/HF ratio between these groups. 
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 Base Stim p Base Stim p Base Stim p 
Total 
power 
(ms2) 
2463.75 
±732.50 
2789.22 
±843.02 
ns 2072.56 
±291.50 
2033.08 
±343.28 
ns 2735.31 
±422.23 
3212.17 
±497.45 
ns 
LF Power 
(ms2) 
615.52 
±168.65 
664.63 
±160.85 
ns 578.83 
±92.29 
588.49 
±81.16 
ns 906.39 
±133.74 
821.49 
±177.62 
ns 
HF Power 
(ms2) 
1109.41 
±395.90 
1286.40 
±469.05 
ns 823.99 
±143.75 
779.12 
±123.28 
ns 972.67 
±208.32 
1043.02 
±178.65 
ns 
LF/HF 
 
1.16 
±0.30 
1.19 
±0.32 
ns 
 
1.18 
±0.11 
1.16 
±0.10 
ns 
 
1.26 
±0.15 
1.04 
±0.14 
0.026 
BRS 
(ms/mmH
g) 
10.47 
±4.01 
11.46 
±4.81 
ns 11.40 
±0.82 
11.28 
±.82 
ns 11.51 
±1.46 
12.55 
±1.75 
ns 
Sham (n = 14)    L-tVNS (n = 63) H-tVNS (n = 34) 
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Table 2.3 Heart rate variability values for H-tVNS and L-tVNS responder 
and non-responder groups. There is a significant decrease in LF/HF 
ratio during stimulation (time effect, p = 0.040). Stimulation parameters 
had no impact on LF/HF (main effect of stimulation parameters, p 
>0.05). There is an interaction between stimulation parameters and 
time (p = 0.048). There is a significant decrease in LF/HF ratio in the H-
tVNS group alone (n=34; time effect, p=0.026). There is no change in 
LF/HF in the L-tVNS (n=63) or Sham (n = 14) groups. There is a 
significant difference in baseline LF power between H-tVNS responders 
and non-responders (*p = 0.041) and in baseline LF/HF ratio between 
H-tVNS (**p = 0.001) and L-tVNS groups (†p < 0.038). There is a 
significant decrease in LF power during stimulation in the H-tVNS 
responder group (time effect, p = 0.001). Both L-tVNS and H-tVNS 
responder groups show a significant decrease in LF/HF ratio during 
stimulation (time effect, p < 0.0005). There is a significant increase in 
LF/HF ratio in the L-tVNS non-responder group (time effect, p < 
0.0005). 
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 Base Stim p Base Stim p Base Stim p Base Stim p 
Total 
Power 
(ms2) 
1953.7 
±345.9 
2041.1 
±298.3 
ns 2187.7 
±340.4 
2025.3 
±293.6 
ns 2957.5 
±590.4 
3183.1 
±836.1 
ns 1895.5 
±853.7 
2799.8 
±1208.9 
ns 
LF 
Power 
(ms2) 
623.0 
±94.8 
567.4 
±93.4 
ns 536.0± 
93.3 
608.9 
±91.9 
ns 1041.9* 
±202.4 
779.9 
±172.1 
0.001 476.0* 
±292.6 
783.6 
±248.8 
ns 
HF  
Power 
(ms2) 
596.4 
±210.3 
761.2 
±163.3 
ns 1044.5 
±206.9 
796.5 
±160.7 
ns 934.3 
±210.9 
964.2 
±226.6 
ns 868.6 
±305.1 
1031.4 
±327.7 
ns 
LF/HF 1.32† 
±0.15 
0.95 
±0.15 
<0.0005 1.04† 
±0.15 
1.35 
±0.14 
<0.0005 1.54** 
±0.14 
1.09 
±0.11 
<0.005 0.64** 
±0.20 
0.88 
±0.17 
ns 
L-tVNS 
Responder Non-responder 
H-tVNS 
Responder Non-responder 
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Table 2.4 Baseline characteristics of H-tVNS, L-tVNS and sham groups. There was a significant difference in baseline LF/HF ratio 
between H-tVNS responders and non-responders (**p = 0.001) and L-tVNS responders and non-responders (*p = 0.038). There 
was also a significant difference in baseline LF/HF ratio between H-tVNS and L-tVNS non-responder groups (†p = 0.041). 
 
 
 Sham tVNS H-tVNS H-tVNS 
responder 
H-tVNS non-
responder 
L-tVNS L-tVNS 
responder 
L-tVNS non-
responder 
Number 
 
14 (6 ♀; 8 ♂) 34 (18 ♀; 16 
♂) 
23 (10 ♀; 13 
 ♂) 
11 (8 ♀; 3 ♂) 63 (34 ♀; 29 
♂) 
31 (16 ♀;  
15 ♂) 
32 (18 ♀;  
14 ♂) 
Age (years) 38±3.48 34±2.3 37±3.1 35±3.3 38±1.66 38±2.39 37±2.35 
BMI 
(kg/m2) 
23.9±0.67 24.9±0.71 25.27±0.95 24.34±0.75 24.5±0.57 24.2±0.54 24.8±1.00 
Heart rate 
(bpm) 
64±2.49 64±1.31 62±1.73 66±1.71 65±1.16 63±1.79 66±1.48 
Mean BP 
(mmHg) 
79±3.59 83±1.99 84±2.62 80±2.57 80±1.46 80±2.17 81±2.00 
LF/HF 
 
1.15±0.28 1.25±0.14 1.54±0.17** 0.64±0.10**,† 1.18±0.11 1.32±0.15* 1.04±0.15*,† 
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Figure 2.8 Comparison of high pulse width and frequency tVNS and low 
pulse width and frequency tVNS on HRV. There is a significant decrease 
in LF/HF ratio during stimulation (time effect, p = 0.040). Stimulation 
parameters had no impact on LF/HF (main effect of stimulation parameters, 
p >0.05). There is an interaction between stimulation parameters and time (p 
= 0.048). There is a significant decrease in LF/HF ratio in the H-tVNS group 
alone (n=34; time effect, p=0.026). There is no change in LF/HF in the L-
tVNS (n=63) or Sham (n = 14) groups (error bars omitted from the sham 
group to aid clarity; * = significantly different from baseline). 
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Linear regression revealed a relationship between baseline LF/HF 
ratio and the change in LF/HF ratio during H-tVNS such that a higher 
baseline LF/HF ratio predicts a greater response to H-tVNS (R2 = 0.58; p < 
0.0005; Figure 2.9). Aging is associated with changes in cardiovascular 
autonomic function with increasing sympathetic activity and decreasing 
parasympathetic activity (Umetani et al., 1998). Indeed, a relationship 
between increasing age and higher baseline LF/HF values was also 
observed in this study (R2 = 0.19; p = 0.013; Figure 2.9) although this 
relationship was weaker. 
There was no change in BRS during tVNS, however, there was a 
modest but significant decrease in heart rate (time effect, p < 0.0005; Figure 
2.10), although this was not affected by stimulation parameters (L-tVNS, H-
tVNS or sham groups; main effect of stimulation parameters, p = 0.05) and 
there was no interaction between stimulation parameters and time. There 
was also a significant increase in mean BP (time effect, p < 0.0005; Figure 
2.10) during stimulation that did not recover. Similar to heart rate, there was 
no impact of stimulation parameters on mean BP (main effect of stimulation 
parameters, p > 0.05) and no interaction between stimulation parameters 
and time. The increase in BP may be due to the method of BP measurement 
(Finometer) which was in place throughout the experiment. The Finometer 
calibration system was used during each experiment, however it was 
temporarily switched off during recordings for 15 minutes. It is possible that 
this affected accurate BP monitoring. It has also been reported that long 
term Finometer measurements may cause local oedema affecting BP 
detection (Ristuccia et al., 1997). To investigate this, 12 subjects also had 
their BP measured from the arm using an automatic BP machine. Three arm 
readings of BP were taken at baseline, during stimulation and during 
recovery and the average of the readings compared to the Finometer 
measurements. A mixed mode ANOVA revealed that there was a significant 
increase in systolic blood pressure during stimulation and recovery (time 
effect, p = 0.006; Figure 2.10) and the method of measurement had a 
significant effect (main effect method of measurement, p = 0.024). 
Furthermore there was an interaction between method of measurement and 
time (p = 0.002). Further analysis of this interaction using repeated 
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measures ANOVA revealed a significant increase in systolic BP in the 
Finometer group (time effect, p = 0.005). There was no change in systolic 
BP measure from the arm. A mixed mode ANOVA also revealed a significant 
increase in mean BP during stimulation and recovery (time effect, p = 0.016; 
Figure 2.10). Method of measurement had no impact on mean BP, however, 
there was an interaction between method of measurement and time (p = 
0.009). Further analyses of these interactions using repeated measures 
ANOVA of BP measurements taken using the arm method alone showed no 
significant change. There was a significant increase in mean BP (time effect, 
p = 0.016) measured using the Finometer alone. As there was no significant 
change in BP measurements taken using an arm sphygmomanometer 
whereas the increase in BP measured using the Finometer persisted into the 
recovery period, this suggests that the increase may be due to the method of 
measurement – perhaps constriction and oedema caused by the finger cuff. 
This may also have affected the analysis of BRS from Finometer records. 
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Figure 2.9 The relationship between baseline LF/HF and response to H-tVNS. There is a relationship between baseline LF/HF 
ratio and change in LF/HF ratio during H-tVNS indicating that higher baseline LF/HF ratios predict a greater decrease in LF/HF 
during H-tVNS (R2=0.58; p<0.0005; A). There is a relationship between age and baseline LF/HF ratio (R2=0.19; p=0.013; B). 
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Figure 2.10 There is a significant reduction in heart rate and an 
increase in BP during tVNS and recovery. There is a small but 
significant decrease in heart rate (time effect, p < 0.0005; A). There is 
also a modest but significant increase in BP (time effect, p < 0.0005; B) 
during stimulation and the recovery period. There is no impact of 
stimulation parameters on heart rate (main effect of stimulation 
parameters, p > 0.05) or mean BP (main effect of stimulation 
parameters, p > 0.05) and no interaction between stimulation 
parameters and time.  
The effects of different methods of measuring BP (arm vs. Finometer) 
was investigated (n = 12; C). There was a significant increase in 
systolic blood pressure during stimulation and recovery (time effect, p = 
0.006) and the method of measurement had a significant effect (main 
effect method of measurement, p = 0.024). Furthermore there was an 
interaction between method of measurement and time (p = 0.002). 
Further analysis of this interaction revealed a siginificant increase in 
systolic BP measured using the Finometer (time effect, p = 0.005). 
There was no change in systolic BP measured from the arm. There 
was also a significant increase in mean BP during stimulation and 
recovery (time effect, p = 0.016). Method of measurement had no 
impact on mean BP, however, there was an interaction between 
method of measurement and time (p = 0.009). Further analysis of this 
interaction revealed a significant increase in mean BP (time effect, p = 
0.016) measured using the Finometer alone. There is no change in 
mean BP measured from the arm (* = significantly different from 
baseline). 
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2.5.3 Contribution of the sympathetic nervous system to 
cardiovascular autonomic changes during H-tVNS 
H-tVNS altered cardiac autonomic control towards vagal predominance, 
however, the lack of increase in HF power suggests this is not due to an 
increase in vagal tone. Alternatively, the shift in HRV towards 
parasympathetic predominance may be due to reduced sympathetic activity. 
While cardiac sympathetic activity can be investigated using cardiac 
noradrenaline spill-over, the invasiveness of this technique was not in 
keeping with the ethos of this study. Instead, vascular vasoconstrictor 
activity was recorded using microneurography. While there are regional 
differences in sympathetic outflow, there is a correlation between HRV and 
MSNA (Pagani et al., 1997). Sympathetic vasoconstrictor single unit activity 
was recorded in 10 healthy volunteers during H-tVNS (Figure 2.11; Table 
2.5). Cardiovascular and MSNA data during the cold pressor test and 
isometric handgrip test confirmed the identification of sympathetic 
vasoconstrictor units (Table 2.6). There was a significant decrease in MSNA 
frequency (time effect, p = 0.001) and incidence (time effect, p = 0.002; 
Figure 2.12) during H-tVNS. Similar to the H-tVNS group as a whole, there 
was a modest but significant decrease in heart rate (time effect, p < 0.0005; 
Table 2.7) and mean BP (time effect, p < 0.0005) during H-tVNS and 
recovery. There was a reduction in LF/HF ratio, however, this did not reach 
significance (time effect, p > 0.05). 
 
Table 2.5 Raw microneurography values. Results are presented as mean 
± S.E.M. 
 Baseline Stimulation Recovery 
MSNA frequency 
(units/min) 
1.20 ± 0.29 0.55 ± 0.28 0.90 ± 0.29 
MSNA incidence 
(units/100 heart beats) 
2.00 ± 0.49 0.91 ± 0.46 1.54 ± 0.48 
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Figure 2.11 Example microneurography recordings from one individual 
before and during H-tVNS. Raw ECG, BP and MSNA activity at 
baseline (A) and during H-tVNS (B). Action potentials from a single 
MSNA unit (C) and overlaid to show consistent morphology (D). 
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Table 2.6 Cardiovascular and MSNA data during cold pressor and 
isometric handgrip tests. 
 Baseline CPT Recovery Baseline IHG Recovery 
Heart rate 
(bpm) 
61 ± 2.7 66 ± 2.8 60 ± 2.8 62 ± 2.8 81 ± 2.9 61 ± 2.7 
Mean BP 
(mmHg) 
87 ± 3.1 108 ± 3.4 89 ± 3.2 86 ± 3.0 123 ± 3.3 90 ± 3.1 
MSNA 
frequency 
(units/min) 
1.24 ± 
0.30 
2.78 ± 
0.32 
1.03 ± 
0.29 
1.30 ± 
0.28 
3.84 ± 
0.28 
1.46 ± 
0.29 
MSNA 
incidence 
(units/100 
heart 
beats) 
2.03 ± 
0.48 
4.21 ± 
0.46 
1.72 ± 
0.46 
1.66 ± 
0.49 
4.74 ± 
0.48 
2.39 ± 
0.49 
 
 
Table 2.7 Effects of H-tVNS on cardiovascular and HRV variables of 
participants who underwent microneurography (n = 10). There is a 
modest but significant decrease in heart rate (time effect, p < 0.0005; 
Table 2.7) and mean BP (time effect, p < 0.0005; * = significantly 
different from baseline). 
 Baseline Stimulation Recovery 
Total Power (ms2) 2822 ± 1469 3603 ± 2127 2783 ± 1290 
LF Power  912 ± 471 711 ± 337 505 ± 140 
HF Power 861 ± 465 906 ± 457 603 ± 170 
LF/HF 1.28 ± 0.19 0.99 ± 0.15 1.13 ± 0.22 
Heart rate (bpm) 60 ± 2.7 59 ± 2.7* 58 ± 2.6* 
Mean BP (mmHg) 86 ± 3.0 94 ± 3.3* 96 ± 3.0* 
BRS (ms/mmHg) 13.15 ±  4.08 14.71 ± 4.96 13.03 ± 2.93 
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Figure 2.12 H-tVNS significantly reduces single unit MSNA frequency (A; p = 0.001) and incidence (B; p = 0.002; normalised data; 
n = 10; * = significantly different from baseline). 
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2.6 Discussion 
This study shows for the first time that transcutaneous vagus nerve 
stimulation can alter cardiovascular autonomic control in healthy 
participants. The results also highlight the role of the sympathetic nervous 
system in mediating tVNS effects. High pulse width and high pulse 
frequency tVNS significantly decreased LF/HF ratio, indicating improved 
heart rate variability with a shift in cardiac autonomic balance towards 
parasympathetic/vagal dominance. A significant decrease in MSNA during 
H-tVNS indicated that this protocol may activate central autonomic centres 
to elicit an indirect decrease in sympathetic nerve activity.  
 
2.6.1 tVNS effects on cardiovascular autonomic function 
Increased sympathetic activity and/or reduced parasympathetic activity as 
indicated by HRV is not only a powerful and independent predictor of poor 
prognosis in patients with cardiovascular disease (Kleiger et al., 1987; Nolan 
et al., 1998), but is also a risk factor in healthy populations (Nunan et al., 
2010). Reduced heart rate variability in a healthy population (n = 2501) was 
associated with a significantly increased risk of subsequent cardiac events 
(Tsuji et al., 1996). Increased MSNA is associated with poor prognosis in 
heart failure and is also elevated in hypertension, obstructive sleep apnoea 
and obesity (Charkoudian and Rabbitts, 2009). The ability to favourably alter 
HRV and MSNA through H-tVNS in a healthy population is significant and 
could be applied to many populations where cardiovascular autonomic 
balance is shifted toward sympathetic predominance e.g. older or sedentary 
populations (Mischel and Mueller, 2011) or in other conditions with 
sympathoexcitation such as hypertension (Charkoudian and Rabbitts, 2009). 
Indeed, the significant correlation between baseline LF/HF ratio and the 
change in LF/HF ratio during stimulation implies that H-tVNS may be even 
more effective in these populations.  
The stimulation parameters used for tVNS are critical. The 
percentage of those who responded to tVNS with a decrease in LF/HF ratio, 
indicating increased parasympathetic predominance, was 67 % in the H-
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tVNS group compared to 49 % in the L-tVNS group. These results suggest 
that H-tVNS parameters are effective in altering cardiac autonomic control 
towards vagal predominance in a healthy population sample. Indeed, the 
baseline LF/HF ratio of H-tVNS non-responders was significantly lower than 
L-tVNS non-responders (0.64 and 1.04 respectively). This was consistent 
with a higher proportion of respondents to H-tVNS, suggesting that H-tVNS 
was more effective than L-tVNS in altering the LF/HF ratio towards 
parasympathetic predominance even in those who have relatively high 
baseline vagal tone. Furthermore, there was a significant decrease in LF 
power in the responder sub-group during tVNS whereas there was no 
significant change in HF power. This was unexpected; tVNS may be 
predicted to increase HF power as this component of HRV represents vagal 
modulation of heart rate. However, as the participants in this study were 
relatively young and healthy and were recorded at rest vagal tone would 
already be high and it may not be possible to increase it further. The 
decrease in LF power is difficult to interpret due to the ambiguity of the origin 
of this component of HRV. 
Of particular interest in this study is the finding that the LF/HF ratio 
remains lower than baseline levels during the recovery period after H-tVNS 
has ceased. The stimulation and recovery periods lasted 15 minutes 
therefore the long term effects of H-tVNS on cardiovascular autonomic 
control require further investigation, however, auricular acupuncture 
increased HF power (indicating increased parasympathetic activity) for at 
least an hour after stimulation had ceased (Haker et al., 2000). The increase 
in HF power reported by Haker et al. (2000) is contrary to our findings. This 
may be due to the smaller sample size used (n = 12) or the use of a different 
stimulation technique - manual auricular acupuncture without any electrical 
stimulation. In addition, these conflicting results may also be due to the 
limitation of HRV analysis as an indirect measure of cardiac autonomic 
activity. La Marca et al. (2010) demonstrated that auricular 
electroacupuncture increased respiratory sinus arrhythmia (RSA, mediated 
by the vagus nerve) in healthy participants (n = 14) suggesting increased 
vagal activity, however, this is also an indirect measure of parasympathetic 
activity. One of the limitations of these studies, including the study presented 
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here, is that they have all used healthy participants therefore the extent of 
the effects that might be observed in patient populations, which 
characteristically have reduced parasympathetic activity, e.g. heart failure 
seems likely to be underestimated. Another limitation of this study was the 
omission of HRV time domain analysis. Time domain analysis of HRV was 
originally recommended for long term (24 hour) recordings (Task Force of 
the European Society of Cardiology and the North American Society of 
Pacing Electrophysiology, 1996), however, analysis of short term measures 
of HRV such as pNN50 may provide more information regarding tVNS 
effects on parasympathetic modulation of heart rate in the future. 
Furthermore, while respiration rate was monitored throughout the study and 
remained unaltered formal analysis of the effects of tVNS should be 
conducted. Another observation is that the MSNA frequencies recorded in 
this study are low in comparison to other studies. This may due to the dearth 
of microneurography studies involving healthy individuals which makes it 
difficult to define a ‘normal’ range, particularly in the presence of high inter-
individual variability. 
Recently, tVNS has gained interest as a possible non-invasive therapy 
in a number of conditions. The first clinical study of tVNS found that 
electroacupuncture of both ears was beneficial for patients with coronary 
artery disease (Zamotrinsky et al., 1997; Zamotrinsky et al., 2001). Patients 
(n = 10) received auricular electroacupuncture for 15mins/day for 10 
consecutive days. After 4 treatments, angina symptoms at rest were 
abolished and patients no longer required vasodilators. After 7 treatments, 
patients had improved exercise tolerance and were able to climb 5-7 flights 
of stairs without developing angina symptoms. These studies also reported 
that the improvement in angina symptoms persisted after the cessation of 
tVNS treatment for up to 3 weeks. Recently, tVNS using surface electrodes 
has been investigated as a possible analgesic (Napadow et al., 2012; Busch 
et al., 2013) and has been trialled as an alternative to invasive cervical VNS 
in patients with refractory epilepsy (Stefan et al., 2012). These studies 
reported no significant changes in heart rate during tVNS. Napadow et al. 
(2012) also analysed ECG data for HRV and found tVNS had no significant 
effect (n = 10). These findings are contrary to the results of the present 
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study, however this seems likely to be due to the smaller sample sizes and 
the different stimulation parameters used. 
 
2.6.2 Potential pathways of tVNS cardiovascular autonomic 
effects 
The neurocircuitry underlying tVNS autonomic effects requires further 
elucidation. The auricular branch of the vagus nerve has previously received 
little attention and hence there is a dearth of information regarding its central 
projections and its peripheral distribution (see General Introduction 1.3.2.1). 
The ABVN has been reported to project to the NTS which plays an integral 
role in relaying vagal afferent visceral information (Nomura and Mizuno, 
1984; Chien et al., 1996). Based on the results of this study, the proposed 
pathway of tVNS autonomic effects could involve activation of the NTS by 
ABVN afferents. This could activate the caudal ventrolateral medulla to 
inhibit the rostral ventrolateral medulla and thus reduce sympathetic output 
(Guyenet, 2006). In addition, the NTS could also activate the dorsal motor 
nucleus of the vagus and the nucleus ambiguus to increase parasympathetic 
activity (Izzo et al., 1993). However, the effects of tVNS on parasympathetic 
activity are unclear. If H-tVNS increased cardiac parasympathetic 
modulation a significant increase in HF power of HRV would be expected. 
This was not observed in the present study, however, this may be due to the 
healthy cohort of volunteers used who were tested under resting conditions 
when parasympathetic activity is already high. It may be that in populations 
with reduced parasympathetic activity e.g. heart failure patients, H-tVNS 
would increase HF power and this requires further investigation. In addition, 
there is no direct measure of vagal/parasympathetic nerve activity in 
humans, therefore, in vivo experiments to record vagus nerve activity directly 
may be required to clarify the effects of H-tVNS on the parasympathetic 
activity. 
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2.6.3 Scope of tVNS therapy for cardiovascular diseases 
VNS is already being trialled as a potential heart failure therapy and has 
resulted in positive clinical outcomes (De Ferrari et al., 2011). The findings 
presented here support the use of tVNS as a non-invasive method of VNS 
for cardiovascular diseases. Of particular interest is the finding that H-tVNS 
reduces sympathetic outflow. Sympathoexcitation is the hallmark of many 
conditions including heart failure, hypertension and obstructive sleep apnoea 
(Charkoudian and Rabbitts, 2009). The tVNS approach described here may 
therefore offer a simple, non-invasive and economical alternative that could 
make vagus nerve stimulation a widely available therapy and potentially 
improve quality of life for patients with heart failure and other conditions 
characterised by sympathoexcitation. 
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Chapter 3 
The influence of transcutaneous vagus nerve stimulation on 
autonomic function in heart failure 
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3.1 Introduction 
The first pilot study of VNS in heart failure was reported in 2008 (Schwartz et 
al., 2008). An implantable neurostimulator that delivered pulses synchronous 
with heart beat was placed on the right cervical vagus nerve of 8 male 
patients. During follow-up at 1, 3 and 6 months there was a modest but 
significant reduction in resting heart rate and a marked improvement in 
quality of life score and symptoms as assessed by the Minnesota quality of 
life questionnaire and New York Heart Association (NYHA) classification. 
There was also improved left ventricular function indicating that VNS 
treatment is beneficial in heart failure. The reason that the changes were 
small may be that the targeted stimulation parameters of either 5.5 mA or a 
reduction in heart rate of 5-10 bpm were not reached due to patient 
discomfort. Interestingly, patients complained of ear pain which may be 
referred pain caused by VNS to the area of skin supplied by the ABVN. This, 
combined with the small sample group used who all had advanced heart 
failure, may account for the relatively small changes reported. This study has 
now been expanded to a multi-centre trial with data from an additional 24 
patients added to the original pilot data (De Ferrari et al., 2011). The results 
are similar with an improvement in NYHA class and quality of life scores 
accompanied by a significant reduction in heart rate and a significant 
increase in left ventricular ejection fraction (LVEF). There was also a 
significant improvement in HRV (time domain measures - RMSSD and 
pNN50) at 3 months and 6 months follow-up. Most patients (n = 23) were 
also followed up at one year and these encouraging data demonstrated that 
the beneficial effects of VNS were maintained or even further improved, 
most notably LVEF continued to improve to 34% at 1 year follow-up 
compared to 21% at baseline. 
If VNS is to become a treatment to restore sympathovagal balance in 
heart failure, a less invasive and better tolerated method is desirable. The 
possibility of using oesophageal vagal afferents has been explored (Bajwa et 
al., 1997). VNS was performed for 2-5 minutes in 13 healthy male subjects 
using a manometer with an electrode inserted into the oesophagus. HRV 
analysis showed an increase in the HF component during stimulation 
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compared to baseline levels indicating increased parasympathetic influence 
on heart rate. While this technique is not surgical it is still invasive and not 
ideal for regular use. 
tVNS utilising the auricular branch of the vagus nerve may provide a 
non-invasive alternative to cervical VNS. tVNS has been investigated as a 
potential therapy for epilepsy, depression, pain and tinnitus but has not been 
investigated as a potential therapy to alter autonomic function in heart 
failure. Based on results of H-tVNS in a healthy population (Chapter 2), 
showing improved HRV and reduced MSNA, permission was obtained to 
pilot H-tVNS in heart failure patients. 
 
3.2 Hypothesis 
Transcutaneous vagus nerve stimulation will alter cardiovascular autonomic 
function in heart failure patients. Based on previous results in healthy 
participants, H-tVNS will decrease LF/HF ratio indicating a shift towards 
parasympathetic predominance. 
 
3.3 Aims and Objectives 
The aim of this study was to investigate the effects of H-tVNS on 
cardiovascular autonomic function in heart failure patients. The objectives 
were to: 
1. determine the effects of H-tVNS, using the optimal parameters 
defined in Chapter 2, on cardiovascular autonomic function in heart 
failure patients. 
2. investigate the tolerability of H-tVNS in heart failure patients.  
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3.4 Methods 
3.4.1 General Protocol 
The study was approved by the National Research Ethics Service (Appendix 
- 12/YH/0354) and was conducted in accordance with the Declaration of 
Helsinki. Informed written consent was obtained from all participants. Heart 
failure patients were recruited from the outpatients heart failure clinic in 
Leeds General Infirmary. Inclusion criteria for heart failure patients were 
male or female over the age of 18 years with a diagnosis of heart failure. 
Heart failure patients also had to be in sinus rhythm for inclusion. Heart 
failure patients were excluded if they were unable to transfer safely to a 
couch for the duration of the procedures or had known bradycardia or 
postural hypotension. Heart failure patients were also excluded if they had 
cardiac arrhythmia including atrial fibrillation. All heart failure patients were 
on optimal medical therapy including angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, beta-blockers and loop diuretics 
(Table 3.1). 4 heart failure patients also had cardiac resynchronisation 
therapy using a pacing device, however, none were atrially paced. None of 
the heart failure patients had diabetes. As patients were recruited directly 
from the clinic, the time at which experiments took place was not controlled. 
In addition, it was not possible to control for medication, caffeine, nicotine or 
physical activity prior to attendance. Experiments were carried out in a quiet 
room in Leeds General Infirmary. Patients were asked to lie semi-supine on 
a couch while heart rate, blood pressure and respiration were recorded as 
described in Chapter 2. 
 
 
3.4.2 Transcutaneous vagus nerve stimulation 
Stimulation was performed using the H-tVNS protocol described in Chapter 
2. Briefly, auricular clips were applied to left and right tragi and connected to 
a TENS machine. Stimulation was delivered as pulses of 200 µs duration at 
30 Hz for 15 minutes. Amplitude was adjusted to the level of sensory 
threshold for each individual (10 – 50 mA). 
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Table 3.1 Heart failure medication for each participant. 
 Beta-blocker ACE Inhibitor Diuretic 
Participant 1 Bisoprolol 10 mg Ramipril 10 mg Furosemide 80 mg  
Participant 2 Bisoprolol 2.5 mg Ramipirl 10 mg Furosemide 40 mg 
Participant 3 Bisoprolol 2.5 mg Ramipril 10 mg NA 
Participant 4 Bisoprolol 5 mg Candesartan 4 mg Furosemide 80 mg 
Participant 5 Bisoprolol 1.25 mg  Perindopril 8 mg Furosemide 40 mg 
Participant 6 Metoprolol 25 mg  Ramipril 5 mg  Furosemide 40 mg 
Participant 7 Bisoprolol 10 mg Ramipril 10 mg NA 
Participant 8 Carvedilol 25 mg  Candesartan 32mg  Furosemide 80mg 
 
3.4.3 Heart rate variability 
HRV was analysed offline using Spike 2 software (version 7.1; CED, UK). 
The ECG was inspected to ensure all R peaks were detected and there were 
no abnormalities in the ECG e.g. premature ventricular complexes. Ectopic 
beats could be corrected by averaging the R-R interval prior to and following 
the ectopic. A threshold was set to detect R peaks from a 5 minute ECG 
recording and R-R intervals used to produce a tachogram. This was saved 
as a memory channel and used to produce a virtual channel on which power 
spectral analysis could be carried out. Data were resampled at 5 Hz and DC 
removal process applied to remove any bias in digitisation and to set the 
channel offset to zero. Fast Fourier Transform was then applied (512 point; 
50% overlap) with a Hanning window to calculate the power spectrum of 
HRV. The power spectrum was divided into VLF, LF and HF (Chapter 2) 
components. This data was exported to Excel (2010) and normalised LF and 
HF calculated to determine LF/HF ratio. 
 
3.4.4 Baroreflex sensitivity 
Systolic blood pressure variability was calculated using a similar method to 
HRV except the threshold was set to detect peak systolic pressure. The 
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coherence between systolic blood pressure and R-R interval was calculated 
using a Spike2 script and the alpha index calculated as described in Chapter 
2. 
 
3.4.5 Tolerability questionnaire 
All heart failure patients were asked to complete a tolerability questionnaire 
at the end of the experiment to assess any possible discomfort caused by H-
tVNS. Participants were asked to rate any discomfort, pins and needles or 
warmth sensations experienced during H-tVNS using a Likert type scale 
accompanied by a visual analogue scale to aid interpretation. The scale 
ranged from 0 to 5 with 0 representing ‘not at all’ and 5 representing 
‘extremely’. Heart failure patients were also asked if they experienced any 
palpitations or feelings of anxiety during the experiment and if they found the 
couch uncomfortable. In addition, there was space for additional comments 
or suggestions they wished to make. 
 
3.4.6 Statistical analysis 
Wilcoxon signed ranks test was used to analyse the effect of H-tVNS on 
HRV compared to baseline. The Mann-Whitney U test was used to compare 
baseline characteristic between heart failure patients and healthy 
participants recruited for the study in Chapter 2. 
 
3.4.7 Study Failures 
24 heart failure patients were recruited for the study, however, 16 patients 
were excluded for the following reasons: 
 10 had ectopic beats or cardiac arrhythmias  
 2 had persistent coughing 
 2 had pre-existing pain conditions (arthritis of back and shoulder) that 
made lying on the couch painful 
 1 had pain in left arm 
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3.5 Results 
3.5.1 H-tVNS significantly improved HRV in heart failure patients 
There was a significant decrease in LF/HF ratio (p = 0.035; n = 8; Figure 3.1; 
Table 3.2) during H-tVNS. BRS was not calculated for many of the heart 
failure patients due to poor coherence between oscillations in heart rate and 
blood pressure. There was no significant change in heart rate or blood 
pressure. 
The heart failure patients were significantly older (66 ± 4.7 vs. 38 ± 
2.3; p < 0.005) than the healthy participants who received H-tVNS. The heart 
failure patients also had a significantly higher LF/HF ratio at baseline (4.23 ± 
1.21 vs. 1.20 ± 0.08; p = 0.009; Table 3.3). There was no significant 
relationship between baseline LF/HF ratio and the change in LF/HF ratio 
during H-tVNS and there was also no significant relationship between age 
and baseline LF/HF ratio. This may be due to the small sample size in this 
study. 
 
 
Table 3.2 Heart rate variability values for heart failure patients. There is 
a significant decrease in LF/HF ratio during H-tVNS (p  = 0.035). 
 
 
 
 
 Baseline Stimulation p 
Total power (ms2) 475.75 ± 172.69 434.36 ± 168.98 ns 
LF Power (ms2) 225.30 ± 54.30 174.71 ± 48.29 ns 
HF Power (ms2) 135.70 ± 88.38 180.98 ± 114.95 ns 
LF/HF 4.23 ± 1.21 3.11 ± 1.14 0.035 
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Table 3.3 Baseline characteristics of heart failure patients. 
 
 
 
 
 
Figure 3.1 The effects of H-tVNS on HRV in heart failure patients. There is 
a significant decrease in LF/HF ratio during H-tVNS (p = 0.035). In the 
one patient (participant 7) where an increase was observed, the patient 
reported that they found lying semi-supine uncomfortable which may 
have caused the increase in HRV. 
Number 8 (2 female, 6 male) 
Age (years) 66 ± 4.70 
LVEF (%) 31.88 ± 3.65 
NYHA class 3 class I; 3 class II; 1 class III; 1 class IV 
Duration of heart failure (months) 36.57 ± 5.29 
Baseline LF/HF 4.23 ± 1.21 
Heart rate (bpm) 68 ± 3.42 
Mean BP (mmHg) 68 ± 7.01 
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3.5.2 Patient tolerability of H-tVNS 
Patients were asked to complete a tolerability questionnaire which included 
specific questions about discomfort or unpleasant sensations caused by H-
tVNS. Patients were also asked if they experienced any dizziness, 
anxiousness or palpitations during the procedure. In terms of the tolerability 
questionnaire, none of the patients reported any side effects or discomfort 
caused by H-tVNS and tolerated the procedure well. However, participant 7 
rated the couch as ‘somewhat uncomfortable’ (Table 3.4). This may explain 
the increase in LF/HF ratio observed in this patient as the discomfort may 
have caused some sympathoexcitation. 
 
 
Table 3.4 Results of tolerability questionnaire. Questions were rated from 
0-5 with 0 = not at all, 3 = somewhat and 5 = extremely. 
 
 
 
 
 
Question Average Score 
(S.E.M.) 
Did you find the ear stimulation uncomfortable? 
 
0.13 ± 0.04 
Did you experience any pins and needles during the 
stimulation? 
0.75 ± 0.25 
Did you experience any warmth sensation during the 
stimulation? 
0.13 ± 0.04 
Did you feel any dizziness during the visit? 
 
0.25 ± 0.08 
Did you feel anxious during the visit? 
 
0 
Did you experience any palpitations? 
 
0 
Did you find lying on the couch uncomfortable? 
 
0.5 ± 0.17 
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3.6 Discussion 
For the first time, this study shows that H-tVNS can decrease LF/HF ratio in 
heart failure patients indicating a shift in cardiac autonomic control towards 
parasympathetic predominance. This is despite maximal medical therapy 
including beta blockers. Decreased parasympathetic activity, as determined 
by impaired HRV and BRS, is associated with an increased risk of mortality 
in heart failure patients and post myocardial infarction (La Rovere et al., 
1997; La Rovere et al., 1998), therefore, the ability to increase 
parasympathetic activity in this population is highly desirable. 
This first indication that H-tVNS may alter cardiac autonomic control 
towards parasympathetic predominance in heart failure is important. Cervical 
VNS is reserved for moderate to severe heart failure patients who are 
unsuitable for other therapies e.g. cardiac resynchronisation therapy. This is 
due to the invasive nature, cost and side effects of implantable VNS. In 
contrast, H-tVNS is a simple, inexpensive and non-invasive therapy that 
could potentially be used by a wider cohort of patients. This study also 
shows that H-tVNS is well tolerated by heart failure patients. Paraesthesia 
(pins and needles) was the most commonly reported sensation during tVNS 
(n = 3; maximum score = 3), however, none of the participants requested the 
procedure to be stopped indicating that this sensation was not sufficient to 
cause marked discomfort. 
The heart failure patients in this study were significantly older (p < 
0.0005) and also had a significantly higher baseline LF/HF ratio (p = 0.009), 
indicating accentuated sympathetic influence on heart rate compared to 
healthy participants (Chapter 2). In healthy participants, there was a 
significant relationship between baseline LF/HF ratio and the magnitude of 
the response to H-tVNS such that higher baseline LF/HF ratios were 
associated with a greater decrease during tVNS. This was not found in the 
heart failure group, however, this may be due to the small sample size. This 
may also explain why there was no relationship between age and baseline 
LF/HF in this group unlike the findings reported in Chapter 2. Age matched 
controls without cardiovascular conditions may help determine the degree of 
elevation in baseline LF/HF that is due to heart failure. In addition, future 
- 105 - 
studies should be controlled for time of day and provide participants with 
information prior to attendance to control caffeine, nicotine and food intake. 
The mechanisms behind the effects of H-tVNS in heart failure patients 
require investigation. There is a decrease in LF power during H-tVNS that is 
similar to the findings in healthy participants, however, this does not reach 
significance. There is also an increase in HF power that does not reach 
significance. The lack of significance may be due to the small sample size in 
this study. Further work to increase patient numbers is required to determine 
the mechanism of H-tVNS effects on HRV in heart failure. The effects of H-
tVNS on sympathetic nerve activity in heart failure patients also need to be 
determined e.g. by recording MSNA using microneurography. Due to the 
sympathoexcitation that occurs in heart failure, the incidence of MSNA 
bursts can be 100% i.e. a burst occurring during every heart beat (Macefield 
et al., 1999). Single units do not fire during every burst, therefore, the 
recording and analysis of single unit MSNA offers vital information that 
MSNA bursts cannot provide. This would determine if the effects of H-tVNS 
on sympathetic nerve activity in heart failure patients are similar to healthy 
participants without cardiovascular disease (Chapter 2). 
The residual effect of H-tVNS on HRV, as observed in healthy 
participants in Chapter 2, was not investigated due to time constraints in the 
clinic. A residual effect may make H-tVNS a more practical and patient 
friendly therapy if only intermittent application is required rather than 
continuous, therefore, this merits investigation in the future. Auricular 
electroacupuncture in coronary artery disease patients was reported to have 
no effect on symptoms after 1 treatment, however after 4 treatments, angina 
no longer occurred at rest and after 7-8 treatments, patients had no 
symptoms during moderate exercise (Zamotrinsky et al., 1997; Zamotrinsky 
et al., 2001). Moreover, tVNS also improved post-surgical (coronary artery 
bypass) outcomes with improved haemodynamics and sinus rhythm 
compared to the sham treated group. This is remarkable as surgery took 
place 2-3 weeks after tVNS ceased and symptoms of angina remained 
reduced during this time (Zamotrinsky et al., 1997; Zamotrinsky et al., 2001). 
This indicates that chronic tVNS may produce a prolonged residual effect 
that precludes the need for constant stimulation.  
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3.6.1 Manifold beneficial effects of H-tVNS in heart failure 
The potential beneficial effects of H-tVNS in heart failure may not be 
restricted to improved cardiac autonomic function. H-tVNS may reduce 
sympathetic activity in heart failure and thereby prevent cardiac remodelling 
as high levels of noradrenaline are cardiotoxic causing apoptosis. Applying 
noradrenaline to cultured isolated rat cardiomyocytes caused apoptosis that 
was eliminated by propranolol indicating that this process is mediated by 
beta-receptors (Communal et al., 1998). Reducing cardiac sympathetic 
activity would reduce catecholamine release and may attenuate pathological 
remodelling of the heart. 
Inflammatory markers (tumour necrosis factor alpha – TNF-alpha and 
interleukin 6 – IL6) are elevated in heart failure and the degree of activation 
is correlated to NYHA classification (Torre-Amione et al., 1996). The 
importance of TNF-alpha in the development of heart failure was 
demonstrated in transgenic mice that overexpressed TNF-alpha in the 
myocardium. All mice developed heart failure and the severity and 
progression of left ventricular impairment were dependent of the degree of 
overexpression (Franco et al., 1999). The vagus nerve is an essential 
component of the inflammatory reflex (Rosas-Ballina et al., 2011) and 
stimulation reduced levels of pro-inflammatory cytokines in a rat model of 
endotoxaemia (Borovikova et al., 2000). Indeed, cervical VNS in a canine 
model of heart failure also reduced plasma levels of inflammatory markers 
(Zhang et al., 2009b). Using a rat model of endotoxaemia, tVNS also 
reduced plasma levels of pro-inflammatory cytokines, moreover, this effect 
was abolished by cervical vagotomy (Zhao et al., 2012). This indicates that 
tVNS may be capable of reducing inflammation in heart failure and thereby 
slow the progression of heart failure. 
Approximately one third of heart failure patients die of sudden cardiac 
death (Narang et al., 1996), most commonly due to ventricular tachycardia 
(84%) (de Luna et al., 1989). In a ground-breaking study, cervical VNS 
reduced the incidence of ventricular tachycardia and improved survival in a 
canine model of heart failure (Vanoli et al., 1991). The mechanisms behind 
the protective effect of VNS against ventricular arrhythmias are under 
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investigation. VNS affects electrical restitution in the heart (the relationship 
between action potential duration and diastolic interval) and this is thought to 
contribute to the anti-fibrillatory effect of VNS. A steep restitution curve 
results in electrical instability and is related to the occurrence of ventricular 
fibrillation (VF) (Riccio et al., 1999). Flattening of the restitution curve with 
drugs such as verapamil (a calcium channel blocker) prevented the induction 
of VF in dogs (Riccio et al., 1999). The effects of VNS on restitution have 
been studied using an isolated rabbit heart preparation in which the 
autonomic innervation is intact (Ng et al., 2001). VNS flattened the restitution 
curve and increased the threshold at which VF could be induced (Ng et al., 
2007). This occurred in the absence of sympathetic nerve activity suggesting 
that the anti-fibrillatory effect of VNS is direct and does not require 
antagonistic sympathetic activity. Zamotrinsky et al. (1997) reported that 10 
days of tVNS treatment reduced the occurrence of post-operative 
arrhythmias in patients undergoing coronary artery bypass surgery, 
however, there has been no specific investigation of the effects of tVNS on 
arrhythmias. 
VNS is approved for treatment resistant depression in the US and this 
is pertinent in light of recent developments in psychogenic heart disease – 
the association between mental stress or psychiatric illness and the 
development of cardiovascular disease (Esler, 2010). Major depressive 
disorder significantly increases mortality risk (Faller et al., 2007; Sherwood 
et al., 2007; Lesman-Leegte et al., 2009) and hospitalisation (Sherwood et 
al., 2007) in heart failure patients. It is also associated with reduced quality 
of life scores (Bekelman et al., 2007) compared to heart failure patients 
without depression. Depression, like heart failure, is associated with 
sympathetic activation. Plasma noradrenaline levels were elevated in 
patients with major depression compared to controls (Veith et al., 1994). 
Pilot data have indicated that tVNS reduced depression symptoms 
measured using the Beck Depression Inventory in MDD patients (Hein et al., 
2013) and results presented in Chapter 2 demonstrated that H-tVNS 
reduced MSNA in healthy volunteers. These results support the potential of 
H-tVNS to reduce comorbidity of depression in heart failure and may 
improve prognosis and quality of life in this patient population. 
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Cervical VNS has led to improved quality of life scores in heart failure 
patients (De Ferrari et al., 2011). Depression was not assessed in this study 
and was not mentioned in the inclusion/exclusion criteria, therefore, it is 
difficult to speculate the impact this may have had on quality of life scores. 
Improved quality of life may be related to improved 6 minute walking test 
results and heart failure symptoms which would lead to increased ability to 
carry out activities of daily life. tVNS in patients with coronary artery disease 
improved exercise tolerance during a cycling test with 90% tolerating 50 W 
after 10 days of treatment compared to 0% at baseline (Zamotrinsky et al., 
1997). These patients also reported an improved ability to carry out activities 
of daily life after treatment. These preliminary results require validation, 
however, tVNS may facilitate independence of heart failure patients and 
thereby improve quality of life. 
 
3.6.2 Is VNS suitable for all heart failure patients? 
Atrial fibrillation (AF) occurs in approximately one third of heart failure 
patients and is associated with an increased risk of mortality (McManus et 
al., 2013). The genesis of atrial fibrillation is complex involving both 
sympathetic and parasympathetic activation. Acetylcholine perfused into the 
sinus node artery in dogs consistently induced AF (n = 20) (Sharifov et al., 
2004). Subsequent perfusion of isoproterenol (beta-receptor agonist) 
facilitated AF induction and reduced the concentration of ACh required 
(Sharifov et al., 2004). Sympathetic activation increased calcium entry and 
spontaneous calcium release from the sarcoplasmic reticulum whereas 
vagal activation reduced the effective refractory period (Shen et al., 2012). 
Combined intracellular calcium mishandling and shortened action potentials 
contribute to the generation and maintenance of AF (Shen et al., 2012). 
Indeed, cervical VNS is commonly used to induce AF in animal models 
(Katsouras et al., 2009; Zhang and Mazgalev, 2011). These findings suggest 
that VNS is not suitable for patients with AF and may risk promoting the 
development of AF in previously unaffected patients, however, AF has not 
been reported as a side effect despite the large numbers of refractory 
epilepsy patients treated with VNS (Zhang and Mazgalev, 2011). 
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Furthermore, VNS may be beneficial in reducing AF in heart failure. Using a 
stimulation protocol similar to that used in patients, left VNS reduced the 
frequency of AF in a canine AF model (atrial pacing) compared to sham 
(Shen et al., 2011). Extracellular recordings from the left stellate ganglion 
showed reduced neuronal discharge during VNS compared to baseline 
indicating a reduction in sympathetic nerve activity. Immunohistochemistry of 
the left stellate ganglion after 1 week of VNS revealed a significant reduction 
in the number of tyrosine hydroxylase positive neurones compared to control 
dogs suggesting that VNS may cause neuronal remodelling in the stellate 
ganglion (Shen et al., 2011). The stimulation parameters for VNS used to 
induce experimental AF are much higher and cause a significant decrease in 
heart rate whereas therapeutic levels of VNS are lower and produce little 
change in heart rate (Zhang and Mazgalev, 2011). This may be crucial to the 
differential effects of VNS on the atria. Transcutaneous VNS (at 80% below 
the voltage required to change heart rate) has recently been investigated in 
a canine model of atrial fibrillation and was capable of supressing AF and 
reversing acute atrial remodelling (i.e. shortened effective refractory period) 
induced by rapid atrial pacing. Furthermore, this effect was abolished by 
transection of left and right thoracic vagus nerves (Yu et al., 2013) indicating 
that H-tVNS may be an alternative approach to cervical VNS. This is 
encouraging, however, a limited number of studies have investigated the 
effects of low level VNS in AF and further evidence of safety is warranted 
before trialling in patients with AF. 
 
3.6.3 Conclusion 
Studies of tVNS in clinical populations or animal models are preliminary in 
nature and require validation, however, initial results are encouraging and 
merit further investigation. tVNS may have manifold effects that could be 
beneficial, not only in heart failure, but a variety of conditions characterised 
by autonomic imbalance such as hypertension (Charkoudian and Rabbitts, 
2009). tVNS is a simple, inexpensive and, crucially, non-invasive technique 
that may be utilised by a wider cohort of patients than cervical VNS. 
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Chapter 4 
Central projections of the auricular branch of the vagus 
nerve in humans 
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4.1 Introduction 
The results presented in Chapters 2 and 3 of this thesis indicate that H-tVNS 
can alter cardiovascular autonomic function in healthy participants and heart 
failure patients towards parasympathetic predominance, however, the 
mechanisms underlying these effects require investigation. There is a lack of 
detailed information regarding the precise innervation of the external ear, 
particularly in humans. The external ear is supplied by the great auricular 
nerve and the lesser occipital nerve, which originate from the cervical plexus 
(C2 and C3 spinal nerve roots), the auriculotemporal nerve (a branch of the 
trigeminal nerve), and the auricular branch of the vagus nerve (ABVN) 
(Peuker and Filler, 2002).  
The ABVN (also called Arnold’s nerve or the Alderman’s nerve) has 
received little attention and hence there is a dearth of information regarding 
its anatomy. The ABVN arises from the superior (jugular) ganglion of the 
vagus nerve (Nomura and Mizuno, 1984; Gupta et al., 1986; Folan-Curran et 
al., 1994; Tekdemir et al., 1998; Folan-Curran and Cooke, 2001). It then 
passes posterior to the internal jugular vein to enter the mastoid canaliculus 
in the lateral wall of the jugular fossa (Gupta et al., 1986; Tekdemir et al., 
1998). The mastoid canaliculus runs through the temporal bone to the 
tympanomastoid fissure (Tekdemir et al., 1998). Before reaching the 
tympanomastoid fissure, the mastoid canaliculus crosses the facial canal 
about 4.5 mm above the stylomastoid foramen at which point the ABVN 
crosses the facial canal and then emerges through the tympanomastoid 
fissure (Gupta et al., 1986; Tekdemir et al., 1998). The ABVN is principally 
distributed to the antihelix, conch, cymba concha and tragus of the ear 
(Peuker and Filler, 2002). 
The central projections of the ABVN have been investigated in cats 
and dogs by applying the neuronal tracer horse radish peroxidase (HRP) to 
the nerve (Nomura and Mizuno, 1984; Chien et al., 1996). The main central 
projection of the ABVN was to the spinal trigeminal nucleus which processes 
touch, pain and temperature sensations from the face (Chien et al., 1996). 
There was also a smaller projection to the nucleus tractus solitarius, a 
nucleus which is integral to central autonomic control. Interestingly, the 
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ABVN projected to the dorsomedial part of the caudal NTS which is the area 
that receives baroreceptor afferents (Ciriello et al., 1981). The central 
projections of the ABVN in humans have never been explored. This could be 
achieved by applying a neuronal tracer to the ABVN in human cadavers, 
however, the majority of neuronal tracers e.g. neurobiotin rely on active 
metabolism for axonal transport and therefore are inappropriate for fixed 
tissue (Lanciego and Wouterlood, 2011). This can be overcome by using a 
strongly lipophilic carbocyanine tracer e.g. DiI (Lanciego and Wouterlood, 
2011). DiI diffuses along the plasma membrane and was first used as a 
neuronal tracer in fixed tissue by Godement et al. (1987) to investigate the 
development of the optic nerve in embryonic mice. DiI was reported to travel 
retrogradely and anterogradely and estimated to travel 6 mm/day in living 
tissue compared to 2 mm/week in fixed tissue (Molnár et al., 2006). 
Clarifying the central projections of the ABVN using neuronal tracing could 
aid interpretation of the effects of H-tVNS on cardiovascular autonomic 
control and the mechanisms involved. 
 
4.2 Hypothesis 
The auricular branch of the vagus nerve projects to the NTS and/or areas of 
the brainstem involved in autonomic regulation in humans. 
 
4.3 Aim 
The aim of this study was to investigate the central projections of the ABVN 
in human cadavers using a neuronal tracer. 
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4.4 Methods 
4.4.1 Obtaining human tissue for research purposes 
Ethics approval was obtained from the University of Leeds (Appendix - 
BIOSCI 11-001). Donors that had provided prior written consent for tissue to 
be used for research purposes and for images to be taken were identified in 
the University of Leeds Anatomy Department. 4 heads that met these 
conditions, had intact auricles and brainstems and were no longer needed 
for teaching purposes were selected. A Tissue Transfer Agreement was 
completed and signed to transfer the tissue from the Anatomy Human 
Tissue license to the Research licence. The donors included 2 females and 
2 males and were > 65 years old at death. Tissue had been embalmed 3-5 
years previously using embalming fluid containing 75% methanol, 1.6% 
formaldehyde, phenol, glycerol and water. 
 
4.4.2 Dissection of the ABVN 
Dissections were made posterior to the ear to locate the ABVN as it 
emerged from the tympanomastoid fissure. The mastoid process was 
palpated and a longitudinal skin incision made 1-2 cm posterior to this 
structure. A horizontal incision was made superior to the external ear and 
extended to the first incision. The skin overlying the temporal bone and the 
posterior surface of the ear was then reflected. The underlying parotid fascia 
was removed and the auricularis posterior muscle reflected. A magnifier with 
a mounted light was used to carefully remove deep fascia and to identify 
auricular nerves. A nerve was accepted as being the ABVN if it:  
1) emerged from the tympanomastoid fissure 
2) continued straight over the posterior surface of the auricle 
3) pierced the auricular cartilage to reach the anterior surface of the ear.  
 
The ABVN could not be located in one head therefore 3 were used for the 
study (2 right and 1 left ABVN; Figure 4.1). In one case, 2 nerves on the 
same side met the criteria and both were utilised for tracer application 
(Figure 4.1 Error! Reference source not found.B). 
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Figure 4.1 Dissections of the right ABVN. Posterior view of dissected ears 
showing the ABVN overlying white card ( A – left ABVN; B and C – right 
ABVN). One case presented with a double right ABVN (B). 
A 
B 
C 
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4.4.3 Application of neuronal tracer 
The tissue used in this study was fixed using formaldehyde, therefore, a 
carbocyanine neuronal tracer was selected as these diffuse along the 
plasma membrane even in fixed tissue. This can be a long process as 
standard DiI (DiIC18 or 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine 
perchlorate) travels along axons at approximately 0.4 mm/day (Godement et 
al., 1987). Dilinoleyl DiI (also called FAST DiI or 1,1'-dilinoleyl-3,3,3',3'-
tetramethylindocarbocynanine perchlorate; Biotium Inc.,USA) is an analogue 
of DiI in which the 2 hydrocarbons chains are unsaturated (in contrast to 
saturated) allowing faster diffusion (Freidland et al., 1996). Dilinoleyl DiI was 
selected as the most appropriate tracer for this study due to the distance of 
diffusion required (approximately 5 cm). Once the ABVN was identified, it 
was sectioned and DiI oil pasted onto the proximal end using forceps. Care 
was taken to ensure DiI was not applied to any other tissue. The proximal 
end of the ABVN was then enclosed in a small, blind-ending plastic tube 
which was fixed in place using superglue to isolate the DiI coated end and 
ensure it did not touch the surrounding tissue. The tissue was then left at 
room temperature in the mortuary for 7 months. 
 
4.4.4 Tissue Preparation 
After 7 months, the ABVN was further dissected into the tympanomastoid 
fissure and removed using scissors. To remove the brainstem, firstly, the 
cervical musculature and the occipital belly of the occipitofrontalis muscle 
were removed using a large scalpel to expose the cervical vertebrae and the 
occipital bone. The pedicles of the upper cervical vertebrae were cut using a 
bone saw and the neural arch of the vertebrae removed to expose the spinal 
cord and caudal medulla. The occipital bone and posterior parts of the 
parietal and temporal bones were removed using a bone saw to expose the 
posterior surface of the occipital lobe and cerebellum. A large scalpel was 
inserted into the fissure between the occipital lobe and cerebellum, inferior to 
the tentorium cerebelli, to section the midbrain. The midbrain, pons, medulla, 
cerebellum and rostral cervical spinal cord were then carefully extracted. 
The superior, middle and inferior cerebellar peduncles were sectioned to 
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detach the cerebellum and the remaining brainstem was divided at the 
pontomedullary junction. Ventral and dorsal rootlets of the first cervical 
spinal root were identified and the spinal cord inferior to this point was 
removed. The meninges covering the medulla were removed using forceps. 
The medulla was then mounted on a vibrating microtome (Leica VT1000M, 
UK) and transverse sections of 50 µm were cut. Sections were mounted on 
glass slides with Vectashield (Vector Laboratories, USA). 
  
4.4.5 Microscopy 
Slides were viewed under a microscope equipped with epi-fluorescence 
(Nikon Eclipse E600) and images were obtained using an integrated CCD 
camera attached to an Aquis image capture system (Synoptics Ltd. UK).  
 
4.5 Results 
DiI was observed in the ABVN proximal to the site of application as the 
nerve entered the tympanomastoid fissure indicating diffusion of the tracer 
along the nerve, however, DiI was not observed in any of the sections of the 
medulla (Figure 4.2). There was a high level of autofluorescence in medulla 
sections which could be observed in both the red and blue fluorescence 
channels and this may have obscured any discrete DiI labelling. 
Autofluorescence was observed in all sections and was present throughout 
the medulla including the NTS and was very pronounced in the inferior 
olivatory nucleus. There was no evidence of any axonal-like labelling, 
indicating that DiI had not entered the medulla through projections of the 
ABVN. There was also no evidence of DiI labelled projections to the spinal 
trigeminal nucleus which receives the majority of ABVN projections. 
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Figure 4.2 Evidence of DiI tracing in the ABVN from two donors and 
autofluorescence in the NTS, spinal trigeminal nucleus (SpV) and 
inferior olive (IO). DiI can be seen diffusing superiorly along fibres of 
the ABVN away from the application site (inferior portion). Intensity is 
greatest at the application site and diminishes with distance. Areas of 
fluoresence in the same section of NTS (demarcated by dotted line), 
SpV and IO are visible in the red channel and blue channel indicating 
that this is autofluoresence and not DiI labelling. 
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4.6 Discussion 
In this unique study an attempt was made to trace the central projections of 
the ABVN in humans using DiI, however, no evidence of DiI reaching the 
medulla was found. This may be due to the extensive autofluorescence that 
was observed and may have obscured DiI labelling or it may be that 7 
months was not sufficient to allow diffusion of DiI from the ABVN at the 
tympanomastoid fissure to the medulla.  
DiI is a lipophilic neuronal tracer that diffuses along the plasma 
membrane, therefore, with enough time DiI should travel along the plasma 
membrane of axons in the ABVN to the medulla. It was estimated that the 
distance from the ABVN as it exits the skull at the tympanomastoid fissure to 
the median of the medulla was 50 mm and that seven months would be 
sufficient time to allow DiI to diffuse this distance. This would require a 
diffusion rate of 1.8 mm per week. There is no published diffusion rate data 
for ‘fast’ DiI (used in this study), however, reports using standard DiI state 
that two weeks were sufficient to obtain staining of axons in fixed mouse 
tissue for a distance of 5 mm (Godement et al., 1987). It has been shown 
that the diffusion rate of standard DiI slows with time and distance from the 
application site. Indeed, this same study found that, by 6 weeks, standard DiI 
tracing had reached a distance of 12 mm (Godement et al., 1987). This 
indicates that the average diffusion rate had slowed from 2.5 mm/week to 
2.0 mm/week. Despite this it was predicted that, as ‘fast’ DiI should have a 
more rapid diffusion rate due to the unsaturated hydrocarbon chains, 7 
months should be sufficient. Detailed investigations of the dynamics of ‘fast’ 
DiI diffusion along peripheral nerves are required to establish the time 
required for long distance neuronal tracing.  
In the future, modifications to the protocol to optimise the performance 
of the neuronal tracer may limit the time needed for diffusion. For example, 
incubating the tissue at 37ºC significantly increased standard DiI diffusion 
time in fixed rat spinal cord compared to tissue kept at room temperature 
(Chen et al., 2006). Applying a direct current to fixed human tissue has also 
been found to increase the diffusion time of DiI along the median and ulnar 
nerves. Applying a DC electric field of 40 V/cm increased the diffusion rate 
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100 times compared to control tissue (Swift et al., 2005). Another option may 
be to dissect the ABVN within the mastoid canaliculus or the jugular foramen 
of the temporal bone in order to reduce the diffusion distance to the medulla.  
 
4.6.1 Sources of autofluorescence  
A high degree of autofluorescence was present in the medulla which may 
have masked DiI labelling. Autofluorescence refers to the presence of 
endogenous fluorescence in the tissue or fluorescence induced by the tissue 
fixation process. A source of endogenous fluorescence is lipofuscin, the 
breakdown product of red blood cells (Billinton and Knight, 2001). Lipofuscin 
is prominent in neurones and levels of lipofuscin increase with normal 
ageing (Katz and Robison Jr, 2002; Ohtaki et al., 2012). The donors in this 
study were elderly, therefore, high levels of lipofuscin may account for the 
prominent autofluorescence present in this tissue. Indeed, the inferior olive is 
reported to accumulate more lipofuscin with ageing than any other area of 
the brain (Rogers et al., 1980) which is in keeping with the observations of 
this study. 
Aldehyde fixation can also result in autofluorescence. Aldehydes react 
with amine groups in tissue to form fluorescent compounds (Clancy and 
Cauller, 1998). Furthermore, aldehyde induced fluorescence increases with 
the duration of fixation. The tissue in this study was previously used in 
anatomy teaching and was fixed 3-5 years ago. The prolonged fixation time 
may have contributed to the intense autofluorescence observed in this study. 
In future studies it would be advisable to utilise tissue from younger 
donors to limit levels of lipofuscin in the tissue, however, it is unlikely that 
tissue would be obtained from younger donors as all the donations to the 
anatomy department are from elderly individuals. An alternative solution may 
be to obtain tissue from post-mortems, however, acquiring consent prior to 
death from younger individuals may be rare. It is possible to alter the fixation 
process to reduce autofluorescence. Reducing the concentration of 
formaldehyde (soft-embalming) would reduce the level of autofluorescence. 
One such technique utilises glycol, salts and boric acid to preserve the 
tissue and reduces the concentration of formaldehyde required (Eisma et al., 
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2013). This is called the Thiel method and results in flexible, life-like fixation 
that is considered ideal for surgical training (Eisma et al., 2013). The degree 
of autofluorescence induced by this method of fixation is unknown, however, 
it would be predicted that the lower concentration of formaldehyde used 
would reduce the level of autofluorescence generated. Furthermore, 
decreasing the levels of formaldehyde used would also reduce cross-linking 
of proteins, facilitating the diffusion of DiI and other lipophilic neuronal 
tracers.  
 
4.6.2 Conclusions 
The results of this study are inconclusive, however, elucidating the central 
projections of the ABVN in humans is vital in understanding the mechanisms 
of H-tVNS and its effects on cardiovascular autonomic function. There are a 
number of possibilities to enhance the neuronal tracing protocol and reduce 
autofluorescence that warrant investigation. This would clarify if the central 
projections of the ABVN in humans are similar to those reported in studies of 
cats and dogs (Nomura and Mizuno, 1984; Chien et al., 1996). Results from 
animal studies indicate that the ABVN is likely to project to the NTS, 
therefore, stimulating this pathway could influence central control of 
autonomic function.  
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Chapter 5 
The influence of transcranial direct current stimulation on 
autonomic function 
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5.1 Introduction 
Transcranial direct current stimulation (tDCS) is a non-invasive 
neuromodulatory technique that has been used to influence cortical 
excitability in a range of conditions, including depression (Brunoni et al., 
2013a) and pain (Borckardt et al., 2011), and has also been investigated in 
stroke rehabilitation (Schulz et al., 2013). Different stimulation parameters 
and electrode montages have been used in tDCS research however the 
most common arrangement consists of one surface electrode placed over 
the motor cortex and the other placed on the contralateral supraorbital 
region (Stagg and Nitsche, 2011; Im et al., 2012). A small direct current, 
typically 1-2 mA, is then applied which influences the spontaneous activity of 
cortical neurones (Nitsche and Paulus, 2000). 
tDCS alters cortical excitability through a polarity-specific shift in 
resting membrane potential resulting in changes in spontaneous neuronal 
firing rates. The effects of tDCS on motor cortex excitability can be assessed 
by measuring the amplitude of muscle evoked potentials (MEPs) elicited by 
transcranial magnetic stimulation of the motor cortex. Transcranial magnetic 
stimulation produces a magnetic pulse that, in turn, produces an electric 
current in the underlying brain tissue (Fregni and Pascual-Leone, 2007). 
Anodal tDCS causes a sub-threshold depolarisation and increases the 
amplitude of MEPs indicating increased cortical excitability. This is mediated 
by voltage dependent calcium and sodium channels, demonstrated by orally 
administering carbamazepine (CBZ; sodium channel blocker), flunarizine 
(FLZ; calcium channel blocker) or placebo drugs to healthy participants prior 
to tDCS. CBZ and FLZ reduced the effects of anodal tDCS and had no effect 
on cathodal tDCS (Nitsche et al., 2003b).  
The effects of anodal tDCS over the motor cortex on MEP amplitude 
persist for up to 90 minutes post stimulation suggesting that tDCS may also 
induce synaptic plasticity through long term potentiation and long term 
depression like mechanisms. This is supported by the finding that 
dextromethorphan (DMO; NMDA receptor antagonist), administered to 
healthy participants prior to tDCS, abolished the residual effects of both 
anodal and cathodal tDCS (Liebetanz et al., 2002). This indicates that 
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changes in glutamatergic signalling through NMDA receptors plays an 
important role in the residual effect of tDCS. Magnetic resonance 
spectroscopy has also revealed a polarity dependent change in 
neurotransmitter levels following tDCS (Stagg et al., 2009). There was a 
decrease in GABA concentration in the motor cortex of healthy human 
volunteers (n = 11) following anodal tDCS and a decrease in glutamate 
concentration following cathodal tDCS (n = 7). This suggests that a reduction 
in GABAergic inhibition contributes to the residual effects of anodal tDCS 
and the inhibitory effects of cathodal stimulation are mediated by a reduction 
in glutamatergic signalling.  
Anodal tDCS has previously been reported to cause respiratory 
depression in a healthy volunteer during frontal tDCS with an extra-cephalic 
electrode (Lippold and Redfearn, 1964; Redfearn et al., 1964). This 
suggests that brainstem respiratory centres may be affected by tDCS. 
Furthermore, this implies that tDCS may also affect autonomic control 
through modulation of neuronal activity in the brainstem, however, only a 
handful of studies have investigated the potential autonomic effects of tDCS 
with conflicting results (see General Introduction Table 1.3) (Accornero et al., 
2007; Vandermeeren et al., 2010; Montenegro et al., 2011; Raimundo et al., 
2012). These studies utilised a variety of tDCS montages and autonomic 
measures making it difficult to draw any conclusions. Indeed, many of the 
autonomic measures used were crude estimates such as heart rate, blood 
pressure and respiratory frequency which are not sufficiently accurate to 
detect potential changes in autonomic function. Clarifying any potential 
influence of tDCS on autonomic function is essential as this may be an 
unknown and underappreciated side effect of tDCS treatment. 
 
5.2 Hypothesis 
Transcranial direct current stimulation over the motor cortex will influence 
central control of cardiovascular autonomic function.  
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5.3 Aims and Objectives 
The aim of this study was to investigate the effects of tDCS on 
cardiovascular autonomic function in healthy human volunteers. The 
objectives were to determine: 
1. the effects of anodal tDCS over the motor cortex on cardiovascular 
autonomic function. 
2. the effects of cathodal tDCS over the motor cortex on cardiovascular 
autonomic function. 
3. the effects of tDCS on sympathetic nerve activity measured by 
microneurography. 
 
5.4 Methods 
5.4.1 General Protocol 
The study was approved by the University of Leeds Ethics Committee 
(Appendix - BIOSCI 11-019) and conducted in accordance with the 
Declaration of Helsinki. Informed written consent was obtained from all 
participants. 22 healthy participants were recruited for the study. Male and 
female participants over 18 years were included. Exclusion criteria were a 
history of cardiovascular disease, diabetes, hypertension, migraine or 
epilepsy. Participants were also excluded if they had any metal implants, 
were taking any psychotropic drugs (e.g. anti-depressants) or were 
pregnant. The study was conducted in the same room and similar 
environment as described in Chapter 2 to avoid confounding factors 
affecting autonomic control. Data were recorded at baseline, during tDCS 
and during recovery. The study used a double-blind, sham controlled design. 
17 participants visited the laboratory twice (at least 7 days apart) and 
received active or sham stimulation. The order of the stimulation was 
random so that half received sham stimulation on the first visit and half 
received active first. An additional 5 participants visited the laboratory once 
for microneurography recordings and received anodal tDCS. 
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5.4.2 Transcranial direct current stimulation 
Different parameters and electrode montages have been used in tDCS 
research however the most common arrangement consists of one surface 
electrode placed over the motor cortex and the other placed on the 
contralateral supraorbital region (Stagg and Nitsche, 2011; Im et al., 2012). 
tDCS was delivered by a specially developed constant current stimulator 
(Eldith DC stimulator, Magstim, UK) connected to rubber surface electrodes 
(5 cm by 7 cm, area = 35 cm2) housed in saline (0.9%) soaked sponges. For 
anodal stimulation over the non-dominant primary motor cortex (M1), the 
anodal electrode was placed over C3/4 (using the International 10-20 EEG 
system) and the cathodal electrode was placed over the contralateral 
supraorbital area. Electrodes were held in place by elastic straps placed 
round the head. For cathodal tDCS, the electrode positions were reversed.  
On the first visit, after experimental setup but before baseline 
recordings, participants experienced 10 s of 1 mA active tDCS to familiarise 
them with the procedure. This was performed in order to attenuate anxiety 
during subsequent monitoring and familiarise participants with any 
sensations they might experience during the stimulation (e.g. itching). The 
aim was to reassure participants thereby minimising changes in heart rate, 
blood pressure and respiration linked to anxiety. 
During active stimulation, a constant current of 1 mA was applied for 
15 minutes, taking 30 seconds to ramp up at the start of stimulation and 30 
seconds to ramp down at the end of stimulation. Current density was 0.029 
mA/cm2 in accordance with safety criteria (Nitsche et al., 2003a). 14 
participants (7 male, 7 female; 21-48 years) received anodal stimulation and 
8 (4 male, 4 female; 21-45 years) received cathodal stimulation. For sham 
stimulation, electrodes were placed in the same positions as for active 
stimulation. There was a 30 s ramping up period at the start of sham 
stimulation then the current was immediately ramped down again. This 
mimicked the cutaneous sensations experienced during active stimulation. In 
all conditions, recording of autonomic variables commenced after the initial 
30s when the current reached maximal test parameters (Figure 5.1). 
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Figure 5.1 Stimulation protocol for active tDCS. Current was applied for 
15 minutes and was either anodal (anode placed over the motor cortex) 
or cathodal (cathode placed over the motor cortex). 
 
 
5.4.3 Blinding procedure 
The participants and the investigator performing data analyses were blinded 
as to whether tDCS was active or sham. The tDCS device remained out of 
the participants’ and investigator’s sight at all times. Another un-blinded 
investigator, not involved in data analysis, administered tDCS. Participants 
were asked after the experiments whether they were able to determine 
which experimental session was "real" (active) stimulation and which one 
was "not real” (sham) stimulation. Half of the participants subsequently 
guessed correctly and as this was no better than chance, this was accepted 
as a suitable sham condition. 
 
5.4.4 Tolerability Questionnaire 
After each visit, participants (n = 9) were asked to provide feedback about 
their experience in the form of a questionnaire. Participants were asked to 
score experiences on a scale of 0-5 with 0 equal to none at all and 5 equal 
to extreme. This was also presented as a visual analogue scale to aid 
interpretation (Likert scale). There was no significant difference between 
scores for active and sham visits (Table 5.1). The most commonly reported 
experiences were itching or tingling during tDCS.  
30 s 
ramp up 
30 s  
ramp down 
15 minute recording period 
1 mA for active tDCS 
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Table 5.1 Summary of tDCS tolerability scores. There was no significant 
difference in scores between active and sham tDCS. tDCS was well 
tolerated and no participants withdrew from the study. 
 Active tDCS Sham tDCS 
Discomfort 1.38 ± 0.32 1.13 ± 0.35 
Tingling  2.44 ± 0.24 2.22 ± 0.32 
Itching  2.78 ± 0.36 2.00 ± 0.29 
Warmth 0.89 ± 0.26 0.78 ± 0.22 
Burning 0.78 ± 0.32 0.56 ± 0.24 
 
 
In addition, space was provided for free-text comments and suggestions. 
Four comments were left in total; 
 “tingling and itching only in first minute or so”  
 “stinging” 
 “initial burning sensation surprising” 
 “hat strap unpleasant” 
Participants were asked to notify the investigator if there were any symptoms 
e.g. headache after tDCS but none were reported. No participants withdrew 
from the study and all returned for the second visit. 
 
5.4.5 Cardiovascular autonomic control and data acquisition 
Heart rate, blood pressure, respiration and MSNA were recorded as 
described in Chapter 2. Muscle sympathetic nerve activity (MSNA) was 
recorded in 5 volunteers during anodal tDCS (2 male, 3 female; 21-46 
years). Microneurography was only performed for anodal tDCS after data 
analyses revealed that anodal tDCS affected HRV. It was considered 
unethical to perform microneurography in cathodal and sham tDCS groups 
as this in an invasive procedure and analyses revealed cathodal tDCS had 
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no effect on HRV. Data acquisition and analyses of HRV, BRS and MSNA 
were conducted as in Chapter 2.  
 
5.4.6 Statistical analysis 
All statistical analyses were carried out using SPSS (version 18). 
Independent t-test or Mann-Whitney U test was used to compare group 
characteristics. Freidman’s test with post hoc Bonferroni correction was used 
to analyse within subject effects of tDCS on HRV. To analyse the effects of 
different modes of stimulation (anodal or cathodal) on heart rate and blood 
pressure, mixed mode ANOVAs were used. Data are presented as group 
mean ± standard error of the mean (S.E.M.) unless stated otherwise. P-
values < 0.05 were considered significant. 
 
5.5 Results 
5.5.1 Effect of transcranial direct current stimulation on heart rate 
variability 
There was an increase in LF/HF ratio during anodal tDCS which continued 
into the post-stimulation phase and reached significance (n = 14;Freidman’s 
test, p = 0.017) whereas there was no significant change in cathodal (n = 8) 
and sham (n = 17) tDCS groups (Figure 5.2; Table 5.2). There was also a 
significant increase in LF power during anodal tDCS (Freidman’s test, p = 
0.011) whereas HF power did not change significantly (Figure 5.3; Table 
5.3). There was no significant difference between those who received active 
tDCS on the first visit compared to those who received sham first. There was 
no significant change in BRS. Mixed mode ANOVAs revealed a significant 
decrease in heart rate (time effect, p = 0.010) and increase in mean BP (time 
effect, p <0.0005). Mode of stimulation (anodal or cathodal) had no impact 
on heart (main effect for mode of stimulation, p > 0.05) or mean BP (main 
effect form mode of stimulation > 0.05). Furthermore, there was no 
interaction between mode of stimulation and time (Figure 5.4). 
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Figure 5.2 The effects of anodal, cathodal and sham tDCS on heart rate 
variability. (A) There was an increase in LF/HF ratio during anodal 
tDCS which continued into the recovery phase and reached 
significance (n = 14; time effect, p = 0.017) indicating a shift in cardiac 
autonomic control towards sympathetic predominance whereas there 
was no significant change during cathodal (n = 8) and sham (n = 17) 
tDCS. There was a significant difference between anodal and cathodal 
groups (interaction, p = 0.005). (B) Illustration of electrode placements 
for anodal and cathodal tDCS (* = significantly different from pre-
stimulation). 
 
Table 5.2 Absolute values of heart rate variability. Results are presented 
as mean ± S.E.M. 
 LF/HF Pre-
Stimulation 
LF/HF 
Stimulation 
LF/HF Post-
Stimulation 
Anodal tDCS 
 
0.81 ± 0.13 1.56 ± 0.51 1.28 ± 0.28 
Cathodal tDCS 
 
0.93 ± 0.13 0.84 ± 0.11 0.75 ± 0.13 
Sham tDCS 
 
0.85 ± 0.14 0.87 ± 0.18 0.81 ± 0.15 
.
* 
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Table 5.3 HRV values for anodal, cathodal and sham tDCS groups. There was a significant increase in LF power in the anodal 
tDCS group during stimulation (Friedman’s test, p = 0.011) and an increase in LF/HF ratio that reached significance in the post-
stimulation period (Friedman’s test, p = 0.017; * = significantly different from pre-stimulation). 
 
 
 Pre-
stimulation 
Stimulation Post-
stimulation 
Pre-
stimulation 
Stimulation Post-
stimulation 
Pre-
stimulation 
Stimulation Post-
stimulation 
Total 
power 
(ms2) 
3047.61 
± 975.71 
3426.90 
± 685.25 
3252.25 
± 778.14 
2459.42 
± 485.35 
2324.99 
± 603.41 
2638.58 
± 578.64 
2903.44 
± 539.23 
2554.96 
± 451.05 
3052.56 
± 624.31 
LF power 
(ms2) 
992.15 
± 324.43 
1316.01 
± 307.35* 
1216.51 
± 360.53 
700.92 
± 136.68 
539.36 
± 115.29 
715.57 
± 214.48 
827.24 
± 199.48 
711.23 
± 189.51 
802.82 
± 187.68 
HF power 
(ms2) 
1426.25 
± 2069.54 
1386.01 
± 1443.43 
1254.48 
± 1443.02 
948.99 
± 224.53 
764.08 
± 202.51 
924.93 
± 164.37 
1137.28 
± 1226.28 
887.23 
± 754.38 
1263.31 
± 1744.50 
LF (nu) 
 
40.49 
± 3.59 
48.12* 
± 5.88 
49.08* 
± 4.65 
45.92 
± 3.77 
43.52 
± 3.26 
40.99 
± 4.65 
40.54 
± 3.37 
38.23 
± 3.78 
38.86 
± 3.67 
HF (nu) 
 
59.50 
± 3.59 
51.81 
± 5.88 
50.92* 
± 4.65 
54.08 
± 3. 77 
56.48 
± 3.26 
59.01 
± 4.65 
59.05 
± 3.41 
61.36 
± 3.72 
61.14 
± 3.67 
LF/HF 
 
1.00 2.07 
± 0.47 
2.50 
± 0.14* 
1.00 0.94 
± 0.09 
0.95 
± 0.18 
1.00 1.00 
± 0.14 
0.97 
± 0.14 
Anodal Cathodal Sham 
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Figure 5.3 Example of the effects of anodal tDCS on HRV power spectra 
in one individual. There is an increase in LF power during anodal 
tDCS whereas there is no significant change in HF power. (A) pre-
stimulation, (B) anodal tDCS, (C) post-stimulation. 
A 
B 
C 
Pre-stimulation 
Anodal tDCS 
Post-stimulation 
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Figure 5.4 Heart rate and mean blood pressure for anodal, cathodal and sham tDCS groups. There was a significant decrease 
in heart rate (time effect, p = 0.010) and a significant increase in BP (time effect, p < 0.0005; measured using a Finometer). 
Mode of stimulation (anodal or cathodal) had no impact on heart rate or blood pressure (main effect for mode of stimulation, p > 
0.05) and there was no interaction between mode of stimulation and time (* = significantly different from pre-stimulation). 
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Figure 5.5 The effects of anodal tDCS on muscle sympathetic nerve 
activity. Example recordings of ECG, blood pressure and MSNA at 
baseline (A), during anodal tDCS (B) and recovery (C) from one 
individual (* = single unit). 
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5.5.2 Transcranial direct current stimulation increases 
sympathetic nerve activity 
Vasoconstrictor muscle sympathetic nerve activity was recorded directly 
using microneurography in participants receiving anodal tDCS (Figure 5.5 
and Figure 5.6; n = 5). There was a significant increase in single unit 
frequency and incidence during the stimulation phase which increased and 
persisted into the post-stimulation phase (time effect, p = 0.046 and p = 
0.029 respectively; Figure 5.7 ; Table 5.4). There was no significant change 
in heart rate or blood pressure during tDCS (Table 5.5). 
 
 
 
 
Figure 5.6 Examples of individual single units from MSNA recordings 
shown in Figure 5.5. MSNA units have a similar morphology as 
demonstrated by superimposition. 
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Figure 5.7 There is a significant increase in MSNA frequency and incidence during anodal tDCS and the post-stimulation 
phase (time effect, p = 0.046 and p = 0.029; normalised group data n = 5; * = significantly different from pre-stimulation). 
 
* * * * 
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Table 5.4 Raw microneurography values. Results are presented as mean 
± S.E.M. 
 
 
Table 5.5 Effects of anodal tDCS on cardiovascular and HRV variables 
of participants who underwent microneurography (n = 5). There is 
no significant change in heart rate, BP, BRS or HRV. 
 
 
5.6 Discussion 
This double-blind sham controlled study provides evidence that anodal tDCS 
of the motor cortex can shift HRV towards sympathetic predominance in 
healthy humans in the post-stimulation period. This study shows, for the first 
time, that tDCS also increases vasoconstrictor sympathetic nerve activity 
measured directly using microneurography. This is the first direct evidence 
that tDCS can affect sympathetic nervous activity and thus reveals potential 
implications for future use of tDCS in a therapeutic setting.  
 Baseline Stimulation Recovery 
MSNA frequency 
(units/min) 
0.32 ± 0.05 0.68 ± 0.21 0.82 ± 0.12 
MSNA incidence 
(units/100 heart beats) 
0.52 ± 0.07 1.12 ± 0.3 1.40 ± 0.20 
 Baseline Stimulation Recovery 
Total Power (ms2) 4902 ± 2480 4692 ± 1607 1310 ± 1936 
LF Power  1676 ± 758 2243 ± 603 1957 ± 808 
HF Power 2642 ± 1457 2041 ± 1005 1938 ± 1037 
LF/HF 0.82 ± 0.26 2.58 ± 1.35 1.62 ± 0.64 
Heart rate (bpm) 62 ± 3.4 61 ± 3.0 59 ± 2.9 
Mean BP (mmHg) 86 ± 3.1 91 ± 5.8 93 ± 3.8 
BRS (ms/mmHg) 15.6 ± 4.8 19.1 ± 4.25 14.37 ± 4.0 
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5.6.1 tDCS and autonomic control 
Since the reports in the 1960s that tDCS may affect respiration, surprisingly 
few studies have investigated the potential effects of tDCS on the brainstem 
further. The original study found that anodal tDCS over the frontal cortex 
caused respiratory depression in a healthy volunteer, however this was 
using a current of 3 mA and small electrodes (1/2 inch diameter or 1.3 cm) 
(Lippold and Redfearn, 1964; Redfearn et al., 1964) with a current density of 
0.564 mA/cm2, much higher than the recommended 0.029 mA/cm2 (Nitsche 
et al., 2003a). In addition, the electrode montage consisted of an extra-
cephalic cathodal electrode unlike the majority of studies that use a bi-
cephalic montage (Lippold and Redfearn, 1964; Redfearn et al., 1964). It 
was thought that this particular montage may pass more electrical current 
through the brainstem, however, modelling of electric fields during tDCS 
suggests that this is not the case (Im et al., 2012). Another extra-cephalic 
electrode montage, with an electrode placed on the neck and the other over 
the occipital cortex, has subsequently been found to have no effect on heart 
rate, blood pressure, body temperature, or respiratory frequency during both 
anodal and cathodal stimulation (Accornero et al., 2007), however, these are 
crude measures of autonomic function. Vandermeeren et al., (2010) also 
found that anodal tDCS over the frontal cortex with an extra-cephalic 
electrode had no significant effect on these indices but also included the 
analysis of HRV. They reported no significant effect, however, they did note 
a small increase in the LF/HF ratio during anodal, cathodal and sham tDCS 
suggesting an increase in sympathetic activity. As this occurred in all three 
groups, including sham, it may be that this was a result of anxiousness 
experienced by the volunteers during the study. Only one study has looked 
at the autonomic effects of the more commonly used bi-cephalic montage for 
tDCS and reported that anodal tDCS over the motor cortex had no 
significant effect on blood pressure, body temperature, respiratory rate or 
cortisol levels (Raimundo et al., 2012). The present study also observed no 
effect on respiratory rate although this was not formally analysed. 
Importantly, this study provides the only direct recording of sympathetic 
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nerve activity and shows that anodal tDCS over the motor cortex may indeed 
influence autonomic control in healthy humans. 
Since bi-cephalic tDCS over the motor cortex can increase 
sympathetic nervous activity it may prove a useful tool to modify autonomic 
activity. Interestingly, the increase in LF/HF ratio and MSNA continued after 
tDCS ceased. tDCS has been reported to have residual effects on motor 
cortical excitability (increased amplitude of MEPs) outlasting stimulation by 
up to 90 minutes in humans (Nitsche and Paulus, 2000, 2001) and this may 
account for the continued sympathoexcitation observed in this study. 
Whether the increase in sympathetic nerve activity is maintained for a similar 
duration of 90 minutes post stimulation merits further attention. In addition, 
whether the effects of tDCS on autonomic function are influenced by 
repeated application may warrant investigation.  
tDCS over other areas of the cortex may have different effects on 
autonomic function. Bi-cephalic anodal tDCS over the temporal lobe has 
been reported to increase the HF component of HRV and decrease LF/HF 
ratio indicating an increase in parasympathetic influence on heart rate 
(Montenegro et al., 2011). The potential for tDCS to alter autonomic function 
towards either parasympathetic (temporal lobe placement) or sympathetic 
predominance (motor cortex placement) is especially pertinent as tDCS has 
recently been applied in the context of stroke rehabilitation (Schulz et al., 
2013). Stroke patients often have compromised autonomic function and the 
degree of autonomic dysfunction is predictive of mortality (Robinson et al., 
2003; Mäkikallio et al., 2004; Sörös and Hachinski, 2012). Decreased HRV 
indicating increased sympathetic predominance is reported after stroke and 
has been reported to last up to 6 months post stroke (Korpelainen et al., 
1996). Reduced BRS and elevated plasma noradrenaline levels are also 
observed following stroke (Myers et al., 1981; Robinson et al., 1997). tDCS 
could have beneficial or detrimental effects in stroke patients depending on 
the sympathovagal balance of each individual. It may be possible to tailor 
tDCS therapy to improve autonomic function by stimulating different areas of 
the cortex e.g. anodal tDCS over the temporal lobe for patients with reduced 
parasympathetic activity. Individual autonomic function could be assessed 
on a case by case basis and would be easily implemented in clinics by using 
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non-invasive measures of autonomic function such as HRV. Further 
research into the use of tDCS in stroke patients may therefore be justified, 
including examining the duration of effects.  
 
5.6.2 Potential pathways involved in cortical modulation of 
autonomic function by tDCS 
Since tDCS is known to influence cortical structures, it may indirectly affect 
autonomic outflow through these structures. Krogh and Lindhard (1913) first 
proposed higher control of autonomic function, later termed ‘central 
command’ to account for the rapid increase in heart rate at the start of 
exercise. Since then numerous studies have detailed areas of the cortex that 
influence autonomic function including the medial prefrontal cortex (mPFC) 
(Bacon and Smith, 1993; Owens et al., 1999; Gabbott et al., 2005), insular 
cortex (Verberne and Owens, 1998) and motor (Schlindwein et al., 2008) 
cortex. 
 
5.6.3 Influence of the medial prefrontal cortex on autonomic 
function  
The medial prefrontal cortex is of particular interest in this study as it may 
have been inhibited by the cathodal electrode placed over the supraorbital 
area. Several lines of evidence indicate that such inhibition of the mPFC can 
explain the sympathoexcitation detected in this study. Stimulation of the 
mPFC in anaesthetised rats resulted in a decrease in blood pressure and 
concomitantly reduced sympathetic nerve activity, suggesting that the mPFC 
has a sympathoinhibitory effect (Owens et al., 1999). Furthermore, inhibiting 
NTS neurones by injecting muscimol (GABAA receptor agonist) bilaterally 
into the NTS attenuated the depressor and sympathoinhibitory effects of 
mPFC stimulation (Owens et al., 1999). The depressor effect of mPFC 
stimulation was also reversed by injecting bicuculline (GABAA receptor 
blocker) into the RVLM (which contains sympathetic premotor neurones) or 
by injecting kynurenic acid (ionotropic glutamate receptor antagonist) into 
the CVLM (which inhibits the RVLM), suggesting that these areas have an 
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important role in mediating the autonomic effects of mPFC stimulation 
(Owens and Verberne, 2000). The mPFC has been shown to project to 
areas of autonomic control including the NTS and RVLM using injection of 
the retrograde neuronal tracer wheat germ agglutinin conjugated to 
horseradish peroxidase (WGA-HRP) in the rat (Gabbott et al., 2005). 
Injecting anterograde neuronal tracer into the mPFC also revealed 
projections to autonomic regions of the spinal cord where sympathetic pre-
ganglionic neurones are located (Bacon and Smith, 1993) therefore the 
mPFC could also influence sympathetic activity through this pathway.  
Imaging studies have provided evidence that the mPFC is involved in 
autonomic control in humans. Combining fMRI and isometric handgrip 
exercise, causing sympathetic activation, revealed a decrease in blood 
oxygen level dependent (BOLD) signal in the ventral mPFC that correlated 
with an increase in heart rate (Wong et al., 2007). The mPFC was also 
deactivated during baroreceptor unloading induced by the application of 
lower body negative pressure (Kimmerly et al., 2005). It can therefore be 
envisaged that one possible route by which tDCS induced 
sympathoexcitation is through inhibition of the mPFC. 
 
5.6.4 Influence of the motor cortex on autonomic function 
There is also evidence that the motor cortex may play a role in autonomic 
regulation. Stimulating the motor cortex in rats induced expression of the 
activity marker c-fos protein in the NTS, DVN and RVLM (Sequeira et al., 
2000). Furthermore, injecting fluorogold (FG) into the NTS/DVN and dextran- 
tetramethylrhodamine (DR) into the RVLM revealed direct projections to the 
motor cortex (Sequeira et al., 2000). Anterograde tracing with WGA-HRP or 
DR from the motor cortex confirmed a reciprocal projection to the NTS, DVN, 
CVLM and RVLM. Moreover, by injecting DR into the ventrolateral spinal 
cord (T2-T4) and FG into the NTS/DVN or RVLM, double labelled neurones 
were found in the motor cortex indicating that corticospinal fibres provided 
collaterals to brainstem autonomic centres. This indicates that there is 
integration between the somatic and autonomic nervous systems in relation 
to movement (Viltart et al., 2003). Interestingly, the densest labelled cortical 
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projection was to the RVLM indicating that the motor cortex plays an 
important role in regulating sympathetic activity. Viltart et al. (2003) 
confirmed that stimulation of the motor cortex in the rat induced c-fos protein 
activation in the CVLM and RVLM. Motor cortex stimulation also decreased 
blood pressure and plasma noradrenaline levels, supporting a role for the 
motor cortex in autonomic regulation (Viltart et al., 2003). The presence of c-
fos protein in the CVLM indicates activation which would, in turn, cause 
GABAergic inhibition of the RVLM and would account for the decrease in BP 
and plasma noradrenaline observed during motor cortex stimulation. 
Conversely, as there was also c-fos protein immunoreactivity in the RVLM 
this would imply activation of the RVLM which would lead to increased 
sympathetic activity, contrary to the autonomic changes observed. However, 
there is a small sub-population of RVLM neurones which, when stimulated, 
caused inhibition of sympathetic preganglionic neurones in the spinal cord 
(Deuchars et al., 1997). This response could be abolished by bicuculline 
(GABAA receptor antagonist) indicating a direct GABAergic projection from 
the RVLM to sympathetic preganglionic neurones (Deuchars et al., 1997). 
This may account for the sympathetic inhibition observed by Vitart et al. 
(2003) upon motor cortex stimulation. The electrical stimulation was 
performed using a bipolar electrode implanted directly onto the motor cortex 
which delivered pulsed stimulation, the polarity of which was reversed every 
2 s. The difference in stimulation modalities used may explain why 
sympathoinhibition was observed by Viltart et al. (2003) whereas we report 
sympathoexcitation. In addition, the rats were under anaesthesia which may 
also have affected the results.  
The motor cortex also influences autonomic function in humans. fMRI 
during lower body negative pressure revealed an increase in BOLD signal in 
the motor cortex that was correlated with increased heart rate (Kimmerly et 
al., 2005). Perhaps the most elegant study of cortical contribution to 
autonomic activity used positron emission tomography with labelled glucose 
to assess cerebral metabolism at rest and relate this to spontaneous 
changes in heart rate and plasma noradrenaline levels. This revealed a 
positive correlation between plasma noradrenaline levels and increased 
regional cerebral glucose metabolism in the motor cortex (Schlindwein et al., 
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2008) supporting a role for the motor cortex in sympathoexcitation. Direct 
activation of the motor cortex by the anodal electrode may also, therefore, 
contribute to the increased sympathetic nervous activity observed in this 
study. 
Currently, few studies have investigated the potential of tDCS to 
modulate autonomic function. These studies are preliminary in nature and 
report mixed results. Further investigation of the effects of tDCS on 
autonomic function is warranted, including electrode positioning and any 
residual effects. The results of this study require consideration when using 
tDCS in patients groups with altered autonomic function e.g. stroke patients 
but also represent a potential therapeutic avenue to target autonomic control 
that may have been overlooked in the past. 
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Chapter 6 
General Discussion 
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6.1 Summary of findings 
6.1.1 H- tVNS altered cardiovascular autonomic function towards 
parasympathetic predominance in healthy humans and heart 
failure patients 
The physiological evidence presented in this thesis indicates that H-tVNS 
can alter cardiovascular autonomic function in both healthy humans and 
heart failure patients. In healthy subjects there was a shift in cardiac 
autonomic control towards parasympathetic predominance, however, this 
was dependent on the stimulation parameters used. Only high pulse width 
(200 µs) and frequency (30 Hz) tVNS caused a significant decrease in 
LF/HF ratio. The effect of these stimulation parameters on sympathetic 
vasoconstrictor nerve activity was also investigated. This revealed that H-
tVNS caused a significant reduction in MSNA. Based on these results, a pilot 
study of the effects of H-tVNS on cardiac autonomic control in heart failure 
patients was conducted. There was a significant decrease in LF/HF ratio 
indicating a shift in cardiac autonomic control towards parasympathetic 
predominance. This is remarkable as heart failure patients were on optimal 
medical therapy including beta-blockers and ACE inhibitors. H-tVNS was 
also well tolerated by heart failure patients and was not associated with any 
side effects. 
 
6.1.2 Anodal tDCS over the motor cortex increased sympathetic 
nerve activity in healthy humans 
Anodal tDCS over the motor cortex had the opposite effect on 
cardiovascular autonomic function compared to H-tVNS. There was an 
increase in LF/HF ratio during anodal tDCS indicating a shift towards 
sympathetic predominance that continued and reached significance in the 
post-stimulation period. This was supported by a significant increase in 
MSNA during anodal tDCS that continued after stimulation had ceased. 
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6.2 Potential mechanisms of H-tVNS cardiovascular 
autonomic effects  
The mechanisms underlying the effects of H-tVNS on autonomic function 
require further elucidation, however, there is evidence through retrograde 
neuronal tracing in cats and dogs that the ABVN projects to the NTS 
(Nomura and Mizuno, 1984; Chien et al., 1996). The NTS is integral to 
autonomic regulation and stimulating the ABVN may alter neuronal 
processing here. Interestingly, the ABVN projects to the dorsomedial part of 
the caudal NTS which also receives baroreceptor afferent projections from 
the carotid sinus and aortic arch (Ciriello et al., 1981). Therefore, stimulating 
the ABVN may activate the baroreceptor pathway through the NTS to the 
CVLM which inhibits the RVLM and decreases sympathetic output (Figure 
6.1). This could account for the microneurography findings of this thesis that 
revealed a decrease in MSNA during H-tVNS in healthy humans. This study 
attempted to define the central projections of the ABVN in humans by 
applying the neuronal tracer DiI to the ABVN in cadaveric tissue, however, 
this was unsuccessful. By adjusting the protocol e.g. applying a direct 
current to the tissue to increase the diffusion rate, it should be possible to 
define the neuroanatomy of the ABVN in humans. This would clarify, at least 
in part, the mechanisms involved in H-tVNS cardiovascular autonomic 
effects.  
The NTS also projects to the DVN and NA (containing 
parasympathetic preganglionic neurones), therefore, H-tVNS could also 
modulate parasympathetic output through this pathway. Unlike sympathetic 
nerve activity, parasympathetic nerve activity cannot be recorded directly in 
humans. The HF component of HRV represents cardiac vagal modulation 
and may provide an indication of H-tVNS effects on HRV. There was no 
significant change in HF power during H-tVNS in healthy humans suggesting 
that H-tVNS does not alter parasympathetic output, however, these 
participants were healthy and stimulation was applied during rest. These 
conditions would result in high parasympathetic tone at baseline and this 
may mask potential effects of tVNS on the parasympathetic nervous system. 
In heart failure patients, there was an increase in HF power, however, this 
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did not reach significance. The heart failure group was small (n  = 8), 
therefore, further investigation is required to explore the possible effects of 
H-tVNS on parasympathetic activity in populations with diminished 
parasympathetic activity. 
 
 
 
 
Figure 6.1 Potential mechanisms of H-tVNS effects on cardiovascular 
autonomic function. Stimulation of the ear could excite the NTS 
through projections of the ABVN. This could lead to activation of the 
CVLM which, in turn, would inhibit the RVLM and reduce sympathetic 
output. The NTS also projects to the DVN and NA therefore tVNS could 
alter parasympathetic output through this pathway. 
 
 
6.4.1 Potential mechanisms of tDCS cardiovascular autonomic 
effects  
The diffuse nature of tDCS stimulation, as revealed by computational models 
(Im et al., 2012), hinders interpretation of the mechanisms underlying the 
changes in cardiovascular autonomic function during anodal tDCS over the 
motor cortex. However, the greatest current density amplitude is under the 
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surface electrodes (Im et al., 2012), therefore, these areas are likely to be 
most affected by the stimulation. This study found that placing the anodal 
electrode over the motor cortex and the cathodal electrode over the 
contralateral supraorbital region increased LF/HF ratio and MSNA. Neuronal 
tracing studies have revealed projections from the motor cortex to areas of 
autonomic control including the NTS, DVN, CVLM and RVLM (Sequeira et 
al., 2000). PET studies in humans have also revealed a correlation between 
increased plasma noradrenaline levels and increased glucose metabolism in 
the motor cortex indicating that the motor cortex plays a role in 
sympathoexcitation (Schlindwein et al., 2008). Stimulation of the motor 
cortex by the anodal electrode may therefore have contributed to the 
increase in sympathetic activity observed in this study. In addition, the 
cathodal electrode may have influenced activity in the medial prefrontal 
cortex. The mPFC has also been found to project to areas of autonomic 
control such as the NTS and RVLM using neuronal tracers (Bacon and 
Smith, 1993; Gabbott et al., 2005). Furthermore, stimulation of the mPFC in 
anaesthetised rats decreased blood pressure and sympathetic nerve activity 
(Owens et al., 1999) suggesting that the mPFC has a sympathoinhibitory 
role. Cathodal stimulation over the mPFC may therefore have caused 
disihbition of sympathetic activity that may have contributed to the 
sympathoexcitation reported in Chapter 5. In the future, fMRI during tDCS 
may aid investigation of the mechanisms of tDCS effects on cardiovascular 
function. 
 
6.3 Neuromodulation of the autonomic nervous system 
Neuromodulation, the alteration of nerve activity through targeted electrical 
or pharmaceutical interventions, is a rapidly expanding field with applications 
in a plethora of conditions. Many of these interventions alter activity of the 
autonomic system e.g. renal sympathetic denervation for the treatment of 
hypertension (Esler et al., 2010) (see Section 6.5.1 below), carotid sinus 
stimulation and deep brain stimulation, however many of these techniques 
are invasive and expensive, limiting application to patient populations.  
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6.3.1 Carotid sinus stimulation 
Electrical stimulation of the carotid sinus to activate baroreceptors and/or 
baroreceptor afferents has been proposed as a possible therapy for 
hypertension (Jordan et al., 2012). This technique aims to mimic activation 
of the arterial baroreflex by increased blood pressure to cause a reflex 
decrease in sympathetic nerve activity and blood pressure. This has proven 
effective in clinical trials in treatment resistant hypertension patients with a 
significant decrease in blood pressure at 3 and 12 months follow-up 
(Bisognano et al., 2011). The acute effects of carotid sinus stimulation on 
MSNA have been evaluated in treatment resistant hypertension patients. 
There was a significant decrease in MSNA burst frequency, incidence and 
area during stimulation with a concomitant decrease in blood pressure and 
plasma renin concentration (Heusser et al., 2010). Interestingly, carotid 
sinus stimulation has also been reported to reduce left ventricular mass and 
wall thickness indicating improved left ventricular structure (Bisognano et al., 
2011). This, coupled with reduced MSNA, suggests that carotid sinus 
stimulation may also be beneficial in heart failure. Indeed, carotid sinus 
stimulation for 3 months in a canine heart failure model attenuated the 
decrease in left ventricular ejection fraction compared to untreated dogs 
(Sabbah et al., 2011b). In addition, carotid sinus stimulation attenuated the 
increase in plasma noradrenaline levels and cardiac remodelling with a 
reduction in interstitial fibrosis and cardiomyocyte hypertrophy. Studies of 
carotid sinus stimulation and the mechanisms involved are few, however, 
these remarkable findings warrant further investigation. 
 
6.3.2 Deep brain stimulation 
Deep brain stimulation of the periaqueductal grey (PAG) matter is performed 
in cases of chronic pain, however, this also affects central autonomic control 
(Carter et al., 2011). The PAG projects to areas of autonomic control as 
revealed by neuronal tracing studies. Injecting neuronal tracer into the PAG 
revealed projections to the NTS, DVN and NA (Farkas et al., 1997) 
indicating that these areas of the PAG influence parasympathetic activity. 
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The PAG was also found to project to sympathetic premotor neurones in the 
RVLM (Farkas et al., 1998). Stimulation of the PAG produces both pressor 
and depressor responses depending on the location of the stimulating 
electrode within the PAG. Stimulation of the dorsal PAG in anaesthetised 
rats increased blood pressure and heart rate (Lovick, 1985) whereas 
microinjection of an excitatory amino acid (D,L-homocysteic acid) into the 
ventral PAG caused bradycardia and reduced blood pressure (Lovick, 1992). 
Similar results have since been reported in humans. Stimulation of the 
ventral PAG in conscious humans caused a significant decrease in blood 
pressure whereas stimulation of the dorsal PAG increased blood pressure, 
however, stimulation at either site had no effect on heart rate (Green et al., 
2005). These effects on blood pressure merit consideration when selecting 
patients for PAG stimulation and during long term follow-up, however, this 
also offers another potential method to therapeutically alter blood pressure 
e.g. stimulation of the ventral PAG may beneficial in reducing blood pressure 
in hypertension whereas stimulation of the dorsal PAG may alleviate 
symptoms of orthostatic hypotension. 
 
6.4 Residual effects of neuromodulation 
Both neuromodulatory techniques investigated in this thesis exhibited a 
residual effect on cardiovascular autonomic function to some degree. LF/HF 
ratio did not return to baseline levels after H-tVNS but remained slightly 
reduced. There was a trend towards a return to baseline levels, however, 
this was not reached in the 15 minute period following stimulation. After 
tDCS, there was a continued increase in LF/HF ratio and MSNA. These 
residual effects imply that continuous stimulation may not be necessary to 
maintain changes in autonomic function which would facilitate the use of 
these techniques by patients and reduce disruption to daily life. This is 
supported by a previous finding that auricular acupuncture (25 minutes) 
produced changes in HRV that persisted for at least 60 minutes post-
stimulation (Haker et al., 2000). Anodal tDCS over the motor cortex (13 
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minutes) is also reported to cause changes in cortical excitability that lasted 
for 90 minutes (Nitsche and Paulus, 2000, 2001).  
Interestingly, chronic, daily administration of both tVNS and tDCS 
produce longer residual effects (Zamotrinsky et al., 1997; Zamotrinsky et al., 
2001; Boggio et al., 2007). 10 consecutive days of auricular 
electroacupuncture (15 minutes duration) in patients with coronary artery 
disease decreased the use of vasodilator medication for up to three weeks 
after stimulation ceased (Zamotrinsky et al., 1997; Zamotrinsky et al., 2001). 
Similarly, 5 consecutive days of tDCS (20 minutes duration) improved motor 
function in stroke patients that lasted 2 weeks after stimulation ended 
whereas 4 tDCS sessions administered weekly had no residual effect 
(Boggio et al., 2007). These are the only studies investigating chronic tVNS 
and tDCS stimulation and the residual effects. The effects of chronic H-
tVNS, as described in this thesis, on cardiovascular autonomic function 
remain to be determined, however, based on these studies it seems likely 
that repeated H-tVNS interventions could lengthen the residual effect on 
cardiovascular autonomic function. This would enable short H-tVNS therapy 
times that would be amenable to patients rather than continuous stimulation. 
 
6.5 Clinical Implications of H-tVNS 
H-tVNS reduced MSNA in healthy participants and therefore may be 
therapeutic in other conditions characterised by sympathoexcitation in 
addition to heart failure. Many conditions, that at first may seem unrelated , 
exhibit underlying sympathoexcitation e.g. hypertension, obstructive sleep 
apnoea and obesity (Charkoudian and Rabbitts, 2009).  
 
6.5.1 H-tVNS and treatment resistant hypertension 
Hypertension is the leading attributable cause of mortality worldwide causing 
7.5 million deaths every year and is characterised by increased levels of 
sympathetic activity (Simplicity HTN-1 Investigators, 2011). Approximately 
half of hypertensive patients are treatment resistant (elevated blood 
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pressure despite lifestyle modifications and ≥3 antihypertensive drugs) 
(Esler et al., 2010). Recently, renal nerve denervation has been trialled in 
treatment resistant hypertensive patients. This neuromodulatory technique 
attempts to attenuate sympathetic activation in hypertension by denervating 
the renal artery using radiofrequency energy delivered through a catheter 
placed in the renal artery (Esler et al., 2010). At 6 months follow-up after 
renal nerve ablation, blood pressure was significantly reduced compared to 
the control group (Esler et al., 2010) and this effect was sustained at 24 
months follow-up (Investigators, 2011). This is encouraging as these effects 
were obtained in a patient population that was resistant to conventional anti-
hypertension treatments. However, the technique is invasive and the 
investigators report several cases of femoral pseudoaneurysm and one case 
of renal artery dissection (Investigators, 2011) therefore a non-surgical 
approach is desirable. Furthermore, a recent study of renal nerve ablation in 
treatment resistant hypertension patients reported no significant change in 
blood pressure at 1 and 6 months follow-up (Hart et al., 2013). These results 
are based on a small sample group (n = 8), however, this indicates that 
further investigation of the efficacy of this technique is required. 
The mechanisms of the potential antihypertensive effects of this 
technique require further investigation. Renal nerve ablation reduced renal 
noradrenaline spill-over and MSNA indicating a decrease in regional and 
systemic sympathetic nerve activity (Schlaich et al., 2009). This could be 
mediated by attenuation of efferent sympathetic nerve activity, reducing 
vasoconstriction of the renal artery and thereby increasing renal perfusion. 
This would reduce renin production which would lead to a decrease in 
angiotensin II levels. Angiotensin II acts at peripheral and central sites to 
increase sympathetic nerve activity and blood pressure, including receptors 
in the vasculature to promote vasoconstriction and in the brainstem to 
increase sympathetic outflow (Arnold et al., 2013). This is similar to medical 
therapies utilising angiotensin converting enzyme (ACE) to reduce the 
production of angiotensin II. However, these results are based on one case 
study (Schlaich et al., 2009). Contrary to this, a recent study reported that 
MSNA was not altered at 1 and 6 months follow-up of 8 patients treated with 
renal nerve ablation (Hart et al., 2013). This same study also investigated 
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the effects of renal nerve ablation in spontaneously hypertensive rats and 
found a consistent decrease in MSNA and blood pressure. The difference in 
responses of rats and humans to renal nerve ablation may be attributed to 
the greater destruction of renal nerves (90%) in rats compared to humans 
suggesting that the procedure of renal nerve ablation requires further 
refinement.  
Alternatively/additionally, renal nerve ablation may affect afferent renal 
signalling and alter central autonomic control. Stimulation of renal afferent 
nerves in rats revealed c-fos immunoreactivity in areas of autonomic control 
including the insular cortex, paraventricular nucleus of the hypothalamus and 
the NTS (Solano-Flores et al., 1997). Activation of renal afferent nerves can 
reflexly increase or decrease efferent renal nerve activity (Johns and 
Abdullah, 2013). Stimulation of renal mechanoreceptors by dilating the renal 
pelvis in anaesthetised rats decreased efferent renal sympathetic nerve 
activity (Kopp et al., 1985) whereas activation of renal afferents throughout 
the kidney by infusing bradykinin increased efferent renal sympathetic nerve 
activity (Smits and Brody, 1984). Given the lack of understanding of afferent 
renal signalling and the effects of renal nerve ablation on renal afferent 
activity, further research is required to elucidate the mechanisms of renal 
denervation on blood pressure and autonomic function. 
This thesis has demonstrated that H-tVNS can reduce MSNA, 
therefore, H-tVNS merits consideration as an antihypertensive therapy. tVNS 
or cervical VNS have not yet been investigated in humans or animals as 
potential therapies in systemic hypertension. Investigating the effects of VNS 
on hypertension in humans would be limited by the invasive nature and 
expense of the procedure, however, H-tVNS offers a non-invasive method 
that could easily be investigated in hypertension patients and may provide 
an alternative to both cervical VNS and renal nerve ablation.  
 
6.5.2 Obesity 
The worldwide prevalence of obesity doubled between 1980 to 2008 to 
approximately 500 million obese adults and is expected to continue rising 
over the next two decades (Malik et al., 2013). Obesity is characterised by 
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elevated MSNA and the degree of sympathetic activation is related to 
increased visceral abdominal fat, independent of total fat mass (Alvarez et 
al., 2002). Moreover, weight loss through a low calorie diet and exercise 
decreased sympathetic nerve activity and plasma noradrenaline levels 
(Grassi et al., 1998; Trombetta et al., 2003). Obesity is an important risk 
factor for cardiovascular disease and this may be related to the underlying 
sympathoexcitation. Although dieting and exercise can decrease 
sympathetic activity in obese individuals, patient compliance is problematic 
(Makris and Foster, 2011). An incidental finding of VNS in epilepsy is weight 
loss and this has been investigated in animal models of obesity (Introduction 
1.3.1.5), however, these studies have not assessed any changes in 
sympathetic activity. Further investigation is required, however, VNS could 
potentially reduce weight and sympathetic activity in obesity, reducing the 
risk of developing cardiovascular disease. Conversely, reducing sympathetic 
activity could decrease metabolic rate and energy expenditure leading to 
further weight gain (Spraul et al., 1993), therefore, further animal studies are 
required to clarify the effects of VNS in obesity before trialling in obese 
humans.  
 
6.5.3 Obstructive sleep apnoea and H-tVNS 
Obstructive sleep apnoea (OSA) is estimated to affect 1-3% of the general 
population (Carlson et al., 1993), however, this increases to 40% of the 
obese population (Narkiewicz and Somers, 2003). OSA is associated with 
increased sympathetic activity demonstrated by increased MSNA and 
plasma noradrenaline levels in OSA patients (Carlson et al., 1993). Episodes 
of apnoea cause repeated periods of hypoxia and hypercapnia that activate 
the chemoreflex to increase sympathetic activity leading to increased blood 
pressure (Narkiewicz et al., 1999). Patients with OSA have an increased risk 
of cardiovascular disease and elevated levels of sympathetic nerve activity 
may contribute to this (Narkiewicz et al., 1999). One therapy for OSA is 
continuous positive airway pressure. This reduced episodes of apnoea and 
decreased MSNA in OSA patients (Narkiewicz et al., 1999), however, it 
requires patients to wear a mask while sleeping and is not well tolerated. 
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One study reported that 10/25 OSA patients recruited for a 
microneurography study refused continuous positive airway pressure 
treatment (Narkiewicz et al., 1999). H-tVNS may provide a more tolerable 
method to reduce sympathetic activity in OSA and decrease the risk of 
developing cardiovascular disease. 
 
6.5.4 Polycystic ovary syndrome 
Polycystic ovary syndrome (PCOS) is an endocrine condition that affects 
approximately 6-10% of women of reproductive age and is associated with 
an increased risk of cardiovascular disease (Yildirir et al., 2006; Lansdown 
and Rees, 2012). PCOS is also associated with obesity and OSA which are 
associated with sympathetic activation and this led to speculation that 
chronic sympathoexcitation may contribute to the pathophysiology of PCOS. 
An investigation of HRV in women with PCOS revealed a significantly 
elevated LF/HF ratio compared to age-matched controls, indicative of 
increased cardiac sympathetic predominance in PCOS patients (Yildirir et 
al., 2006). Heart rate recovery was also diminished in PCOS patients, 
compared to healthy controls, supporting evidence of autonomic imbalance. 
Indeed, impaired HRR suggests that there is parasympathetic withdrawal in 
PCOS (Giallauria et al., 2008). Microneurography has provided direct 
evidence of autonomic dysfunction in PCOS. MSNA burst frequency and 
incidence were significantly higher in PCOS patients compared to matched 
controls (Sverrisdóttir et al., 2008). These studies indicate underlying 
sympathoexcitation in PCOS, however, it is not known if this contributes to 
the pathophysiology of the condition. It is therefore difficult to predict if 
reducing sympathetic nerve activity would alleviate the symptoms of PCOS. 
Nevertheless, H-tVNS is a simple, non-invasive and safe technique to 
investigate this further. Importantly, H-tVNS may reduce sympathetic nerve 
activity in PCOS and thereby attenuate the risk of cardiovascular disease in 
this patient population. 
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6.5.5 The potential beneficial effects of H-tVNS post-stroke 
VNS may also benefit stroke patients by reducing infarct size. Cervical VNS 
applied 30 minutes after the initiation of cerebral ischaemia and lasting 1 
hour reduced infarct size by 50% in rats (Ay et al., 2011). There was no 
significant difference between VNS performed ipsilateral or contralateral to 
the area of ischaemia. The mechanisms behind VNS in reducing infarct size 
are unknown. It was hypothesised that VNS may increase cerebral blood 
flow through vasodilation of the cerebral arteries, however, measures of 
cerebral blood flow using Doppler ultrasound revealed no significant 
changes (Ay et al., 2011). Systemic inflammation and neuroinflammation 
occur as a result of stroke and the degree of inflammation is associated with 
poor prognosis post-stroke. VNS may, therefore, exert a beneficial effect 
through the anti-inflammatory reflex, however, this requires further 
investigation (General Introduction 1.3.1.3) (Cheyuo et al., 2011). Despite 
positive results in animal models of stroke, VNS in its current form is not a 
feasible acute intervention in human stroke patients due to the need for 
surgery. However, H-tVNS could be applied by paramedics or accident and 
emergency staff if a stroke is suspected. The effects of tVNS in stroke have 
not yet been investigated in animal models, however, it could potentially 
decrease the size of the infarct and thus could preserve a greater degree of 
neurological function. Furthermore, H-tVNS could reduce the risk of sudden 
death post stroke by reducing sympathetic activity (Chapter 5 Section 5.6.1) 
 
6.5.6 Vagus nerve stimulation and neurogenesis 
It has been postulated that VNS may facilitate adult neurogenesis in the 
subgranular zone of the hippocampus. Serotonin and noradrenaline have 
both been implicated in adult neurogenesis (Rajendran et al., 2009). The 
firing rates of locus coeruleus (LC) noradrenergic neurones and dorsal raphe 
serotonergic neurones recorded extracellularly in vivo in rats were increased 
by vagus nerve stimulation (Dorr and Debonnel, 2006), therefore, VNS may 
promote neurogenesis in the adult brain. Indeed, stimulation of the left 
cervical vagus nerve in rats for 24 hours increased hippocampal progenitor 
proliferation by 50% compared to sham stimulation (Revesz et al., 2008). 
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Vagus nerve stimulation also activates the central cholinergic pathway 
through the LC. The central cholinergic pathway projects to the 
hippocampus (Cheyuo et al., 2011) and acts on nicotinic acetylcholine 
receptors. Alpha 7 containing nicotinic ACh receptors play an important role 
in the survival, maturation and integration of new-born neurones in the 
hippocampus (Campbell et al., 2010). Rats in which alpha-7 containing 
nicotinic receptors were knocked down by injection of a retrovirus into the 
hippocampus exhibited reduced survival of new-born neurones and those 
that survived had truncated dendrites with reduced arborisation (Campbell et 
al., 2010). The hippocampus is involved in learning and memory processing 
therefore increasing neurogenesis and facilitating the integration of new-born 
neurones in this area may attenuate some of the symptoms of Alzheimer’s 
disease and other dementias. Indeed, a pilot study of VNS in 17 Alzheimer’s 
patients found that 70% showed no decline in cognitive function at 1 year 
follow-up and 40% showed an improvement in cognitive function (Merrill et 
al., 2006). These results are remarkable considering the progressive nature 
of Alzheimer’s disease, however, no other trials have since been conducted. 
This may be due to the invasiveness and expense of VNS, therefore, H-
tVNS may provide a non-invasive route to investigate the effects of VNS on 
cognition as a possible therapy to attenuate the progression of Alzheimer’s 
disease and dementia. 
 
6.5.7 Ageing and autonomic function 
Currently, 10 million people in the UK are over 65 years old and this is 
estimated to increase to around 19 million by 2050 (Cracknell, 2010). Good 
health is essential if older people are to remain independent and play an 
active role in family and community life. However, ageing is associated with 
an increase in the prevalence of many chronic conditions, which can 
contribute to loss of independence. Common chronic conditions affecting the 
elderly are those concerning the cardiovascular system (North and Sinclair, 
2012) and mental health (Luppa et al., 2012). One element linking these 
areas is altered function of the autonomic nervous system. 
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Age is the most important factor in determining cardiovascular health 
(North and Sinclair, 2012). Ageing is associated with alterations in 
cardiovascular autonomic control. Respiratory sinus arrhythmia is reduced, 
suggesting a decrease in parasympathetic influence on sinus node function 
(Kuo et al., 1999) and sympathetic activity is increased, evidenced by 
increased plasma noradrenaline levels (Esler et al., 1995) and muscle 
sympathetic nerve activity (Ebert et al., 1992; Ng et al., 1993). These 
parasympathetic and sympathetic changes contribute to a continuous 
decline in baroreflex sensitivity (BRS) and heart rate variability (HRV) in 
ageing males and females (Barantke et al., 2008), which is related to 
predisposition to cardiovascular disease (Umetani et al., 1998; Felber 
Dietrich et al., 2006; Abhishekh et al., 2013). Indeed reduced HRV is an 
indicator of poor prognosis in both healthy and patient populations (Kleiger 
et al., 1987; Nunan et al., 2010). Improving cardiovascular autonomic 
function in the elderly may, therefore, prevent or slow the development of 
cardiovascular disease.  
Depression is one of the most common mental health disorders in the 
elderly and is associated with functional decline, decreased quality of life, 
increased health care costs and increased mortality (Luppa et al., 2012). 
Indeed, depression increases the risk of developing cardiovascular disease 
by 1.5 in the general population (Luppa et al., 2012). Furthermore, patients 
with both cardiovascular disease and depression are 2-3 times more likely to 
suffer a cardiac event. Depression is also an independent indicator of poor 
prognosis after myocardial infarction. Similarly to cardiovascular disease, 
patients with depression exhibit reduced parasympathetic and enhanced 
sympathetic activity, evidenced by reduced heart rate variability (Taylor, 
2010), increased noradrenaline spill-over (Barton et al., 2007) and increased 
muscle sympathetic nerve activity (Scalco et al., 2009). Cervical VNS is 
currently approved for treatment resistant depression in the USA (General 
Introduction 1.3.1.2) and is therefore restricted to a small subset of patients. 
tVNS may provide a non-invasive adjunctive therapy for depression that 
could also attenuate associated cardiovascular risks and improve quality of 
life in the elderly. The invasive nature and expense of cervical VNS does not 
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justify its use as a prophylactic treatment, however, H-tVNS may provide an 
alternative solution. 
 
6.6 Clinical Implications of tDCS 
Sympathetic activation is associated with a wide range of conditions as 
discussed above. Furthermore, the degree of sympathoexcitation has been 
correlated with poor prognosis, including post stroke (Cohn et al., 1984; 
Kleiger et al., 1987; Kaye et al., 1995; Robinson et al., 2003; Barretto et al., 
2009). tDCS is being investigated as a potential therapy to aid stroke 
rehabilitation by promoting cortical plasticity, however, the possible effects 
on autonomic function may be underestimated. The results of this study 
indicate that tDCS, using a similar electrode montage and parameters to 
those used in stroke motor rehabilitation studies, increased MSNA. The 
effects of a single tDCS treatment are transient, however, chronic stimulation 
caused long-lasting effects on cortical excitation such that 5 daily treatments 
produced effects that lasted 2 weeks (Boggio et al., 2007). The effects of 
chronic tDCS on autonomic function are unknown, however, based on these 
results, caution is warranted before applying chronic tDCS over the motor 
cortex in stroke patient populations. It would be advisable to monitor 
autonomic function in patients undergoing such a trial e.g. regular analyses 
of HRV, to ensure there was no worsening of autonomic function that could 
potentially impact on patient prognosis. 
 Additionally, tDCS is being investigated as a potential therapy for 
depression which is also associated with sympathoexcitation. The electrode 
montage utilised in studies of tDCS in depression differs from that used in 
the present study with the anode and cathode placed over the left and right 
dorsolateral prefrontal cortex. The effects of this set-up on autonomic 
function are unknown, however, this merits investigation. Recently, 
combining fMRI and microneurography revealed a positive correlation 
between spontaneous MSNA burst activity and activation of the left and right 
dorsolateral prefrontal cortex (Macefield et al., 2013). This suggests that the 
dorsolateral prefrontal cortex may be involved in sympathoexcitation. This 
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finding warrants caution in using tDCS to treat depression until the potential 
effects on autonomic function are better understood.  
 
6.7 Limitations of the study 
A major limitation of this study is the small number of heart failure patients 
recruited. The high incidence of atrial fibrillation and other arrhythmias in 
patients attending the heart failure clinic hampered recruitment. 
Furthermore, many patients were recruited who had no diagnosis of 
arrhythmia but presented with regular ectopic beats that prevented 
acquisition of 5 minute long ECG recordings with < 2 ectopics beats as 
required for HRV analyses. In addition, recruitment and testing of patients 
during clinic restricted the time available for each experiment - hence 
recovery recordings to explore any residual effect of H-tVNS in heart failure 
were not made. In the future, patients could be recruited and undergo a 
screening ECG at the clinic prior to returning on a convenient day to take 
part in the study. This would allow adequate time for the study and the 
incorporation of microneurography into the protocol which would provide vital 
information on the effects of H-tVNS on MSNA in heart failure patients. 
The initial investigation of H-tVNS in healthy participants and heart 
failure patients relied on non-invasive measures that provide an estimate of 
autonomic balance rather than direct measurements. Two non-invasive 
measures of autonomic function, HRV and BRS analyses, were utilised in 
order to verify any changes during H-tVNS and tDCS. Whilst there were 
significant changes in HRV during H-tVNS and tDCS there was no 
significant change in BRS during either condition. This could be due to 
recruiting healthy volunteers with optimal reflex blood pressure control that 
was not affected by either intervention. Unfortunately, it was not possible to 
analyse BRS in the majority of the heart failure patients due to poor 
coherence between spontaneous changes in heart rate and blood pressure. 
Many of the heart failure patients were also excluded due to the frequent 
occurrence of ectopic heart beats. Heart rate turbulence could be used in 
future studies to both overcome the difficulty of obtaining ECG records free 
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of ectopic beats and also as an alternative to spontaneous BRS analysis in 
heart failure patients. The lack of effect of L-tVNS, cathodal tDCS and sham 
stimulation for both interventions implies that changes in HRV during H-tVNS 
and anodal tDCS were valid. Using microneurography to record MSNA in 
healthy participants partially overcame the restriction of non-invasive 
autonomic measures, however, this was not performed in heart failure 
patients and did not provide information on any regional changes in 
autonomic function. Regional changes in sympathetic activity could be 
explored in the future using the noradrenaline spill-over technique to 
examine specific changes in cardiac sympathetic nerve activity. 
Furthermore, the reproducibility of HRV and MSNA responses during both 
H-tVNS and tDCS has not been evaluated. 
Another limitation of this study is that tDCS was only performed in 
healthy participants and has not yet been investigated stroke patients. Given 
the results of this study and the clinical implication of potentially 
exacerbating sympathoexcitation in this group, determining the effects of 
tDCS on autonomic function in stroke patients is crucial. It may be that tDCS 
has no effect on autonomic function in stroke patients due to pre-existing 
sympathoexcitation and only increases MSNA in populations in which 
baseline levels are relatively low. Despite this, it is not ethical to apply tDCS 
to stroke patients at this stage without confirmation or refutation of the 
results presented in this study. A larger study of tDCS in healthy participants 
is required before contemplating a study of autonomic function in stroke 
patients.  
The findings of the neuronal tracing study of the ABVN were limited by 
restrictions on collecting the superior vagal ganglion for analysis as the cell 
bodies of the neurones that comprise the ABVN reside in the superior 
ganglion. It would have been useful to section this to determine if DiI had 
reached this point. Unfortunately, this procedure was not included in the 
original ethics application and tissue transfer agreement and there was not 
sufficient time to amend these and gain approval from the ethics committee 
and human tissue license holder. This could have provided information that 
would have informed the design of future experiments and will be included in 
subsequent studies.   
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6.8 Future studies 
6.8.1 H-tVNS in heart failure patients 
The preliminary data presented in Chapter 3 indicate that H-tVNS can 
improve cardiac autonomic function in heart failure patients, however, a 
larger sample group of heart failure patients is required to confirm this. It is 
also necessary to perform microneurography on heart failure patients during 
H-tVNS to establish if H-tVNS reduces MSNA in this population.  
The residual effect of H-tVNS on HRV in healthy participants 
represents an interesting phenomenon that may preclude the need for 
continuous stimulation. The residual effect was not explored in heart failure 
patients due to time constraints in the clinic therefore this requires 
investigation in the future. Heart failure patients would undergo a similar 
protocol as described in Chapter 3 (with the addition of microneurography) 
and would then undergo further recordings to establish the duration of the 
effect of H-tVNS on HRV and MSNA. Recordings would be made every 15 
minutes for two hours post-stimulation. If HRV and MSNA had still not 
returned to baseline levels recordings would continue every 15 minutes until 
they reach baseline levels. 
Chronic H-tVNS may have a cumulative effect on cardiovascular 
autonomic control. To investigate this, heart failure patients would be 
recruited to undergo H-tVNS twice daily for 1 month. To facilitate this, 
patients would be provided with a device and instructions to take home and 
perform H-tVNS. To monitor patient compliance, TENS machines that record 
a log of when the device was used would be utilised. A similar protocol to 
that used in Chapter 3 would be used on day 1 of the study. This would 
establish the baseline values of HRV and the acute effects of H-tVNS in 
each patient. In addition, microneurography would also be conducted. 
Patients would then undergo physiological recordings every fortnight for 2 
months to monitor the effects of chronic H-tVNS and any residual effects. 
This would provide data on cardiovascular autonomic function halfway 
through the chronic stimulation phase and on the last day of stimulation plus 
2 weeks and 4 weeks after H-tVNS had ceased. Clinical tests, such as the 6 
minute walking test and quality of life scores, would also be incorporated to 
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establish the effectiveness of H-tVNS in heart failure. If a residual effect was 
still present after one month, it may be necessary to extend the duration of 
the study to continue monitoring.  
The experiments described above would establish the efficacy of H-
tVNS in heart failure patients and would inform the design of future studies. 
In particular, determining the duration of the residual effect of H-tVNS and 
the impact of chronic stimulation may alter the length and number of H-tVNS 
periods per day. Positive results - a significant reduction in MSNA and LF/HF 
ratio - may lead to a clinical trial. A randomised controlled clinical trial would 
allow comparison of the effects of H-tVNS therapy in heart failure to a control 
group of heart failure patients receiving standard clinical care. To achieve 
this, the patients would be asked to utilise H-tVNS twice daily for 6 months 
with follow-up sessions at 1 month, 3 months and 6 months. At baseline and 
follow-up sessions, physiological measures (e.g. microneurography, HRV) 
and clinical tests (6 minute walking test, quality of life scores) would be used 
to establish the effectiveness of H-tVNS in heart failure. A multi-centre trial of 
cervical VNS in heart failure patients reported a significant increase in left 
ventricular ejection fraction at 3 months that was maintained at 1 year follow-
up (De Ferrari et al., 2011) therefore echocardiography should be included in 
future clinical studies of tVNS to investigate any effects on cardiac function. 
 
6.8.2 Elucidating the mechanisms of H-tVNS 
The central mechanisms of the cardiovascular autonomic effects of H-tVNS 
require further investigation. The working heart brainstem preparation 
(WHBP) provides an ideal method to explore this further in rats or mice. The 
WHBP is an intra-arterially perfused decerebrate in situ preparation. This 
eliminates the need for anaesthetic while preserving brainstem autonomic 
neuronal circuits and allowing intracellular neuronal recordings (Paton, 
1996). The preservation of autonomic circuits in this preparation can be 
demonstrated by increasing perfusion pressure. This stimulates 
baroreceptors and leads to a decrease in heart rate (Lall et al., 2012). 
Similarly, injecting sodium cyanide into the perfusate results in a decrease in 
heart rate and an increase in phrenic nerve discharge characteristic of 
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chemoreceptor activation (Lall et al., 2012). By adapting the electrodes used 
for tVNS, it would be possible to stimulate the ABVN in rats and record 
efferent activity of the vagus nerve directly. This would clarify the effects, if 
any, of tVNS on parasympathetic nerve activity. Moreover, to determine the 
effects of H-tVNS on neuronal activity in the NTS, intracellular recordings of 
neuronal activity would be made. By applying a neuronal tracer to the ABVN 
approximately 5 days prior to the experiment and including a fluorescent 
label (e.g.rhodamine) in the electrode utilised for intracellular recordings, it 
would then be possible to subsequently identify the NTS neurone that was 
recorded from and observe any close appositions from the ABVN.  
The consequences of H-tVNS on cardiac remodelling could also be 
investigated in vivo in an animal model of heart failure. There are many 
animal models of heart failure and one of the most commonly used involves 
ligation of the anterior interventricular coronary artery to cause myocardial 
infarction. However, this causes rapid onset heart failure which differs from 
the gradual development of heart failure in humans (Patten and Hall-Porter, 
2009). Aortic banding is an alternative technique in which a stricture is 
placed around the ascending aorta in young rats (3-4 weeks). As the rats 
grow, flow through the aorta is increasingly impeded leading to pressure 
overload in the left ventricle. At 8 weeks after banding there is left ventricular 
hypertrophy and symptoms of heart failure, such as dyspnoea, manifest at 
18 weeks post-banding (Patten and Hall-Porter, 2009). Aortic banding is a 
less invasive technique than coronary artery ligation and the gradual 
development of heart failure is more consistent with human disease. This 
model could be used to compare the effects of H-tVNS therapy to untreated 
rats with aortic banding. The development of heart failure can be monitored 
in vivo using echocardiology to assess left ventricular hypertrophy. After 18 
weeks the animals would be sacrificed and histological changes in cardiac 
tissue such as cardiomyocyte diameter and the degree of fibrosis could be 
assessed. This would elucidate the effects of H-tVNS on the 
pathophysiological remodelling of the heart.  
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6.8.3 Distribution of the ABVN 
This study attempted to determine the central projections of the ABVN in 
humans in order to clarify the potential mechanisms of H-tVNS effects on 
cardiovascular autonomic function. The results of this study were 
inconclusive and future studies to improve the protocol are outlined in 
Section 4.6. In addition to the central projections of the ABVN, the peripheral 
distribution to the external ear also merits investigation. This has only been 
investigated in one study in which the ABVN was dissected in 7 cadavers 
(Peuker and Filler, 2002). Dissection of the terminal branches of the ABVN 
would be technically challenging due to their small size. DiI travels 
anterogradely as well as retrogradely, therefore application to the distal end 
of the ABVN would label the distribution of the ABVN to the ear which could 
then be sectioned and viewed under a microscope as described in Chapter 
4. It would be beneficial to determine if there is any anatomical variation in 
the distribution of the ABVN between individuals as this may account for any 
non-responders to H-tVNS and may also inform future tailoring of H-tVNS 
electrode placement to maximise success rates. 
 
6.8.4 Autonomic effects of tDCS in stroke patients 
This thesis reports that anodal tDCS over the motor cortex, as proposed for 
stroke motor rehabilitation therapy, increased MSNA in healthy participants. 
This result requires confirmation, however, it may warrant consideration 
before tDCS is utilised in stroke patients. The effects of tDCS on autonomic 
function in stroke patients may differ from healthy participants, however, 
investigating this poses ethical dilemmas based on results presented in this 
thesis. It may be that a future collaboration with researchers investigating 
tDCS in stroke patients would minimise the number of patients exposed to 
tDCS and as the effects of tDCS are temporary, it may have no long-lasting 
effect. Despite this, an investigation of tDCS in an animal model of stroke 
would be a valuable initial investigation. The most common type of stoke in 
humans is caused by occlusion of the middle cerebral artery, therefore, 
performing a similar occlusion of the middle cerebral artery in rodents is 
frequently used to model stroke (Howells et al., 2010). Middle cerebral artery 
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occlusion in rats and mice can be performed by introducing a filament to the 
internal carotid artery and advancing this superiorly into the middle cerebral 
artery (Braeuninger et al., 2012). There are a number of established 
behavioural correlates that could be used to assess the effectiveness of 
tDCS on motor rehabilitation e.g. the ladder rung test (Balkaya et al., 2013). 
Telemetry could also be used to continuously record heart rate and blood 
pressure to allow HRV and BRS analyses. The consistency of infarct size 
could be assessed at the end of the experiment by sectioning the brain and 
using triphenyltetra-zolium chloride (TTC) to stain non-infarcted tissue red, 
leaving infarcted tissue pale (Braeuninger et al., 2012). By investigating the 
cardiovascular autonomic effects of tDCS over different areas of the cortex it 
may be possible to tailor this technique to fine tune central autonomic control 
in patients.  
 
6.9 Conclusion 
This thesis has demonstrated that it is possible to modulate autonomic 
function using tVNS and tDCS. Non-invasive neuromodulation of the 
autonomic nervous system could provide an adjunctive therapy to redress 
autonomic imbalance in many conditions and improve prognosis. These 
techniques do not require surgery and are therefore applicable to a wider 
cohort of patients than surgical techniques such as cervical VNS. 
Furthermore, tVNS and tDCS are simple and inexpensive techniques. Based 
on the results presented in this thesis, these techniques merit further 
investigation to determine the exact mechanisms involved and to explore 
their application to other conditions that exhibit autonomic imbalance such 
as hypertension and polycystic ovary syndrome. This may aid refinement of 
these techniques and enable translation to clinical practice. 
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